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Abstract 
 
 
In Western Australia, community-associated methicillin-resistant Staphylococcus 
aureus (CA-MRSA) continues to be a public health concern. Antibiotic resistance 
places additional burdens on the community and health-care systems. Updates in 
MRSA typing and molecular characterisation techniques have benefits in 
furthering understanding of the evolution and emergence of MRSA and ultimately 
result in improvements in the control and prevention of its spread. Molecular 
studies not only give an understanding of how MRSA evolve but enable typing to 
be improved so that isolates can be better identified and improvements made to 
their control and prevention of spread.  
 
Forty-five prototypes of CA-MRSA lineages isolated in Western Australia (WA) 
between 2003 and 2006 were used in this study and were provided by the 
Australian Collaborating Centre for Enterococcus and Staphylococcus Species 
(ACCESS) Typing and Research Unit, situated at PathWest Laboratory Medicine, 
Royal Perth Hospital, Perth, WA, which is also associated with Curtin University, 
School of Biomedical Sciences, Molecular Genetics Research Unit in a joint 
collaboration. 
 
The polymorphic region of the staphylococcal protein A (spa) gene is considered 
a useful typing tool for differentiation of MRSA. A spa typing protocol was 
trialled in this study. To assess the method’s suitability for typing MRSA, all 45 
isolates were tested to determine their spa type. Significant diversity was revealed 
with 28 different spa types identified. The spa type t002 was the most prevalent 
(7/45). Except for one isolate, which could not be typed, spa types correlated with 
the  multi locus sequence typing (MLST) and clonal complex designations of the 
45 CA-MRSA. A major outcome of this study has been the introduction of a 
standardised protocol for spa typing as a routine typing technique by the ACCESS 
Typing and Research Unit. 
 
  
 xxiii
 
Ciprofloxacin and other fluoroquinolones have restricted use in the community 
with their availability more accessible in hospitals and at the initiation of this 
study it was unusual to find ciprofloxacin resistance in CA-MRSA, however, eight 
of the prototype CA-MRSA possessed high-level ciprofloxacin resistance. This 
study therefore included an investigation of genetic mutations that result in 
resistance to ciprofloxacin in S. aureus. The subset of eight isolates were tested 
for mutations in the genes grlA, grlB, gyrA and gyrB. Sequence analysis revealed 
that all eight isolates contained point mutations resulting in amino acid changes at 
codon 80 in grlA and at codon 84 in gyrA. Additional mutations were seen in three 
of the eight isolates analysed. One isolate contained previously unreported 
mutations that may be associated with ciprofloxacin resistance. It was concluded 
that the CA-MRSA isolates could have developed resistance to ciprofloxacin 
when the patients may have received fluoroquinolones as a course of treatment for 
infection caused by other organisms such as Gram-negative bacteria. 
 
The staphylococcal cassette chromosome mec (SCCmec) is a genomic resistance 
island found in MRSA and a primary typing target for their classification. The 
SCCmecs of a subset of eight of the 45 prototype CA-MRSA isolates that had 
novel classifications were analysed as part of this study. The novel classifications 
for four of the eight were resolved into already classified SCCmec types, three of 
them had novel sub-types, two remained novel and the SCC region of one, WA 
MRSA-40 was completely sequenced. The J regions of the SCCmec elements 
were found to be structurally heterogeneous leading to the conclusion that they are 
“hot spots” for recombination, rearrangement and acquisition of genetic 
information that enables adaptation for survival of the host cell in changing 
environments. 
 
The SCC region of WA MRSA-40 was found to be a composite genomic island 
named SCCmecWA MRSA-40-CI (GenBank Accession No JQ746621). The 72,522 bp 
SCCmecWA MRSA-40-CI, was found to be comprised of three elements, ΨSCCpls, 
SCCsorbitol and SCCmecVT (5C2&5) integrated in tandem into the attB site of 
the conserved hypothetical protein gene orfX. Each element was delineated by 
direct and inverted repeats. ΨSCCpls is 11,736 bp and was homologous to the ΔJ1 
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region of SCCmec type I which encodes a pls gene. SCCsorbitol is 19,497 bp, and 
encodes a sorbitol operon, type 1 restriction modification genes, and a ccrA2B2 
gene complex together with seven open reading frames. This is the first time that a 
sorbitol operon has been reported in a SCC element and only the second time that 
a sorbitol operon has been reported in a staphylococcus, with it previously being 
found in S. carnosus. Acquisition of a sorbitol operon has been linked to dietary 
sorbitol usage. The SCCmec of WA MRSA-40 is 41,289 bp and is highly 
homologous with the SCCmec VT of the Taiwan strain PM1; it carries a class C2 
mec complex and two ccrC1 gene complexes with ccrC1, alleles 8 and 2. An 
insertion sequence ISSau4-like was found in the J2 region. Polymorphisms that 
generated premature stop codons that would prevent transposase activity and 
stabilise the mec complex were detected in the sequences of the transposases of 
IS431L and IS431R that flank the mec region.  
 
In conclusion this study has provided important and relevant information on the 
utilisation of spa typing for routine typing, the genetics and emergence of 
ciprofloxacin resistance in CA-MRSA and the analysis of the SCCmec region and 
SCC elements of CA-MRSA, particularly WA MRSA-40. 
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Chapter One 
Literature Review 
 
1.1 Staphylococcus aureus 
 
Staphylococci were first described by Pasteur and Koch. The genus 
Staphylococcus aureus was named by Ogstan in 1881, after describing grape-like 
clusters of bacteria in pus from human abscesses. S. aureus was observed by 
Rosenbach and named because of the yellow to orange pigmented appearance of 
their colonies in culture (Fluit and Schmitz 2003). 
 
In the pre-antibiotic era, S. aureus was a serious life threatening pathogen often 
responsible for wound infections, post-surgical infections, fatal pneumonia and 
meningitis.  Staphylococcal infections can be superficial skin infections or deep 
tissue and systemic infections. Superficial skin infections are commonly seen as 
furuncles or boils usually on the neck and buttocks, while deep tissue infections 
are seen in conditions such as endocarditis, osteomyelitis, arthritis and breast 
abscesses. S. aureus can also cause pneumonia as a secondary infection frequently 
following a viral infection (Fey et al. 2002). Some S. aureus produce enterotoxins 
which cause food poisoning if contaminated food is eaten (Livermore 2000). 
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1.2 History of MRSA 
1.2.1 History of Penicillin Resistance 
 
The antibiotic effect of the fungus Penicillium notatum against S. aureus was 
observed by Alexander Fleming in 1928. Fleming named a culture filtrate of the 
Penicillium mould, “Penicillin”. In 1939, Howard Florey and colleagues 
demonstrated the in vivo bactericidal action of penicillin (Hoephrich 1968). 
 
By 1940, the effectiveness of treating staphylococcal and other Gram-positive 
infections with penicillin was evident. Mass production of penicillin was soon 
required and went from harvesting penicillin from mouldy cantaloupes to large 
scale production by deep tank fermentation using the strain P. chrysogenum 
(Stefaniak et al. 1947; Hoephrich 1968). The use of penicillin during World War 
II greatly aided in the treatment of infected wounds and reduced the mortality rate 
(Hoephrich 1968). 
 
By 1942, however, the occurrence of S. aureus strains resistant to penicillin were 
being reported, first in hospitals and then in the community. This resistance 
resulted from the acquisition of a plasmid encoding the penicillin-hydrolysing 
enzyme penicillinase or β-lactamase. By 1948 about 60% of S. aureus in the 
United Kingdom (UK) were resistant to penicillin and by the late 1960s, more 
than 80% of S. aureus in the United States of America (USA) were resistant 
(Lowy 2003). By 1957 a strain known as the hospital staphylococcus was 
responsible for a large number of infections in the USA and the UK. This strain 
was termed 80/81 according to the phage typing method. The incidence of the 
80/81 strain declined in the 1960s following the introduction of methicillin 
(Rountree and Beard 1958; Robinson et al. 2005). 
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1.2.2 History of Methicillin Resistance 
 
Methicillin is a narrow spectrum β-lactamase stable, semi-synthetic β-lactam 
antibiotic that was developed in 1959 to treat infections caused by bacteria that 
had acquired resistance to penicillin. By 1961, however, the first cases of S. 
aureus resistance to methicillin were recorded in a British hospital (Stewart and 
Holt 1963). These resistant strains were called methicillin-resistant 
Staphylococcus aureus (MRSA) and they became known as the classic MRSA 
(Townsend et al. 1985; Casewell 1986). 
 
Once the first case of MRSA was reported in 1961 in a UK hospital, the strain 
rapidly spread. During the 1960s, MRSA were identified in other European 
hospitals. Soon after, MRSA were also identified from countries around the 
world. By the mid 1970s, the incidence of MRSA in Europe declined, possibly 
due to changes in prescribing antibiotics and the introduction of infection control 
policies (Rosdahl and Knudsen 1991; Westh et al. 1992). 
 
In the 1980s, a new strain of MRSA that was gentamicin resistant was reported in 
several countries including Australia (King et al. 1982; Pavillard et al. 1982), the 
UK (Duckworth, Lothian, and Williams 1988) and the USA (Boyce, White, and 
Spruill 1983). This strain was unlike the classic MRSA previously seen, as it was 
found to be multi-resistant (resistant to three or more antibiotics) (Pearman et al. 
1985), and to carry plasmids that variably encoded resistance to aminoglycosides, 
chloramphenicol, macrolides, tetracycline, trimethoprim, quaternary ammonium 
compounds (QACs) and nucleic-acid binding (NAB) compounds (Firth and 
Skurray 1998; Grubb, Coombs, and O'Brien 2004). This strain, now known as 
EMRSA-1 (epidemic methicillin resistant staphylococcus aureus) , is thought to 
have originated in Australia and then imported into the UK by an Australian 
health-care worker (Grubb, Coombs, and O'Brien 2004). EMRSA-1 spread readily 
within and between hospitals and tertiary care institutions by person to person 
contact between patients and staff causing extensive outbreaks. Serious infections 
with high mortality rates were reported. This strain was considered to have a high 
epidemic potential due to its ability to spread among patients in hospitals (Ayliffe 
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1997; Livermore 2000). EMRSA-1 was followed by other epidemic stains with 
multi-resistance such as EMRSA-3 (Livermore 2000). In England 17 epidemic 
strains (EMRSA-1 to EMRSA-17)  have been identified to date (Grubb, Coombs, 
and O'Brien 2004).  
 
The mid-1990s saw the emergence of EMRSA-15 and EMRSA-16 in the UK, 
with EMRSA-15 resistant to ciprofloxacin with variable resistance to 
erythromycin and EMRSA-16 usually resistant to ciprofloxacin, erythromycin, 
kanamycin, neomycin and occasionally gentamicin. It has been suggested that 
these strains are successful due to their ability to survive on hands and inanimate 
objects (Livermore 2000).  
 
Over the years several strains of MRSA have emerged, become dominant and 
displaced other strains in health-care environments. The more successful strains 
have spread pandemically. The dominant hospital-associated MRSA (HA-MRSA) 
are presented in Table 1.1. HA-MRSA of the clonal complex eight lineage 
predominate and include the Archaic, Brazilian/Hungarian, Iberian, Irish-1, UK 
EMRSA-2 and UK EMRSA-6 clones. HA-MRSA of clonal complex five includes 
the New York/Japan, Paediatric, Southern German and UK EMRSA-3 clones. 
Other HA-MRSA include clonal complex 45, 22 and 36, being the Berlin, UK 
EMRSA-15 and UK EMRSA-16 clones respectively (Deurenberg and 
Stobberingh 2008).  
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Table 1.1 Major HA-MRSA Worldwide 
HA-MRSA Strain ST/SCCmec Clonal Complex 
Geographic 
Spread 
Archaic ST250-MRSA-I 8 
Aust, UK, Europe, 
Canada, USA, 
China 
Berlin ST45-MRSA-IV 45 Aust, UK, Europe, USA, China 
Brazilian/Hungarian ST239-MRSA-III 8 
Aust, UK, Europe, 
USA, Canada, 
China, Korea 
Iberian ST247-MRSA-I 8 Aust, UK, Europe, USA 
Irish-1 ST8-MRSA-II 8 
Ireland, UK, 
Austria, Canada, 
USA 
New York/Japan ST5-MRSA-II 5 
Japan, USA, UK, 
Europe, China, 
Korea 
Paediatric ST5-MRSA-VI 5 Aust, Europe, UK, USA 
Southern German ST228-MRSA-I 5 Aust, Europe 
UK EMRSA-2/-6 ST8-MRSA-IV 8 
Aust, Europe, UK, 
USA, Canada, 
China, Japan 
UK EMRSA-3 ST5-MRSA-I 5 Europe, UK, Japan 
UK EMRSA-15 ST22-MRSA-IV 22 Aust, Europe, UK, New Zealand 
UK EMRSA-16 ST36-MRSA-II 36 Aust, Europe, UK, Canada 
 
 
1.2.3 Community MRSA – Global 
 
Up until the late 1980s MRSA were largely hospital-associated, however from the 
1990s, community-associated MRSA (CA-MRSA) have emerged worldwide 
(Deurenberg and Stobberingh 2008). CA-MRSA infections are defined as those 
occurring either in the community or within 48 hours of admission to a hospital. 
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CA-MRSA infections can also be classified as CA-MRSA with healthcare 
associated risk factors and those without. Healthcare associated risk factors 
include recent contact with hospitals, health-care facilities or their staff. CA-
MRSA in this category may be multi-resistant. CA-MRSA infected patients with 
no health-care associated risk factors have little or no contact with hospitals, 
health-care facilities or their staff. CA-MRSA in this category are generally non-
multi-resistant (Herold et al. 1998; O'Brien et al. 2004). 
 
CA-MRSA and HA-MRSA differ from each other both phenotypically and 
genotypically with CA-MRSA tending to be non-multi-resistant and susceptible to 
most non-β-lactam antibiotics. Pulsed Field Gel Electrophoresis (PFGE) and 
Multi Locus Sequence Typing (MLST) analysis of MRSA shows that there is far 
more genetic diversity among CA-MRSA strains than HA-MRSA. It is not 
characteristic of CA-MRSA to spread in a hospital or health-care environment, 
possibly because they lack the ability to survive on hands and inanimate objects as 
epidemic strains do (Livermore 2000; Fey et al. 2002; Naimi et al. 2003). The 
CA-MRSA strain ST8-MRSA-IV, commonly known as USA300, is a recent 
exception however, with the clone causing a cluster of infections in patients, 
health-care workers and their families in a neonatal intensive care unit in 2005. 
Extensive infection control practices were required to prevent further infections 
(McAdams et al. 2008). 
 
In 2006 it was revealed that USA300, a Panton-Valentine leukocidin (PVL) 
positive CA-MRSA strain in USA, had disseminated into tertiary institutions. The 
study, based on isolates from a tertiary care Veterans Affairs Medical Center, 
showed 100% of nosocomial infections were associated with USA300 (Gonzalez 
et al. 2006). 
 
The first reported CA-MRSA were in Detroit USA during the early 1980s, 
following an outbreak in a large urban hospital. The majority of those infected 
were drug abusers though occurrence in patients with serious underlying illnesses, 
previous antimicrobial therapy and previous hospitalisation were also noted. 
Infection control measures were effective in preventing ongoing transmission 
(Saravolatz et al. 1982; Saravolatz, Pohlod, and Arking 1982). Another early 
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report of CA-MRSA in the 1980s was in Canada involving seven intravenous 
drug abusers over a 15 month period. Infections included bacterial endocarditis, 
septic thrombophlebitis and soft tissue infections. All isolates were of the same 
phage type that was distinct from previous HA-MRSA. The likely source of the 
transmission was determined to be the drug “shooting gallery” patronised by the 
drug addicts (Craven et al. 1986). Both the outbreaks in Detroit and Canada were 
in the category of CA-MRSA infections with the added risk factor of drug abuse 
(O'Brien et al. 2004). 
 
The first genetically defined CA-MRSA were from remote regions in Western 
Australia (WA) in 1993 (Udo, Pearman, and Grubb 1993). It was found among 
hospitalised people from remote Aboriginal communities with no previous health-
care exposure or other risk factors for MRSA infections. 
 
In 1997-1999, four cases were recorded in the US states of Minnesota and North 
Dakota where four children died of severe infections caused by a PVL positive 
CA-MRSA, designated as MW2. With the development of MLST and SCCmec 
typing MW2 was found to belong to the ST1-MRSA-IVa (2B) lineage (CDC 
1999; Fey et al. 2002). The PVL determinant was found to be associated with CA-
MRSA in some countries (Vandenesch et al. 2003). 
 
A study in the Saxony region of Germany found there was a 30% occurrence of 
the PVL gene in MSSA (methicillin sensitive staphylococcus aureus)  from skin 
and soft tissue infections. This study further suggested the possibility that the PVL 
genes may spread to other S. aureus by phages or that a PVL positive MSSA 
acquired a SCCmec element to become a PVL positive CA-MRSA (Monecke et 
al. 2007). 
 
Spain has also seen an increase in the occurrence of a ST8 strain related to 
USA300, primarily among immigrants from South America (Manzur et al. 2008). 
 
There have been CA-MRSA clones that have emerged in defined geographical 
regions. This was seen with the Western Samoan Phage Pattern (WSPP) ST30-
MRSA-IV (2B) from the South Pacific region (Collignon et al. 1998), the 
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Queensland clone ST93-MRSA-IV (2B) from Ipswich, Queensland, Australia 
(Munckhof et al. 2003), the European clone ST80-MRSA-IV (2B) (Vandenesch et 
al. 2003) from Europe, USA300 ST8-MRSA-IV (2B) from USA (Tenover et al. 
2006), the Taiwan clone ST59-MRSA-VT (5C2&5) from Taiwan (Boyle-Vavra et 
al. 2005) and the Bengal Bay clone ST772-MRSA-V (5C2) from Bangladesh 
(Afroz et al. 2008). These clones have appeared initially in distinct regions and 
then disseminated to neighbouring areas and countries, and now each can be 
found worldwide. Common features among these CA-MRSA are their ability to 
cause severe infections and the presence of PVL genes in the strains (Coombs et 
al. 2011).  
 
Apart from USA300, CA-MRSA do not generally cause hospital outbreaks, 
however some CA-MRSA have also been associated with hospital outbreaks. In 
1995 an outbreak occurred in a major teaching hospital in WA,  following the 
admission of an infected patient from a remote community (O'Brien et al. 1999). 
Another occurrence of a CA-MRSA outbreak occurred in a New York hospital 
where eight post-partum women were infected with the PVL positive strain MW2. 
Extensive screening was conducted of staff, patients, family members and hospital 
equipment to find the source to transmission but without success (Saiman et al. 
2003) 
 
1.2.3.1 MRSA in Animals 
 
There have been increasing reports of MRSA in companion or domestic animals, 
where MRSA can colonize skin, nasal and oral mucosa in animals. A case was 
reported in 1994 where two nurses from the same household were found to be 
nasal carriers of the strain EMRSA-1. De-colonisation treatment with mupirocin 
and triclosan washes was successful. Follow up screenings six months later were 
again positive for EMRSA-1. It was discovered that their dog had an eye 
infection, with eye and nose swabs from the dog also growing EMRSA-1. All 
were successfully treated with nasal mupirocin and triclosan washes and the 
EMRSA was eliminated. It is suggested that animals can act as a reservoir for 
MRSA carriage (Cefai, Ashurst, and Owens 1994). A study in Hong Kong 
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reported the occurrence of ten MRSA strains from healthy dogs and their owners. 
Between the dogs and humans were found five HA-MRSA SCCmec type III and 
five CA-MRSA SCCmec type IV, one of which was PVL positive. This study also 
suggested dogs as a possible reservoir for MRSA in the community (Boost, 
O'Donoghue, and Sui 2007). 
 
Horses and staff at a veterinary teaching hospital in Michigan USA were 
investigated following the occurrence of post-procedural infections in 11 horses 
over a 13 month period. Five staff volunteered nasal swabs. Three staff and all 11 
horses were found to have identical MRSA. It was suggested that members of the 
veterinary teaching hospital staff were the source of the infections in the horses 
(Seguin et al. 1999). 
 
In Europe, the emergence of a MRSA strain among pigs and pig farmers in the 
Netherlands has been observed. Following intensive surveillance, the occurrence 
of this clone has been reported to have increased from 0% in 2002 to >21% in 
2006 with a finding of 25% in Dutch hospitals. Molecular typing showed it 
belonged to a new clonal complex, CC398. The study concluded that MRSA from 
an animal reservoir had recently entered the human population (van Loo et al. 
2007). ST398 has also been reported in other European countries, Canada and 
China (Wulf et al. 2007; Yu et al. 2008) and has now been isolated in Australia 
(GPBTRU 2009). 
 
 
1.2.4 Community MRSA – Australia 
 
The first community MRSAs in Australia were reported in the early 1990s. These 
MRSAs were isolated from people in remote Indigenous communities in the far 
north of WA who had no previous hospitalisation or other risk factors. These 
MRSA isolates were unusual in that they were resistant to very few antibiotics 
other than the β-lactams. The MRSA were analysed by plasmid characterisation 
and PFGE; two MRSA types were identified and determined to be genetically 
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different to the previously studied Australian EMRSA (Udo, Pearman, and Grubb 
1993). In 2004, five types of WA CA-MRSA, ST1-MRSA-IVa (2B), ST78-
MRSA-IVa (2B), ST5-MRSA-IVa (2B), ST45-MRSA-V (5C2), and ST8-MRSA-
IVa (2B) were identified in WA communities (O'Brien et al. 2004). 
 
In the eastern states of Australia, in the 1990s, community strains were found that 
were indistinguishable by phage typing and PFGE from CA-MRSA reported in 
New Zealand (Nimmo et al. 2000; Gosbell et al. 2001). This strain, which was 
subsequently found to be ST30-MRSA-IV (2B), became known as the Western 
Samoan Phage Pattern (WSPP). WSPP had a high incidence among people of 
Polynesian decent (Collignon et al. 1998). The WSPP clone was thought to have 
originated in Western Samoa after it was detected in New Zealand in individuals 
who came from, or had visited Western Samoa. WSPP has a MLST of ST30 and 
appears related to a non-typable MSSA strain isolated in Denmark in 1962 and 17 
MSSA isolates from a UK study, and also closely related to EMRSA-16 (Enright 
et al. 2000; Crisóstomo et al. 2001; Smith and Cook 2005). WSPP encodes the 
PVL determinant and is responsible for cutaneous and systemic infections. WSPP 
has also been isolated in California, the USA, from members of a Samoan family 
found to be infected, and or, carriers of WSPP (Gross-Schulman, Dassey, and 
Mascola 1998). 
 
A second clone emerged at this time in Queensland (Qld) Australia, known as the 
Qld or Oceanic Clone. It was subsequently found to be of the ST93-MRSA-IVa 
(2B) genetic lineage (Nimmo et al. 2000). In a retrospective study in 1993 of 
isolates from 44 patients from a Qld hospital, the Qld clone was revealed to be 
responsible for superficial abscesses, or boils, as well as four serious life-
threatening infections. The Qld clone was assigned pulsotype “R” by PFGE and, 
like WSPP, was PVL positive (Munckhof et al. 2003). The first fatal case of 
necrotising pneumonia due to a CA-MRSA in Australia resulted from an infection 
by the Qld clone with the pulsotype “R” (Peleg and Munckhof 2004). 
  
A study by the Australian Group for Antimicrobial Resistance (AGAR) surveyed 
S. aureus isolates collected Australia-wide between 2004-2005 and compared 
results with a similar survey from 2000-2002 (Nimmo et al. 2006). The major CA-
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MRSA clones within Australia were determined to be WA-MRSA-1, WSPP and 
the Qld clone. In 2004 14.9% of 2,652 S. aureus isolates surveyed were MRSA, 
with the number of CA-MRSA increasing from 4.7% in 2000 to 7.3% in 2004. 
WA MRSA-1 decreased from 18% in 2000 to 16% in 2004. The Qld clone 
increased from 5% in 2000 to 15% in 2004. WSPP decreased from 13% in 2000 
to 7% in 2004. PVL analysis in 2004 showed that 46% of CA-MRSA were PVL 
positive with 8% WA MRSA-1, 97% Qld clone and 96% WSPP. These results are 
presented in Table 1.2. The major HA-MRSA isolated were Aus-2 and Aus-3 
(both ST239-MRSA-III) and ST22-MRSA-IV or UK EMRSA-15. In 2000, 35% 
of MRSA identified were Aus-2, 7% Aus-3 and 12% UK-15. In 2004 Aus-2 had 
decreased to 23%, Aus-3 to 6% while UK-15 had increased to 16%. Conclusions 
were that CA-MRSA were spreading throughout Australia and the PVL 
determinant was present in two of the most common CA-MRSA (Qld clone and 
WSPP) (Nimmo et al. 2006).  
 
Table 1.2 Major CA-MRSA in Australia 2000-2004 
 
Strain 2000 2004 
Total CA-MRSA 4.7% 7.3% 
WA MRSA-1 18% 16% 
Qld Clone 5% 15% 
WSPP 13% 7% 
PVL positive CA-MRSA NA 46% 
 
Abbreviations: NA, Not Available 
 
 
By 2006, WA MRSA-1 (ST1-MRSA-IV) was the most prevalent CA-MRSA 
isolated throughout Australia, and was seen in higher numbers in WA. The Qld 
clone was the second most common CA-MRSA with WSPP third. Both Qld 
Clone and WSPP predominated in Brisbane and Sydney (Nimmo et al. 2006) 
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By 2008, there was a significant rise in the incidence of MRSA in Australia due 
mainly to the emergence of CA-MRSA. Of 3,075 S. aureus isolates, 18% were 
classified as MRSA, with 62.2% CA-MRSA and 37.8% HA-MRSA. The HA-
MRSA were ST22-MRSA-IV, the most predominant at 54.1%, followed by 
ST239-MRSA-III at 44.9% (Aus-2 and Aus-3 combined), ST5-MRSA-II (New 
York/Japan) 0.5% and ST36-MRSA-II (EMRSA-16) 0.5% (AGAR 2009). 
 
Twenty two CA-MRSA clones were identified with the Qld clone being the most 
prevalent. The top six, which comprise 90.6% of total CA-MRSA studied in 2008, 
are presented in Table 1.3. 
 
 
Table 1.3 The Most Prevalent CA-MRSA in Australia 2008 
 
Clone Alternative Name % of CA-MRSA 
ST93-MRSA-IV (2B) Qld  CA-MRSA 44.1% 
ST1-MRSA-IV (2B) WA MRSA-1 18.5% 
ST30-MRSA-IV (2B) WSPP CA-MRSA 13.8% 
ST5-MRSA-IV (2B) WA MRSA-3 5.9% 
ST78-MRSA-IV (2B) WA MRSA-2 5.3% 
ST8-MRSA-IV (2B) USA 300 2.9% 
 
 
PVL positive clones made up 64.7% of CA-MRSA. The top five are presented in 
Table 1.4. 
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Table 1.4 The Most Prevalent PVL Positive CA-MRSA in Austalia 2008 
 
Clone Alternative Name No. of Isolates 
ST93-MRSA-IV (2B) Qld CA-MRSA 149 
ST30-MRSA-IV (2B) WSPP CA-MRSA 46 
ST8-MRSA-IV (2B) USA 300 10 
ST80-MRSA-IV (2B) European CA-MRSA 2 
ST59-MRSA-VT 
(5C2&5) Taiwan CA-MRSA 1 
 
 
By 2009 there had been a 136% increase in the number of CA-MRSA Australia-
wide, with the PVL positive Qld clone, being the most prevalent (AGAR 2009). 
 
 
1.2.5 Community MRSA - Western Australia 
 
In 1982, an infection control policy was introduced in WA, which required all 
new staff and patients who had been in a hospital in the previous year, outside 
WA, to be screened for MRSA and the isolates be sent to a central laboratory for 
epidemiological typing and storage. Positive patients were decolonised and were 
not admitted to general wards until they returned three negative swabs (Pearman 
et al. 1985). This was in response to an incident in which a patient who was 
infected with an MRSA was transferred from another state into Royal Perth 
Hospital. An outbreak resulted with numerous patients and staff being infected or 
colonised. The policy has been very successful in preventing serious outbreaks of 
MRSA within WA hospitals and also in maintaining a low incidence of HA-
MRSA (Pearman et al. 1985; Nimmo et al. 2006). It has not, however, prevented 
the emergence of CA-MRSA in the wider WA community (Coombs et al. 2006). 
 
While the first community MRSA reported in Australia, were isolated in remote 
Indigenous communities in the north of Western Australia (Udo, Pearman, and 
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Grubb 1993; O'Brien et al. 2004) the same clones were later identified in Perth, 
the state capital (Coombs et al. 2006). These clones are now known as WA 
MRSA-1 ST1-MRSA-IVa (2B), WA MRSA-2 ST78-MRSA-IVa (2B), WA 
MRSA-3 ST5-MRSA-IVa (2B), WA MRSA-4 ST45-MRSA-V (5C2) and WA 
MRSA-5 ST8 MRSA-IVa (2B). 
 
Between the years 1983-1992 a total of 631 notifications of MRSA were recorded, 
ranging from 36 in 1988 and increasing to 117 in 1992. It was noticed that there 
was a significant increase in numbers after 1989 of WA MRSA, now known as 
CA-MRSA, especially from the remote Kimberley region. Strains were classified 
as either EMRSA or WA MRSA solely according to their antimicrobial resistance 
profile. A panel of eight antibiotics; Gentamicin, Erythromycin, Tetracycline, 
Trimethoprim, Rifampicin, Fusidic acid, Ciprofloxacin and Mupirocin, was used 
to distinguish CA-MRSA from HA-MRSA. Strains resistant to two or less of the 
antibiotics were regarded as being non-multi-resistant, strains resistant to three or 
more of the antibiotics were regarded as being multi-resistant (Riley and Rouse 
1995). 
 
MRSA notification data 1994-1997 showed that numbers of EMRSA remained 
quite stable during this period while WA MRSA (CA-MRSA) increased. In 1994 
there was a total of 327 MRSA notifications, with 86% being WA MRSA. By 
1997, there were 998 notifications of MRSA with 93% being WA MRSA. There 
was an increase in fusidic acid resistance from 4.6% in 1994 to 12.4% in 1997, 
due to the availability of topical fusidic acid treatment. Conversely, mupirocin 
resistance decreased from 6.4% in 1994 to 0.3% in 1997, due to a change in 
policy which restricted the use of mupirocin. This study also differentiated 
EMRSA and WA MRSA according to their antibiotic resistance profiles 
(Torvaldsen, Roberts, and Riley 1999). 
 
In 1995, a single-strain CA-MRSA outbreak occurred in a major Perth hospital in 
WA in which the index case was a patient from a remote WA community. 
Screening two communities in the region where the patient had come from 
revealed that 39% of people in one community and 17% in the second community 
were carriers of a CA-MRSA identical to the outbreak strain. The MRSA was 
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named WA-MRSA-1 (O'Brien et al. 1999) and subsequently was shown to be of 
the ST1-MRSA-IVa (2B) genetic lineage (O'Brien et al. 2004). 
 
By 2004, 26 different CA-MRSA types had been identified in WA, 25 were 
designated as WA-MRSA with the 26th being ST30-MRSA-IVa (2B) or WSPP 
and it appeared that resistance was emerging in CA-MRSA. The Gram Positive 
Bacteria Typing and Research Unit (GPBTRU) analysed 4,099 MRSA isolates 
from July 2003 to December 2004 with 77.5% being CA-MRSA. A sub-group of 
22 CA-MRSA were characterised further by MLST, staphylococcal cassette 
chromosome mec (SCCmec) typing and PFGE. MLST determined 10 clonal 
complexes and two singleton groups. The two predominant CA-MRSA clones 
identified were ST1-MRSA-IV (WA MRSA-1), 55.3% and ST78-MRSA-IV (WA 
MRSA-2), 29.8%. Five PVL positive strains were identified. 44% of CA-MRSA 
were resistant to β-lactam antibiotics only, 54.5% were non-multi-resistant and 
1.5% were multi-resistant. Conclusions were that some CA-MRSA have become 
multi-resistant. Of concern was the number of PVL positive clones, with the 
apparent emergence of PVL in a previously PVL negative CA-MRSA clone 
(Coombs et al. 2006). 
 
By mid 2006, 45 CA-MRSA clones had been identified. These were characterised 
by phenotype and genotype with analysis including SCCmec, MLST, PFGE and 
staphylococcal protein A (spa) type.  In 2007, an increase in ST93-MRSA-IV 
(Qld clone) was seen in WA, with surveillance studies showing the Qld clone 
currently the third most prevalent CA-MRSA in WA following ST1-MRSA-IV 
(WA MRSA-1) and ST78-MRSA-IV (WA MRSA-2) (GPBTRU 2008). 
 
In 2010 the GPBTRU was renamed the Australian Collaborating Centre for 
Enterococcus and Staphylococcus Species (ACCESS) Typing and Research. 
 
At the end of 2011, 108 CA-MRSA clones had been identified (ACCESS Typing 
and Research unpublished data). 
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1.3 Antibiotic Resistance 
 
Antibiotic-resistant organisms cause an increasing healthcare burden with 
increasing healthcare costs, morbidity and mortality (Jones and Pfaller 1998). The 
spread of antibacterial-resistant organisms can be related to selective pressure 
caused by the overuse of antibiotics in medicine, agriculture, fisheries and animal 
feed (Trzcinski et al. 2000). The use of invasive devices and procedures and less 
than adequate infection control procedures in healthcare facilities leads to the 
transmission of resistant organisms (Jones and Pfaller 1998).  
 
S. aureus is an adaptable pathogen that gains resistance and virulence factors as a 
result of horizontal gene transfer due to the selective pressures caused by the miss-
use and over-use of antimicrobials in hospital and health care environments. 
These organisms have then found their way into the community (Chambers and 
DeLeo 2009). Controlling the spread of MRSA requires effective polices for both 
infection control and antibiotic usage (Trzcinski et al. 2000). 
 
CA-MRSA are usually resistant to β-lactam antibiotics only. Multi-resistance, 
associated with HA-MRSA, such as ST239-MRSA-III (3A), commonly known in 
Australia as Aus-3, is not often seen in CA-MRSA. There is, however, concern 
that multi-resistance may develop among CA-MRSA and place an additional 
burden on community and health-care systems. Although most CA-MRSA 
currently do not spread readily in hospitals, the combination of multi-resistance 
and virulence in CA-MRSA would be a serious situation should they become 
endemic in hospitals (Grundmann et al. 2006). PVL positive CA-MRSA such as 
the Taiwan clone and USA300 are currently regarded as non-multi-resistant 
strains however, there is great concern should these clones become multi-resistant. 
A multi-resistant PVL positive CA-MRSA strain ST772-MRSA-V (5C2) has been 
reported with its origin thought to be India or Bangladesh (Afroz et al. 2008). This 
strain has been reported in Europe, USA and Australia (D'Souza, Rodrigues, and 
Mehta 2010). In WA it was first identified in 2007 as WA MRSA-60 and in 2010 
it was designated as the Bengal Bay clone (ACCESS 2011). 
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In bacteria, antibiotic resistance is mediated via three main mechanisms: 
1. Inactivation of the antibiotic as seen with resistance to β-lactam and 
aminoglycoside antibiotics. 
2. Exclusion of the antibiotic from the target by efflux as seen with resistance 
to ciprofloxacin, erythromycin and tetracycline. 
3. Target modification as seen with resistance to ciprofloxacin, erythromycin, 
mupirocin, rifampicin, fusidic acid and tetracycline (McCallum, Berger-
Bächi, and Senn 2009). 
 
Acquisition of resistance determinants may be associated with a physiological 
fitness cost or burden on the bacterial cell. Bacterial clones may compensate with 
other chromosomal functions to alleviate this fitness loss which may reduce the 
cell’s viability, however, the cell is able to survive, become multi-resistant and 
cause further disease. Bacterial strains may also be able to regulate the expression 
of the resistance determinants in the absence of the antibiotic to conserve fitness 
to the cell (McCallum, Berger-Bächi, and Senn 2009). 
 
Antimicrobial agents, mechanisms of action, mechanisms of resistance, genetic 
determinants of resistants and genetic locations are summarised in Table 1.5. 
 
 
1.3.1 Penicillin 
 
Penicillin is a naturally occurring antimicrobial agent initially obtained from the 
fungus Penicillium notatum and commercially from P. chrysogenum and has been 
in use as an antibiotic since the 1940s (Hoephrich 1968; Stefaniak et al. 1947). 
Penicillin contains a β-lactam ring structure consisting of four atoms and belongs 
to the β-lactam group consisting of penicillin and derivatives such as methicillin 
and cephalosporins. Penicillin is a generic term for benzylpenicillin (Penicillin G), 
procainepenicillin (procaine penicillin), benzathine benzylpenicillin (benzathine 
penicillin) and phenoxymethylpenicillin (Penicillin V) (Hoephrich 1968). 
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1.3.1.1 Mechanism of Action 
Penicillin has a bactericidal activity by inhibiting the synthesis of the 
peptidoglycan layer of the bacterial cell wall. The β-lactam ring structure of 
penicillin mimics the D-alanyl-D-alanine terminal amino acid residue of the 
pepdidoglycan layer and will bind in its place to the active site of penicillin-
binding proteins (PBPs). This prevents the final cross-linking or transpeptidation 
of the peptidoglycan layer and disrupts cell wall synthesis, which results in a build 
up in peptidoglycan precursors without new peptidoglycan being made which then 
leads to the eventual death of the cell (Waxman, Yocum, and Strominger 1980). 
 
1.3.1.2 Mechanism of Resistance 
Resistance to penicillin is due to the production of the enzyme β-lactamase or 
penicillinase, which hydrolyses the β-lactam ring of the antibiotic, deactivating its 
antibacterial properties (Geronimus and Cohen 1958; Imsande 1978). β-lactamase 
is the product of the blaZ gene, which is regulated by blaR1-blaI inducer-
repressors (Wang, Projan, and Novick 1991). The genetic determinant for β-
lactamase production is mostly located on plasmids and often transposes into the 
chromosome (Novick 1989). 
 
 
1.3.2 Methicillin 
 
Methicillin is a semi-synthetic, β-lactam antibiotic with narrow spectrum activity. 
Methicillin was first developed in 1959 to treat infections caused by penicillin-
resistant S. aureus (Stewart and Holt 1963). Methicillin is structurally different 
from benzylpenillicin with the addition of methoxy groups to the phenol group. 
This produces a steric hindrance around the amide bond and reduces the affinity 
for staphylococcal β-lactamases (Stapleton and Taylor 2002).  
 
Methicillin is no longer used as a therapeutic agent and has been replaced by other 
semi-synthetic penicillins such as flucloxacillin and dicloxacillin (Fluit and 
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Schmitz 2003). For clinical antimicrobial susceptibility testing, oxacillin is more 
stable than methicillin and more likely to detect heterogeneous strains, however 
cefoxitin resistance tests are easier to read than oxacillin as it is a better inducer of 
the mecA gene, and will give a clearer endpoint with disc diffusion testing (Brown 
2001; Skov et al. 2003; Felton et al. 2002). 
 
1.3.2.1 Penicillin-Binding Proteins 
The cell wall of S. aureus forms a protective barrier against the environment, 
contributes to colonisation, virulence and resistance and maintains the bacterial 
shape, especially against high internal osmotic pressure. Structurally the cell wall 
is composed of multi-layers of highly cross-linked peptidoglycan, with teichoic 
acids covalently linked to the peptidoglycan. Also found are membrane-associated 
proteins, peptidoglycan-anchored surface proteins and extracellular-
polysaccharide matrices, all of which contribute to the properties of the bacterial 
cell surface (Georgopapadakou, Dix, and Mauriz 1986; Pinho, De Lencastre, and 
Tomasz 2001). The peptidoglygan, which is the major component, is a 
macromolecular network of glycan strands cross-linked through short peptides. 
The glycan strands are comprised of chains of alternating amino sugars, N-
acetylglucosamine (NAG) and N-acetylmuramic acid (NAM) connected by a β-
(1,4)-glycosidic bond. A short amino acid chain is attached to the NAM amino 
sugar residue, containing L-Ala-iD-Glu-γ-L-Lys-D-Ala peptide units (Giesbrecht 
et al. 1998; Berger-Bächi and Tschierske 1998). A pentaglycine side-chain is 
found at the lysine amino group, that allows three-dimensional cross-linking of 
the multi-layered peptidoglycan, and can also be an attachment site for cell wall 
anchored surface proteins, such as the plasmin-sensitive protein, Pls (Schneewind, 
Fowler, and Faull 1995; Foster and Höök 1998). See Figure 1.1.  
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Figure 1.1 The Peptidoglycan Layer 
Abbreviations: NAG, N-acetylglucosamine; NAM, N-acetylmuramic acid  
This figure is from Google Images with permission for use in the public domain 
by the author Mouagip. 
 
Continual production and processing of peptidoglycan components are essential 
for cell-wall synthesis, with PBPs essential in the last extracellular enzymatic 
reactions. Five different PBPs have been found in S. aureus, PBP1, PBP2, PBP3, 
PBP4 and PBP2a/2' (Georgopapadakou, Dix, and Mauriz 1986). 
 
PBP1 is a protein of 85 kDa encoded by the pbpA gene. The function of PBP1 is 
unclear, but it is thought to be essential for cell wall growth with a partial function 
in the synthesis of the peptidoglycan septum (Wada and Watanabe 1998; 
Komatsuzawa et al. 1999). 
 
PBP2 is a protein of 81 kDa encoded by the pbpB gene. PBP2 is bifunctional with 
transpeptidase and transglycosylase activities. Transpeptidase is essential for the 
cross-linkage formation in the peptidoglycan layer (Wada and Watanabe 1998; 
Pinho, De Lencastre, and Tomasz 2001). 
 
PBP3 is a protein of 75 kDa encoded by the pbpC gene and is thought to be non-
essential for cell growth. PBP3 is thought to be a peptidoglycan transpeptidase 
involved in septum formation similar to PBP1 (Wada and Watanabe 1998; Pinho, 
De Lencastre, and Tomasz 2001). 
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PBP4 is a protein of 45 kDa encoded by the pbpD gene, which is associated with 
an ATP-binding transporter gene. PBP4 is bifunctional with carboxypeptidase and 
transpeptidase activities. While considered not essential for cell growth, 
overproduction of PBP4 has been shown to increase β-lactamase resistance 
(Komatsuzawa et al. 1999; Domanski and Bayles 1995). 
 
PBP2a/2' is a protein of 78 kDa encoded by the mecA gene found in the genomic-
resistance island, the staphylococcal cassette chromosome mec (SCCmec). 
PBP2a/2' confers intrinsic resistance to all β-lactams and their derivatives. 
PBP2a/2' has a low affinity for binding β-lactam antibiotics, due to an altered 
active site and is able to continue transpeptidation activity of PBP2 at 
concentrations of antibiotics that might otherwise be lethal (Chambers 1997; 
Berger-Bächi and Rohrer 2002). 
 
1.3.2.2 Mechanism of Action 
Methicillin and other β-lactam antibiotics act by inhibiting the synthesis of the cell 
wall by preventing cross-linkages between the peptidoglycan polymer chains. 
They are structural analogues of D-alanyl-alanine that competively bind and 
inhibit the transpeptidase enzyme PBPs ability, by acylation, to cross-link the D-
alanyl-alanine peptide used in peptidoglycan synthesis (Chambers 1997). 
 
1.3.2.3 Expression of Resistance 
Resistance to methicillin occurs with the acquisition of the genomic resistance 
island SCCmec which contains the mecA gene, encoding the protein PBP2a/2'. 
PBP2a/2' is able to continue with cell wall synthesis in the presence of methicillin. 
The expression of methicillin resistance has been seen to be heterogeneous, 
homogeneous or borderline with factors both genetic and environmental affecting 
and influencing methicillin resistance (Berger-Bächi and Rohrer 2002). 
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1.3.2.3.1 Homogeneous Resistance 
Homogeneous resistance to methicillin occurs where all the cells in a population 
are uniformly resistant to high concentrations of methicillin (>128 mg/L). 
Homogeneous resistance appears not to be influenced by the level of PBP2a/2' 
produced indicating that other factors are involved. A chromosomal mutation(s) 
chr* that occurs outside the SCCmec is thought to be responsible for the 
conversion of a heterogeneous cell population to a homogenous cell population 
(Ryffel et al. 1994; Chambers 1997). 
 
1.3.2.3.2 Heterogeneous Resistance 
The heterogeneous resistance of methicillin is seen when the majority of cells 
within a population (typically 99% or more) express a wide variation of resistance 
levels (1-5 µg/ml methicillin), with a smaller population resistant to methicillin at 
higher concentrations (> 50 µg/ml). The in vivo degree of heterogeneity varies 
according to the sub-clone of the strain, culture conditions and the β-lactam 
antibiotic being used (Matthews and Stewart 1984; Hartman and Tomasz 1986) 
 
1.3.2.3.3 Borderline Resistance 
Borderline or low-level methicillin resistance is characterised by a minimum 
inhibitory concentration (MIC) at, or just above, the susceptibility breakpoint 
(oxacillin MIC 4-8 µg/ml). Borderline strains may or may not have mecA present. 
Borderline strains that contain mecA are heterogeneous and will have a small sub-
population that can grow at high antibiotic levels. Borderline strains that do not 
contain mecA are thought to result from alterations in PBP genes or an over-
production of β-lactamase (McDougal and Thornsberry 1986; Hackbarth et al. 
1995; Chambers 1997). 
 
1.3.2.3.4 Eagle-Type Resistance 
Eagle-type methicillin resistance was found only in experimental mutants of strain 
N315 (h4), ST5-MRSA-II (2A). The eagle-type resistance characteristically 
showed resistance to high concentrations of methicillin (64-512 µg/ml) and 
susceptibility at lower concentrations of methicillin (2-16 µg/ml). Two novel 
genes hmrA and hmrB were detected, which conferred homogeneous-methicillin 
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resistance. A homogeneous to heterogeneous resistance conversion occurred when 
these genes were transferred to strain LR5 via multi-copy plasmids, strongly 
indicating that genetic alteration is responsible for heterogeneous to homogeneous 
conversion of methicillin resistance in S. aureus (Kondo et al. 2001). 
 
1.3.2.3.5 Environmental Factors Affecting In Vitro Resistance 
The degree of methicillin resistance is influenced by environmental factors and 
cultural conditions such as temperature, osmolality, pH, light, anaerobiosis, 
chelating agents, metal ions and previous exposure to β-lactam antibiotics 
(Matthews and Stewart 1984). Discrepant results may be seen between MICs 
conducted at 30ºC and 37ºC. Changes in osmolality of media with sodium 
chloride, ammonium sulphate or sucrose can have an effect on the expression of 
methicillin resistance of MRSA strains. Increases in sucrose and these salts will 
increase the resistance of MRSA strains. The pH has a major effect on methicillin 
resistance with MICs in broths at pH5.2 being reduced by as much as 128-fold. 
Visible light affects methicillin resistance in those strains that don’t produce 
pigment, with highly pigmented strains not affected. Chelating agents/metal ions 
have been shown to have varying effects on resistance to methicillin. Chelating 
agents such as EDTA reduce MICs while addition of metal ions such as 
magnesium will increase the MIC.  Anaerobic conditions result in an increase in 
methicillin MICs.  
 
1.3.2.3.6 Genetic Factors Affecting Resistance 
Chromosomal genes outside of the SCCmec have been found to be associated 
with the expression of methicillin resistance. These genes have been identified by 
transposon insertional mutagenesis producing susceptible mutants. Factors 
essential for methicillin resistance (fem) or auxiliary (aux) factors have been found 
in both methicillin-sensitive and -resistant strains. Over 20 fem or aux factors have 
been found (Chambers 1997; Berger-Bächi and Rohrer 2002). 
 
1.3.2.3.7 fem AB operon 
The femAB operon has the greatest impact on the methicillin-resistance levels. 
The femAB operon is thought to be a duplication of sequences that code for two 
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similar cytoplasmic proteins each of 49 kDa, which are required for the formation 
of the pentaglycine interpeptide bridge cross-link of peptidoglycan. femA is 
responsible for glycines Gly2-Gly3 and FemB for Gly4-Gly5. femB mutants 
produce cross-links with only three glycines, while femA mutants only produce a 
monoglycine interpeptide bridge and do not incorporate the second and third 
glycines into the bridge. The resulting poor peptidoglycan cross-linking and 
reduced cell wall turnover results in the cell becoming hyper-susceptible to 
methicillin and other β-lactams, with PBP2a/2' losing its function even though it is 
still being produced (Henze et al. 1993; Strandén et al. 1997). 
 
1.3.2.3.8 femX 
femX or fmhB, like femAB, is involved with pentaglycine interpeptide bridge 
formation, being responsible for the attachment of the first glycine residue Gly1 to 
the stem peptide (Rohrer et al. 1999). 
 
1.3.2.3.9 femC 
femC was identified by a Tn551 insert in the gene glnR which encodes a 
glutamine synthetase repressor and is found in the glnRA operon. This insertion 
results in a reduction in glutamine synthesis due to a polar effect in glnA 
transcription, leading to reduced glutamine availability and reduced amidation of 
iD-glutamate of the stem peptide in the peptidoglycan pentapeptide. The cell wall 
will have reduced peptidoglycan cross-linking and reduced methicillin resistance 
(Gustafson et al. 1994). 
 
1.3.2.3.10 femD 
femD (femR or glmM) was identified by a Tn551 insert in the gene glmM, which 
encodes phosphoglucosamine mutase and functions by catalysing the inter-
conversion of glucosamine-6-phosphate to glucosamine-1-phosphate, a 
cytoplasmic peptidoglycan precursor. Inactivation of femD results in reduced 
methicillin resistance (Jolly et al. 1997). 
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1.3.2.3.11 femE 
The function of femE is unknown with its inactivation only slightly reducing 
methicillin resistance. femE was identified by a Tn551 insert (De Lencastre et al. 
1994). 
 
1.3.2.3.12 femF 
femF (murE) mutation results in an abnormality in peptidoglycan composition 
with the absence of the unsubstituted pentapeptide and incorporation of 
alanylglutamate and alanylisoglutamate into the muropeptide, before the lysine 
addition step. This results in reduced methicillin resistance (Ornelas-Soares et al. 
1994). 
 
1.3.2.3.13 fmtA 
fmtA encodes a cell wall associated protein containing two of three conserved 
motifs typically found in PBPs and β-lactamases. Mutants of fmtA show reduced 
amidation of glutamate residues and reduced cross-linking in the peptidoglycan, 
and reduce methicillin resistance (Komatsuzawa et al. 1999). 
 
1.3.2.3.14 fmtB 
fmtB (mrp) encodes a cell surface protein, that when inactivated affects the 
monomer section of the cell wall muropeptide and the disaccharide-pentapeptide-
pentaglycyl-monomer is converted to an unsubstituted pentapeptide. This reduces 
methicillin resistance (Wu and De Lencastre 1999). 
 
1.3.2.3.15 fmtC 
fmtC (mprF) encodes a hydrophobic membrane-associated protein, that when 
inactivated reduces the modification of the membrane lipid phosphatidyl-glycerol 
with L-lysine, resulting in a reduced negative charge on the membrane surface. 
This reduces methicillin resistance (Peschel et al. 2001). 
 
1.3.2.3.16 llm 
llm encodes a 38 kDa hydrophobic membrane-associated protein, TarO (TagO) 
which catalyzes the first step in teichoic acid synthesis (Swoboda et al. 2010). llm 
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was identified by insertional inactivation by Tn918 carrying a tetracycline-
resistance marker. Inactivation of llm reduces growth and changes homogeneous 
methicillin resistance to the heterogeneous phenotype. In some strains inactivation 
of llm increases autolysis and reduces resistance (Maki, Yamaguchi, and 
Murakami 1994). 
 
1.3.2.3.17 lytH 
The lytH gene encodes a lytic enzyme that has homology to a cell-wall 
hydrolysing enzyme. Deletion or inactivation of lytH results in high levels of 
methicillin resistance (Fujimura and Murakami 1997). A recent study showed the 
inactivation of the lytH gene by the insertion of IS1182 (Fujimura and Murakami 
2008). 
 
1.3.3 Gentamicin 
 
Gentamicin is a broad spectrum antibiotic with bactericidal activity first 
discovered in 1944. The chemical structure of gentamicin is comprised of 
aminated sugars joined to a dibasic cyclitol. Gentamicin belongs to the 
aminoglycoside group of antibiotics along with tobramycin, kanamycin and 
streptomycin (Kotra, Haddad, and Mobashery 2000) and often acts in synergy 
when used in combination with another antibiotic. 
 
1.3.3.1 Mechanism of Action 
Gentamicin, along with all aminoglycosides, acts by inhibiting protein synthesis 
by binding to the 30S ribosomal subunit at the 16S rRNA component. This action 
results in a misreading of mRNA codons which is thought to result in the 
production of faulty proteins, or disruption of the cell membrane in some way 
(Hancock 1981; Lyon and Skurray 1987). 
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1.3.3.2 Mechanism of Resistance 
The mechanism of resistance to aminoglycosides is via inactivation by 
aminoglycoside-modifying enzymes, acetyltransferase (AAC), phosphotransferase 
(APH) and nucleotidyltransferase (ANT) or adenytransferase (AAD) either singly 
or in combinations. Resistance to gentamicin is mediated by AAC(6′) – APH(2″) 
which is encoded by the aac(6′)+aph(2″) genes (Lyon and Skurray 1987). The 
genes encoding the aminoglycoside-modifying enzymes for gentamicin are 
commonly located on transposon Tn4001, which is found on the chromosome and 
on many plasmid types (Wood, Carter, and Best 1977; Kayser, Homberger, and 
Devaud 1981; Lyon and Skurray 1987). It has been shown that Tn4001 is found 
inserted at various chromosomal locations including within the SCCmec 
(Gillespie et al. 1987; Heusser et al. 2007). The plasmid types where Tn4001 may 
be found include the pSK1 family, conjugative plasmids such as pSK41 and 
occasionally on β-lactamase/heavymetal resistance plasmids (Gillespie et al. 
1987). 
 
1.3.4 Tetracycline 
 
Tetracyclines are a broad spectrum class of antibiotic that have a bacteriostatic 
action against bacteria. Tetracycline is derived from the soil bacterium, 
streptomycetes, and was discovered in the late 1940s. The originally developed 
tetracyclines are known as first generation tetracyclines. Later, second generation 
tetracyclines were developed, such as doxycycline and minocycline (Chopra and 
Roberts 2001). Third generation tetracyclines, now being developed, are known 
are glycylcyclines, such as tigecycline (Chopra 2001). 
 
1.3.4.1 Mechanism of Action 
Tetracycline inhibits bacterial protein synthesis by reversibly binding to a high 
affinity site on the 30S subunit of the bacterial ribosome. This action blocks the 
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binding of aminoacyl-tRNA to the acceptor site on the ribosome, preventing 
protein synthesis (Buck and Cooperman 1990). 
 
1.3.4.2 Mechanisms of Resistance 
There are two mechanisms of resistance: active efflux of the antibiotic from the 
cell and ribosomal protection. 
 
1.3.4.2.1 Active Efflux 
Resistance to tetracyclines by active efflux occurs when efflux genes code for 
membrane-bound proteins to export tetracycline out of the bacterial cell. The third 
generation glycylcyclines are not affected by these proteins (Trzcinski et al. 2000; 
Chopra and Roberts 2001). These membrane-bound proteins are encoded by genes 
tet(K) and tet(L) and belong to the major facilitator superfamily (MFS). These 
genes are often found on small plasmids such as pT181 (Khan and Novick 1983; 
Guay, Khan, and Rothstein 1993). The tet genes may also become integrated into 
larger staphylococcal plasmids or into the bacterial chromosome (Chopra and 
Roberts 2001). Plasmid pT181 also integrates into the chromosome and is found 
in the SCCmec (Gillespie, May, and Skurray 1986).  
 
1.3.4.2.2 Ribosomal Protection 
Tetracycline resistance occurs when ribosomal protection proteins bind to the 
bacterial ribosome thereby removing any bound tetracycline by the hydrolysis of 
GTP. This action allows continuing protein synthesis and results in resistance to 
tetracycline (Lyon and Skurray 1987). The genes that encode the ribosomal 
protection proteins in S. aureus are tet(M) and tet(O), and they are located on a 
transposon or on the chromosome (Khan and Novick 1983; Nesin et al. 1990). 
The tet(M) gene is found on the putative conjugative transposon Tn5801 which is 
found on the S.aureus chromosome (Kuroda et al. 2001). 
 
S. aureus with the tet(K) gene only have been found to be resistant to tetracycline 
but sensitive to minocycline, while the tet(M) gene confers resistance to all the 
drugs in the group (Bismuth et al. 1990). The presence of both tet(K) and tet(M) 
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has been shown to result in a higher MIC for tetracycline resistance than in strains 
carrying just one of the genes (Schmitz et al. 2001). 
 
 
1.3.5 Erythromycin 
 
Erythromycin is a naturally occurring antimicrobial agent obtained from 
Streptomyces erythreus and has been in use as an antibiotic since the early 1950s 
(Fluit and Schmitz 2003). Erythromycin is a macrolide with a 14 membered-ring-
structure, and belongs to the macrolide-lincosamide-streptogramin B group 
(MLSB) of antibiotics (Douthwaite and Champney 2001). 
 
1.3.5.1 Mechanism of Action 
Macrolides such as erythromycin have a bacteriostatic action on bacteria, by 
binding reversibly to the 50S bacterial ribosome subunit at the peptidyl transferase 
region resulting in the inhibition of protein synthesis (Champney and Tober 
2000). A second action of macrolides prevents the assembly of functionally active 
50S subunits. This results in the accumulation of the 50S subunit precursor 
particles which are then degraded by cellular ribonucleases (Champney and 
Burdine 1998). 
 
1.3.5.2 Mechanism of Resistance 
There are four mechanisms of bacterial resistance to erythromycin: target site 
modification, antibiotic modification, mutation and active efflux of the antibiotic 
from the cell (Weisblum 1995). 
 
1.3.5.2.1 Target Site Modification 
Target site modification occurs with the production of a resistance determinant 
known as erythromycin ribosome methylase encoded by the erm gene. This 
protein methylates the adenine residue A2058 in the peptidyltransferase region in 
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domain V of 23S rRNA. This prevents the binding of erythromycin to the 
bacterial ribosome and results in high-level resistance (Weisblum 1995). 
 
Expression of methylase genes can be either constitutive or inducible. Strains with 
constitutive resistance to erythromycin can show a cross-resistance to MLSB 
antibiotics. This occurs due to overlapping binding sites on the 50S subunit of the 
individual antimicrobial agents (Garrod 1957; Champney and Tober 2000). 
Strains with inducible MLSB resistance will be resistant to erythromycin, which is 
an inducer antibiotic, while appearing susceptible to a non-inducer antibiotic such 
as clindamycin. Exposure to erythromycin induces cross-resistance to all the 
MLSB antibiotics (Drinkovic et al. 2001; Daurel et al. 2008). This can be detected 
in vitro using a D-zone test. 
 
In S. aureus the most commonly found methylase genes are ermA and ermC 
(Westh et al. 1994). The ermA gene is found on the transposon Tn554 located on 
the staphylococcal cassette chromosome mec (SCCmec) and plasmids, while the 
ermC gene is found on plasmids (Thakker-Varia et al. 1987). 
 
1.3.5.2.2 Antibiotic Modification 
Resistance to erythromycin due to antibiotic modification or inactivation results 
with the production of phosphotransferases encoded by mph(C) (Leclercq 2002), 
or mph(BM) (Matsuoka et al. 1998). 
 
1.3.5.2.3 Target Site Mutation 
Resistance to erythromycin due to mutations has been recorded, although rare. 
This was seen with erythromycin resistance and mutations in rrl and rplV genes 
on 23S rRNA in S. aureus from cystic fibrosis patients (Prunier et al. 2002). 
 
1.3.5.2.4 Antibiotic Efflux 
Active efflux of the antibiotic from the cell is another mode of resistance. The 
efflux proteins known as ABC transporters are encoded by msrA genes found on 
plasmids. ABC transporters require ATP to function and are comprised of two 
                                                                                        Literature Review  
 31
membrane-spanning domains and two ATP-binding domains (Ross et al. 1990; 
Leclercq 2002). 
 
 
1.3.6 Ciprofloxacin 
 
Ciprofloxacin is a synthetic antimicrobial from the fluoroquinolone group, with its 
mode of action directed against bacterial DNA replication (McCallum, Berger-
Bächi, and Senn 2009). Ciprofloxacin is a broad spectrum antimicrobial with good 
activity towards Gram-positive bacteria such as S. aureus (Fluit and Schmitz 
2003). Fluoroquinolones were developed in the mid 1980s with the addition of a 
fluorine atom to a quinolone. This resulted in the improvement of its antibacterial 
spectrum and pharmokinetics (Fluit and Schmitz 2003). Soon after, however, 
resistances were reported (Hooper 2002). 
 
1.3.6.1 Mechanism of action 
Ciprofloxacin targets two essential enzymes of the Type II DNA topoisomerase 
group, DNA gyrase and topoisomerase IV (Drlica and Zhao 1997). The action of 
ciprofloxacin blocks the replication fork, resulting in the breakage of the DNA 
strand, inhibition of DNA synthesis and death of the cell. 
 
1.3.6.1.1 DNA gyrase 
DNA gyrase is an enzyme that controls DNA supercoiling and relieves stresses 
during transcription and replication. This is achieved when the enzyme cuts 
strands of the DNA double helix, passing a strand through the resulting gap before 
the DNA is resealed. DNA gyrase is comprised of two subunits GyrA and GyrB 
encoded by the genes gyrA and gyrB respectively. The main function of DNA 
gyrase is to maintain the correct level of negative supercoiling in preparation for 
DNA replication, to remove knotted forms from the DNA and to help bend and 
fold DNA (Drlica and Zhao 1997; Fluit and Schmitz 2003). 
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1.3.6.1.2 Topoisomerase IV 
Topoisomerase IV is an enzyme that has a decatenating or separating action. 
Topoisomerase IV is comprised of two subunits, GrlA and GrlB encoded by the 
genes grlA and grlB respectively. The main feature of topoisomerase IV is its 
ability to decatenate DNA, by the breakdown of ATP, before replication is 
complete. This occurs where one DNA molecule passes through a cut made in a 
separate DNA molecule (Drlica and Zhao 1997; Fluit and Schmitz 2003). 
 
1.3.6.2 Mechanisms of Resistance 
 
1.3.6.2.1 Chromosomal Mutations 
The primary mechanism of resistance to ciprofloxacin and fluoroquinolones in S. 
aureus involves chromosomal mutations in the DNA gyrase genes (gyrA and 
gyrB) and/or topoisomerase IV genes (grlA and grlB). Studies have shown that 
ciprofloxacin resistance occurs as a stepwise selection, with higher-level 
resistance resulting with the combination of single point mutations within the grlA 
gene and grlB genes (Ferrero, Cameron, and Crouzet 1995; Schmitz, Jones, et al. 
1998). Furthermore, combinations of single point mutations with the gyrA gene 
show a higher-level resistance than a single point mutation within that gene 
(Takenouchi et al. 1995). This is also seen within the grlA gene (Schmitz, Jones, 
et al. 1998). This study by Schmitz et al. 1998, from 116 isolates, found 9 
combinations of amino acid changes resulting from single point mutations within 
grlA, grlB and gyrA. These changes were all associated with ciprofloxacin 
resistance. 
 
Ciprofloxacin, at low concentrations, is reported to be mutagenic due to its ability 
to damage bacterial DNA during transcription of the SOS and methyl-mismatch 
repair (MMR) genes (Mesak, Miao, and Davies 2008). 
 
Resistance to newer fluoroquinolones is at a much lower rate because they are less 
susceptible to the dual mutations within the gyrase and topoisomerase IV genes 
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than the older fluoroquinolones such as ciprofloxacin (McCallum, Berger-Bächi, 
and Senn 2009). 
 
1.3.6.2.2 Efflux Mediated Resistance 
Another process that causes ciprofloxacin resistance in S. aureus is via a 
chromosomally encoded efflux pump protein, NorA (Fluit and Schmitz 2003). 
NorA protects the cell from lipophilic and monocationic compounds such as 
ethidium bromide, centrimide, chloramphenicol as well as ciprofloxacin. The S. 
aureus NorA protein is a multi-drug transporter in the MFS (Truong-Bolduc, 
Zhang, and Hooper 2003) that depends on a transmembrane protein gradient for 
active efflux (Fluit and Schmitz 2003), which is essential to maintain a 
homeostatic environment in the bacterial cell.  
 
Efflux mediated resistance is usually seen as a lower-level resistance when 
compared with topoisomerase mutations. Resistance results from point mutation 
within a regulatory region 89 base pairs (bp) upstream of the norA gene rather 
than within the norA gene itself. The mutation increases the stability of norA 
mRNA by altering its structure causing an overexpression of the norA mRNA, 
resulting in the reduction of ciprofloxacin accumulation within the bacterial cell 
(Fluit and Schmitz 2003). 
 
1.3.6.2.3 Plasmid-Mediated Resistance 
To date, resistance of ciprofloxacin in S. aureus has been due to chromosomal 
mutation. No evidence has been shown to suggest plasmid-mediated resistance. 
There has previously been some suggestion of plasmid-mediated quinolone 
resistance in Gram-negative bacteria, Shigella dysentieriae (Ambler et al. 1993) 
and also Klebsiella pneumoniae (Jacoby, Chow, and Waites 2002). A possible 
suggestion for this is that in Gram-negative bacteria, the mode of resistance is 
mostly due to the action of DNA gyrase while in staphylococci, the mode of 
action is mostly due to topoisomerase IV (Drlica and Zhao 1997). Perhaps the 
dynamics between these two enzymes and their encoding genes lends itself to a 
predisposition to being either plasmid mediated as with Gram-negative bacteria or 
chromosomal, as with staphylococci. 
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1.3.7 Fusidic Acid 
 
Fusidic acid is a steroid-like antibiotic that is derived from the fungus Fusidium 
coccineum (Fluit and Schmitz 2003). 
 
1.3.7.1 Mechanism of Action 
Fusidic acid antibacterial action inhibits bacterial protein synthesis. This occurs 
when fusidic acid binds to the ribosome-elongation factor-G-GDP complex and 
prevents its dissociation from the ribosome. This prevents the next stage of protein 
synthesis, the entry of aminoacyl-tRNA species into the ribosomal A site (Willie 
et al. 1975; Besier et al. 2003). 
 
1.3.7.2 Mechanism of Resistance 
There are two mechanisms of resistance to fusidic acid: alteration of the antibiotic 
target site and protection of the antibiotic target site. 
 
1.3.7.2.1 Alteration of the Antibiotic Target Site 
Alterations of the antibiotic target site occur due to mutations in genes encoding 
elongation factor-G (EF-G)  This category includes FusA, FusA-SCV and FusE 
classes (Besier et al. 2003). 
 
The fusA gene encoding EF-G has a chromosomal location that has been shown to 
have a possible 30 different amino acid substitution mutations that result in fusidic 
acid resistance (Besier et al. 2003). These mutations occur mostly in domain III of 
EF-G and occasionally in domains I and V (Laurberg et al. 2000). 
 
FusA-SCV class resistance is a subset of the mutations in fusA, with most 
mutations located in domain V of EF-G. This is a small-colony variant (SCV) 
phenotype (Norstrom, Lannergard, and Hughes 2007). 
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FusE class resistance may also express the SCV phenotype. Fusidic acid 
resistance results following mutations in the rplf gene which encodes the 
ribosomal protein L6. Protein L6 interacts with EF-G (Norstrom, Lannergard, and 
Hughes 2007). 
 
1.3.7.2.2 Protection of the Antibiotic Target Site 
This mechanism of resistance to fusidic acid prevents the antibiotic from 
interacting with EF-G. The exact mechanism of the interaction is still unknown 
(O'Brien et al. 2002; O'Neill and Chopra 2006). This category includes FusB and 
FusC Classes of resistance.  
 
The fusB gene is found on a plasmid, pUB101, a 22kb class II staphylococcal 
replicon that also encodes penicillinase production and cadmium resistance 
(O'Neill and Chopra 2006). fusB has been reported in SCCmecN1, which is a 45.7 
kb SCC element consisting of a class B mec complex and a truncated Tn4003 that 
encodes resistance to trimethoprim (dfr) (Ender, Berger-Bächi, and McCallum 
2007). fusB has also been reported on a chromosomal location on a 16.6 kb 
genomic island designated SaRIfusB (S. aureus resistance island carrying fusB) 
(O'Neill et al. 2007).  
 
The gene fusC was found following the complete genome analysis of a S. aureus 
strain that revealed the existence of a novel staphylococcal cassette chromosome 
(SCC) designated SCC476 encoding fusC (Holden et al. 2004). 
 
 
1.3.8 Rifampicin 
 
Rifampicin is a broad spectrum antibiotic used mostly to treat Gram-positive 
bacteria. Rifampicin is a semi-synthetic antibiotic belonging to the family of 
rifamycins produced by the actinomycete Amycolatopsis mediterranea (Floss and 
Tin-Wein 2005). Rifampicin has strong activity, being most effective when used 
in combination with other antibiotics such as ciprofloxacin (Robertson et al. 
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2008), especially when treating a deep-tissue infection (Kunin 1996). Rifampicin 
is also effective when combined with fusidic acid for difficult to treat MRSA 
infections (Howden and Grayson 2006; Aboltins et al. 2007). 
 
1.3.8.1 Mechanism of Action 
Rifampicin binds to the bacterial RNA polymerase β subunit and prevents 
transcription. The RNA polymerase is encoded by the rpoB gene (Aboshkiwa, 
Rowland, and Coleman 1995). 
 
1.3.8.2 Mechanism of Resistance 
Resistance to rifampicin results after an alteration in the β subunit of the RNA 
polymerase that reduces the affinity of the antibiotic to bind to it. These 
alterations result from base pair mutations in the rpoB gene (Morrow and Harmon 
1979). A study in 1998, showed that rifampicin resistance levels are dependent on 
both the location and nature of the amino acid substitution (Aubrey-Damon, 
Soussy, and Courvalin 1998). 
 
 
1.3.9 Mupirocin 
 
Mupirocin is a topical antibiotic and commonly used for MRSA decolonisation 
practices. Originally known as pseudomonic acid, mupirocin is derived from 
Pseudomonas fluorenscens and is unrelated to any other antibiotics (Eltringham 
1997). 
 
1.3.9.1 Mechanism of Action 
Mupirocin is bacteriostatic but may be bactericidal at lower pH (Cookson 1998). 
Mupirocin acts as an inhibitor of protein synthesis by binding irreversibly at the 
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isoleucyl-tRNA synthetase (Iles) at a site near an ATP-binding sub-site 
(Yanagisawa et al. 1994).  
 
1.3.9.2 Mechanism of Resistance 
Resistance to mupirocin is expressed according to its MIC, and falls into two 
distinct categories of low-level resistance and high-level resistance (Eltringham 
1997). 
 
1.3.9.3 Low-Level Resistance 
Low-level resistance is defined by an MIC of ≥4 mg/L to <256 mg/L. Low-level 
resistance is not considered of clinical importance (Cookson 1998). The 
mechanism of resistance for low-level resistance to mupirocin is due to a 
chromosomal base change in the isoleuyl-tRNA sythetase gene iles (Antonio, 
McFerran, and Pallen 2002). 
 
1.3.9.4 High-Level Resistance 
High-level resistance is defined by an MIC of ≥256 mg/L. High-level mupirocin 
resistance has been found to be plasmid-borne via the mupA gene which codes for 
an alternative isoleucyl-tRNA sythetase that does not bind mupirocin (Udo, Jacob, 
and Mathew 2001). 
 
The occurrence of the genetic locations of these resistance determinants resulting 
in low-level or high-level resistance to mupirocin have also seen some exceptions. 
The gene for mupA has been detected on the chromosome expressing low-level 
mupirocin resistance (Ramsey et al. 1996) and a study in 2005, suggested that 
there could be a clonal transmission of the mupirocin mupA resistance determinant 
(Yoo et al. 2006). 
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Table 1.5 Antibiotic Resistance in S. aureus 
Antimicrobial 
Agent 
Mechanism 
of Action 
Mechanism 
of Resistance 
Genetic 
Determinant Location 
Methicillin Cell wall PBP2a/2' mecA C 
Gentamicin 
Inhibits 
protein 
synthesis 
Drug 
modification aacA-aphD C, Tn, P 
Tetracycline 
Inhibits 
protein 
synthesis 
Active efflux 
Active efflux 
Ribosomal 
protection 
tet(K) 
tet(L) 
tet(M) 
 
C, P 
P 
C, Tn 
 
Erythromycin 
Inhibits 
Protein 
Synthesis 
Target alteration 
ermA, ermB, 
ermC 
msrA 
C, Tn, P 
P 
Ciprofloxacin Inhibits DNA replication Target alteration 
grlA, grlB, 
gryA, grlB 
norA 
C 
C 
C 
Fusidic Acid 
Inhibits 
protein 
synthesis 
Target alteration fusA far1 
C 
P 
Rifampicin 
Inhibits 
protein 
synthesis 
Target 
alteration rpoB C 
Mupirocin 
Inhibits 
protein 
synthesis 
Target alteration mupA C, P 
Trimethoprim Inhibits folate synthesis Target alteration 
dfrA 
dfrC 
C, Tn, P 
P 
Vancomycin Cell wall 
Target alteration 
Thicken cell 
wall 
vanA 
VISA/GISA 
C, Tp 
C 
Abbreviations: C, Chromosome; P, Plasmid; Tn, Transposon 
 
1.3.10 Trimethoprim 
 
Trimethoprim is a synthetic antibacterial agent that was first used in the early 
1960s. It is a broad spectrum antimicrobial, being effective for both Gram-positive 
and Gram-negative micro-organisms. Trimethoprim is most effectively used in 
combination with sulphonamides due to a synergistic effect (Bushby and 
Hitchings 1968; Huovinen et al. 1995). 
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1.3.10.1 Mechanism of Action 
Trimethoprim affects bacterial folic acid synthesis by inhibiting dihydrofolate 
reductase (DHFR). This prevents the formation of tetrahydrofolate from 
dihydrofolate and blocks folic acid synthesis (Huovinen 2001). 
 
1.3.10.2 Mechanism of Resistance 
The mechanism of resistance to trimethoprim is via the production of a type S1 
trimethoprim-resistant DHFR, which is encoded by the dfrA gene (Dale et al. 
1995). This gene is located on transposon Tn4003, either on a plasmid, or on the 
chromosome (Lyon and Skurray 1987). Trimethoprim resistance can be high-level 
or low-level depending on the level of transcription of dfrA. A study has 
suggested the involvement of insertion sequence IS257, which flanks Tn4003, in 
variations in trimethoprim-resistance levels (Leelaporn et al. 1994). Trimethoprim 
resistance is a consequence of a point mutation in the dfrA gene resulting in an 
amino acid substitution of Phe to Tyr at position 98 of the DfrA molecule (Dale et 
al. 1997). 
 
A novel trimethoprim-resistance gene has been identified and designated dfrK. 
This gene was found on a plasmid that also contained the gene for tetracycline 
resistance in the porcine MRSA ST398 (Kadlec and Schwarz 2009). 
 
 
1.3.11 Vancomycin 
 
Vancomycin was first discovered in 1956. It is produced by the actinomycete 
Streptomyces orientalis that was cultivated from soil collected in Borneo. 
Vancomycin was introduced into clinical use in 1958 with the intention of 
treatment for penicillin-resistant S. aureus. Even though staphylococci did not 
develop significant resistance, use of vancomycin was limited for the next two 
decades, due to vancomycin needing to be administered intravenously, other β-
lactamase resistant antimicrobials such as methicillin and its successors being 
                                                                                        Literature Review  
 40
developed, and early impure forms of vancomycin being found to be toxic (Barna 
and Williams 1984).  
 
Vancomycin is a glycopeptide antibiotic that is comprised of large, rigid 
molecules containing glycosylated cyclic or polycyclic nonribosomal peptides. 
Other glycopeptide antibiotics include teicoplanin, telavancin, bleomycin, 
ramoplanin and decaplanin. Glycopeptides are narrow-spectrum antibiotics with 
activity against Gram-positive bacteria. Vancomycin is reserved as a last resort 
treatment for S. aureus, used when other antibiotics cannot be used due to multi-
resistance. Vancomycin-resistant organisms may be treated with newer 
antimicrobials, linezolid and daptomycin (Barna and Williams 1984). 
 
1.3.11.1 Mechanism of Action 
Vancomycin, like all glycopeptides acts by inhibiting a late step in cell wall 
peptidoglycan synthesis and cross-linking. Vancomycin acts by binding to the D-
alanyl-D-alanine terminus of the N-acetyl-muramyl-pentapeptide subunit and 
sterically hindering enzymatic reactions necessary for the formation of 
peptidoglycan chains (Barna and Williams 1984; Hiramatsu et al. 1997). 
 
1.3.11.2 Mechanism of Resistance 
Intermediate resistance to vancomycin occurs following acquired mutations 
resulting in thickening of the cell wall due to accumulation of excess amounts of 
peptidoglycan (Hiramatsu et al. 1997). 
 
Generally this type of vancomycin resistance is seen as intermediate, with a MIC 
of 8 mg/L, and is known as VISA for vancomycin-intermediate S. aureus or GISA 
for glycopeptide-intermediate S. aureus  (Hiramatsu et al. 1997). VISA/GISA 
resistance is associated with thickening and poorly cross-linked cell wall 
peptidoglycan, with increased D-alanyl-D-alanine dipeptide targets able to bind 
glycopeptide molecules. This form of glycopeptide resistance is due to multiple 
genetic alterations including genomic mutations and regulatory changes that may 
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also burden the cell with high fitness costs, causing slower growth and decreased 
expression of some virulence factors (Cui et al. 2003; McCallum et al. 2006). 
 
VISA/GISA organisms partially overcome the fitness costs by expressing 
heterogeneous resistance. Heterogeneous VISA/GISA (hVISA/hGISA) have a 
low resistance levels with MICs of 1-4 mg/L but are able to segregate sub-
populations of higher resistant organisms in the presence of glycopeptides, leading 
to vancomycin therapy failure (Hiramatsu et al. 1997). 
 
In enterococci high-level vancomycin resistance is seen with a MIC ≥ 32 mg/L, 
and is encoded by the vanA, vanB and vanD gene clusters. The first high-level 
vancomycin resistant S. aureus was recorded in 2002 from a dialysis patient in 
Michigan USA, who also harboured a vancomycin-resistant Enterococcus faecalis 
(VRE) with vanA (Chang et al. 2003). This first case of high-level vancomycin 
resistance had a recorded MIC of 1024 mg/L with the vanA operon found on a 
Tn1546-like element that was carried by a pSK41-like multi-resistance 
conjugative plasmid (57.9 kb) (Weigel et al. 2003). The van operon encodes 
enzymes VanH and VanA that synthesise an altered stem peptide D-alanyl-D-
lactate that replaces the D-alanyl-D-alanine residue reducing the affinity for 
glycopeptides 1000 fold (Bugg et al. 1991). The van operon contains seven van 
genes, vanR, vanS, vanH, vanA, vanX, vanY and vanZ. The vanR and vanS genes 
encode a two-component regulatory system that activates transcription of vanH, 
vanA and vanX. The genes vanH, vanA and vanX are essential for vancomycin 
resistance, with vanA encoding a ligase that acts on the D-2-hydroxyacid substrate 
which is produced by the dehydrogenase encoded by vanH, while vanX encodes a 
polypeptide with unknown function. The genes vanY and vanZ are not required for 
resistance (Arthur et al. 1993). 
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1.4 Vectors / Mobile Genetic Elements 
 
The acquisition of antibacterial resistance in S. aureus can be classified into two 
main mechanisms. The mutation of a bacterial gene on the chromosome or the 
acquisition of resistance-encoding genetic material, transferred from other 
bacteria, also known as horizontal gene transfer (Ito et al. 2003b). 
 
Mutations in a bacterial gene can result in antibacterial resistance. This is seen 
with mutations in DNA gyrase (gyr) and/or topoisomerase IV (grl) genes, 
resulting in resistance to ciprofloxacin (Drlica and Zhao 1997). 
 
The acquisition of resistance-encoding genetic material occurs by conjugation, 
transposition, transduction or transformation of mobile genetic elements such as 
plasmids, insertion sequences (IS), transposons or genomic islands (GIs) (Ito et al. 
2003b). These mobile genetic elements are also known as vectors. 
 
 
1.4.1 Genomic Islands 
 
Genomic islands are regions of chromosomal DNA usually >10 kb, that mostly 
contain genes that confer pathogenicity. Genomic islands are flanked by 
characteristic repeat sequences and can contain integrated mobile-genetic 
elements such as transposons and plasmids. Some genomic islands have the 
ability to excise spontaneously from the chromosome due to the action of 
intrinsically encoded recombinase/integrase genes. In others, these genes are 
truncated and non-functional (Baba et al. 2002; Ito et al. 2003b). 
 
Genomic islands that confer virulence can contain genes for leukocidins, 
staphylococcal superantigens and superantigen-like toxins (entertoxins and 
exotoxins). Genomic islands may also carry genes for antibacterial resistance. 
These resistance genes are found mostly on the SCCmec (Ito et al. 2003b).  
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1.4.2 Staphylococcal Cassette Chromosome mec 
 
The Staphylococcal cassette chromosome mec (SCCmec), is a genomic island that 
can range in size between 21 kb – 67 kb depending on the SCCmec type (Okuma 
et al. 2002). It is demarcated by flanking direct and inverted repeat sequences and 
contains recombinase genes for incision and excision from the chromosome. The 
SCCmec is the site for the methicillin-resistance gene mecA which is contained in 
the mec complex region (Katayama, Ito, and Hiramatsu 2001). Other resistance 
determinants may be found in the J regions of the SCCmec  (Oliveira and De 
Lencastre 2002). 
 
CA-MRSA are not known to carry antibiotic-resistance genes other than the mecA 
gene on the SCCmec. An exception is ST100-MRSAZH47 which carries genes for 
aminoglycoside resistance, aac(2')-aph(6″) on the integrated transposon Tn4001, 
which truncates the mec complex region of its SCCmec (Heusser et al. 2007). The 
SCCmecs of HA-MRSA, however, contain multiple resistance genes. Type II 
SCCmec contains plasmid pUB110 in the J3 region, encoding resistance to 
aminoglycosides and transposon Tn554 in the J2 region encoding resistance to 
erythromycin (Ito, Katayama, and Hiramatsu 1999). Type III SCCmec contains 
plasmid pT181, transposon Tn554 and pseudo Tn554, that encode resistance to 
tetracycline, erythromycin and cadmium, respectively (Ito et al. 2001). Integrated 
beside the type III SCCmec in some strains is the SCCHg. This genomic island 
contains a mer operon, transposon Tn544, a ccrC recombinase gene and confers 
resistance to the heavy metal Hg and erythromycin (Ito et al. 2003b). 
 
 
1.4.3 Insertion Sequences 
 
The properties of S. aureus insertion sequences (IS) are summarised in Table 1.6. 
IS are small transposable elements, being less than 2.5 kb and can be found 
flanking antibacterial-resistance genes within transposons as well as on their own 
at random sites on the bacterial chromosome. IS are themselves flanked by 
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inverted repeat (IR) sequences (10-40 bp) and contain only the genes needed for 
transposition and also a regulatory gene that stimulates or inhibits transposition 
activity (Lupski 1987). There are five ISs associated with S. aureus, IS256, 
IS431/257, IS1181,  IS1182, IS1272 (Firth and Skurray 1998) 
 
ISs can exert an influence by insertion directly into the gene or by a polar effect, 
inactivating nearby genes. Conversely, ISs may contain promoters that activate 
nearby genes, as cited by Ito et al. 2003. 
 
1.4.3.1 IS256 
IS256 is 1.3 kb in length, consists of a single ORF (open reading frame), that 
encodes a 45.6 kDa protein and is flanked by 26 bp terminal IR (Byrne, Rouch, 
and Skurray 1989). IS256 is not site specific and can be found at numerous sites 
on the S. aureus chromosome and on plasmids (Dyke, Aubert, and el Solh 1992). 
IS256 contains promoter sequences located at each end which act as promoters for 
neighbouring genes (Byrne, Rouch, and Skurray 1989). This is seen in Tn4001, 
which contains the resistance genes aacA-aphD which encode resistance to the 
aminoglycosides, gentamicin, kanamycin and tobramycin. The promoter action of 
IS256 increases the level of aminoglycoside resistance (Rouch et al. 1987). 
 
1.4.3.2 IS431/257 
IS431/257 is comprised of one ORF of 675 bp which has a 40% homology with 
IS26 of Proteus vulgaris and is flanked by terminal IR of 22 bp. IS431/257 is non-
site specific and can be found in numerous sites on the S. aureus chromosome and 
on plasmids (Barberis-Maino et al. 1987). It has been shown that IS431/257 
undergoes non-resolved replicative transposition by mediating replicon fusion. 
This results in the cointegration of various DNA segments such as plasmids, with 
each junction containing directly repeated copies of IS431/257 (Leelaporn et al. 
1996). IS431/257 plays a role in the evolution of, and accumulation of resistance 
genes on plasmids (Firth and Skurray 1998). In the transposon Tn4003, IS431/257 
has been found to have a controlling effect by acting as a promoter  on the level of 
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transcription of dfrA, which results in variations of trimethoprim resistance levels 
(Leelaporn et al. 1994). 
 
1.4.3.3 IS1272  
IS1272 is 1,934 kb in length and is comprised of 2 ORFs of 819 and 687 bp with 
flanking terminal IR of 16 bp and no flanking target-site duplications. A truncated 
IS1272 has been found in the mecA complex of MRSA replacing mecI and a 
truncating mecR1 (Archer et al. 1996). The presence of truncated IS1272 classifies 
the mec complex as class B, which is a component of SCCmec types I, IV and VI 
(Ma et al. 2002; Oliveira, Milheirico, and de Lencastre 2006). IS1272 is also 
found in S. haemolyticus and S. epidermidis in multiple copies. IS1272 is rarely 
seen in MSSA with only truncated single copies found in the mec complex of 
MRSA. It has been suggested that S. haemolyticus is the natural host for IS1272 
and that S. aureus has acquired it by horizontal transfer (Archer et al. 1996; Ito et 
al. 2001).  
 
1.4.3.4 IS1181 
IS1181 is 1,985 bp in length and is comprised of a single ORF of 1,317 bp with 
flanking terminal IR of 23 bp. IS1181 is found only in S. aureus with up to eight 
copies found on both the chromosome and on plasmids (Derbise, Dyke, and El 
Solh 1993). 
 
1.4.3.5 IS1182 
IS1182 is 1,864 bp in length and is comprised of either one ORF or two ORFs 
separated by a stop codon, with flanking terminal IR of 33 bp. IS1182 has been 
found flanking the transposon Tn5405 which is contained in the transposon 
Tn5404 and contains genes that encode resistance to aminoglycosides. IS1182R of 
Tn5405 contains a copy of IS1181 flanked by 8 direct repeats (DR) (Derbise, 
Dyke, and el Solh 1996). IS1182 has also been found in the mec complex of 
SCCmec type II subtypes. IS1182 has been found to have inserted into mecI of 
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SCCmec IIA and SCCmec IID (IS431mec-mecA-mecR1-∆mecI-IS1182) and 
truncated the mecI of SCCmec IIC and SCCmec IIE (IS431mec-mecA-mecR1-
∆mecI-IS1182) (Shore et al. 2005). IS1182 has also been shown to influence the 
chromosomal lytic gene lytH of MRSA by insertional inactivation (lytH::IS1182) 
resulting in an increase in the methicillin resistance level (Fujimura and Murakami 
2008). 
 
Table 1.6 Insertion Sequences in S. aureus 
Element Size (kb) Associated Resistance 
Resistance 
Genes Location 
IS256 1.3 Gentamicin,Kanamycin, Tobramycin aacA-aphA C,P 
IS431/IS257 0.8 
Antiseptics,disinfectants 
Bleomycin 
Gentamicin, Kanamycin, 
Tobramycin 
Kanamycin, Neomycin, 
Paramycin, Tobramycin 
Mercury 
Mupirocin 
Tetracycline 
Trimethoprim 
Virginiamycin 
smr 
ble 
aacA-aphA 
 
aadD 
 
merA,merB 
mupA 
tetA(K) 
dfrA 
vgb 
P 
C,P 
C,P 
 
C,P 
 
C,P 
P 
C,P 
P 
P 
IS1181 2.0 Kanamycin, Neomycin, Streptomycin 
aphA-3 
aadE 
C 
C 
IS1182 1.9 Kanamycin, Neomycin Streptomycin 
aphA-3 
aadE 
C 
C 
IS1272 1.9 Methicillin mecA C 
Abbreviations: C chromosome; P plasmid.  
This table is according to Firth, N and Skurry, R (1998) 
 
 
1.4.4 Composite Transposons 
 
The properties of S. aureus composite transposons are summarised in Table 1.7. 
Composite transposons are mobile genetic elements varying in size from 2.5 – 23 
kb that are only able to replicate by integrating into a chromosome or plasmid by 
transposition. Transposons are usually characterised by flanking IR and contain 
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genes that encode a transposase to enable site specific incision and excision of the 
element. Transposons may also contain insertion sequences, which are capable of 
independent movement by themselves  (Lupski 1987). Transposons are classified 
according to their components and complexity (Brown and Evans 1991). 
 
1.4.4.1 Aminoglycoside Resistance Transposons 
There are three transposons described, that confer resistance to aminoglycosides 
in S. aureus, Tn4001, Tn3854 and Tn5404 (Lyon, May, and Skurray 1984; Udo 
and Grubb 1991; Derbise, Dyke, and el Solh 1996). 
 
1.4.4.1.1 Tn4001 
Transposon Tn4001 is 4.7 kb in length, carries the aacA-aphD gene which 
encodes the 56.9-kDa bifunctional modifying enzyme AAC(6′)-APH(2″) and 
confers resistance to gentamicin, kanamycin and tobramycin. Tn4001 is found on 
the chromosome and on plasmids and is flanked by two copies of IS256 reading in 
opposite directions (Lyon, May, and Skurray 1984; Rouch et al. 1987; Byrne, 
Rouch, and Skurray 1989). The central region of Tn4001, 1918 bp in length, is 
comprised of two ORFs. The larger ORF, 1,437 bp in length, contains the coding 
region for the aacA-aphD genes (Rouch et al. 1987). The second ORF (ORF 132) 
is truncated by IS256(R) and does not possess signals for the initiation of 
translation (Byrne, Rouch, and Skurray 1989).  
Transposition of Tn4001 generates 8 bp repeats of the target sequence. Additional 
copies of IS256 have been found increasing the level of resistance due to promoter 
action (Byrne, Rouch, and Skurray 1989). Tn4001 may also be flanked by 
IS431/257 (Byrne, Gillespie, and Skurray 1990). Tn4001 has been found in the 
SCCmec of ST100-MRSAZH47 (Heusser et al. 2007). Tn4001 is also associated 
with multi-resistant plasmids of the pSK1 family and conjugative plasmid family 
pSK41/pGO1 (Firth and Skurray 1998). 
The rapid emergence of resistance to gentamicin, kanamycin and tobramycin in 
the early 1980s is thought to have been caused by the transposition of Tn4001 
from the chromosome to a readily disseminating plasmid (Gillespie et al. 1987). 
                                                                                        Literature Review  
 48
1.4.4.1.2 Tn3854 
The transposon Tn3854 is 4.5 kb in length and carries the genes aphA-3 and aadE 
which encodes the enzyme APH(3′)-III, conferring resistance to kanamycin, 
neomycin and streptomycin, but not gentamicin (Gray and Fitch 1983). Tn3854 is 
found on plasmid pWBG628 isolated from a Nigerian S. aureus (Udo and Grubb 
1991). 
 
1.4.4.1.3 Tn5404 and Tn5405 
The transposon Tn5404 is 16 kb in length and, like Tn3854, also carries the genes 
aphA-3 and aadE conferring resistance to kanamycin, neomycin and streptomycin 
(Gray and Fitch 1983). Tn5404 is comprised of a transposase and contains the 
insertion sequence IS1181. Tn5404 is structurally related to the transposon Tn552 
with similar transposition and resolution systems, and is flanked with terminal IR 
of 116 bp and DR of 6 bp. The insertion of this transposon into the plasmid 
pIP1066 carrying β-lactamase genes generates a 3.5 kb invertible segment flanked 
by inversely repeated resolution sites (resR, resL). This invertible segment carries 
p480 encoding a probable transposase, p271 encoding a putative ATP-binding 
protein, and binL encoding a resolvase (Rowland and Dyke 1990; Derbise, Dyke, 
and el Solh 1995). 
Contained within Tn5404 is the transposon Tn5405, which is 12 kb in length and 
also carries the aminoglycoside genes aph-3 and aadE, which confer resistance to 
kanamycin, neomycin and streptomycin. Also found is the sat4 gene which 
encodes resistance to streptothricin and three ORFs orfx, orfy and orfz of unknown 
functions (Derbise, Aubert, and El Solh 1997). Tn5405 is flanked by IS1182, with 
IS1182R truncated by IS1181 (Derbise, Dyke, and el Solh 1996).    
 
1.4.4.2 β-Lactamase Resistance Transposons 
There are four closely related β-lactamase transposons found in S. aureus that 
carry the bla gene complex (blaZ, blaR1 and blaI) which encodes the production 
and regulation of β-lactamase. These are Tn552, Tn4002, Tn3852 and Tn4201 
which are found on the chromosome and on plasmids (Rowland and Dyke 1989; 
Lyon and Skurray 1987; Kigbo et al. 1985; Weber and Goering 1988). 
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1.4.4.2.1 Tn552 
The transposon Tn552 is 6.5 kb in length and is flanked by DR of 6 bp (Rowland 
and Dyke 1989). Tn552 carries the gene blaZ which encodes β-lactamase 
production and the regulatory genes blaRI and blaI which encode a signal 
transducer and repressor (Gregory et al. 1997). Tn552 is found on plasmids such 
as pI258 and pI9789 (Rowland and Dyke 1989, 1990). Tn552 is structurally 
similar to Tn5404 (Derbise, Dyke, and el Solh 1996). 
 
1.4.4.2.2 Tn4002 
The transposon Tn4002 is 6.7 kb in length and is structurally similar to Tn552 
except with flanking DR of 7 bp. A bla gene complex  is found on the transposon 
and it is carried by the pSK1 family of plasmids (Gillespie, Lyon, and Skurray 
1988). 
 
1.4.4.2.3 Tn3852 
The transposon Tn3852 is 7.3 kb in length and is closely related to Tn552 and 
Tn4002. Tn3852 is found on the plasmid pWBG53 (Kigbo et al. 1985; Gillespie, 
Lyon, and Skurray 1988). 
 
1.4.4.2.4 Tn4201 
The transposon is 6.7 kb in length and is also structurally similar to the other β-
lactamase transposons. Tn4201 is able to be expressed equally well in either 
orientation, as it can be found in the inverted orientation, and is capable of 
movement between plasmid and chromosome sites (Weber and Goering 1988). 
 
1.4.4.3 Macrolide, Lincosamide and Streptogramin B 
Resistance Transposons 
 
Macrolide, Lincosamide and Streptogramin B (MLSB) resistance in S. aureus is 
encoded on the transposons Tn551 and Tn554 (Novick, Edelman, Schwesinger, et 
al. 1979; Murphy 1983; Haroche, Allignet, and El Solh 2002). 
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1.4.4.3.1 Tn551 
The transposon Tn551 is 5.2 kb in length, with terminal IR of 40 bp and is flanked 
by 5 bp DR. Tn551 has 99.8% homology with Tn917, found in enterococci. 
Tn551 consists of four ORFs including the ermB gene, which confers constitutive 
resistance to erythromycin, a resolvase and a transposase. Tn551 is found on the 
chromosome and on plasmids (Novick, Edelman, Latta, et al. 1979; Lyon and 
Skurray 1987). 
 
1.4.4.3.2 Tn554 
The transposon Tn554 is 6.7 kb in length and lacks terminal repeats. Tn554 
carries six ORFs with two containing the genes ermA and spc that confer 
inducible MLSB (rRNA methylase) and spectinomycin (AAD(9) 
nucleotidyltransferase) resistance respectively (Murphy 1983; Lyon and Skurray 
1987). Tn554 is site specific and can be found on the chromosome and on 
plasmids. One of these sites in the chromosome is within the SCCmec of types II 
and III. A Tn554-like element known as pseudo Tn554 (ΨTn554) is found in 
SCCmec type III, carrying the cadCA determinant which confers resistance to 
cadmium (Ito et al. 2001). 
 
1.4.4.4 Other Resistance Transposons 
 
1.4.4.4.1 Tn4003 
The transposon Tn4003 is 4.7 kb in length, has imperfect terminal repeats of 27-
28 bp and is flanked by DR of 8 bp. Tn4003 contains three copies of IS431/257 
and the genes dfrA, which encodes the SI dihydrofolate reductase (DHFR) which 
confers trimethoprim resistance, and thyE which encodes thymidylate synthetase. 
Tn4003 is found on the pSK1 family of plasmids (Rouch et al. 1989) and pSK41 
(Leelaporn et al. 1996). Tn4003 is also found in SCCmecN1 (Ender, Berger-Bächi, 
and McCallum 2007). 
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1.4.4.4.2 Tn4004 
The transposon Tn4004 is 6.4 kb in length contains seven ORFs, and is flanked by 
IS431/257. Tn4004 contains the gene merA, which encodes organomercurial 
lyase, conferring resistance to the heavy metal mercury. Tn4004 is found on the 
plasmid pI258 (Laddaga et al. 1987). 
 
1.4.4.4.3 Tn5801 
The transposon Tn5801 is 28.5 kb in length with flanking DR of 11 bp. Tn5801 
contains the gene tet(M) which confers resistance to tetracycline (Ito et al. 2003b). 
 
1.4.4.4.4 Tn4291 
The transposon Tn4291 is 7.8 kb in length. Tn4291 is thought to carry the mecA 
gene, which encodes PBP2a/2′ conferring resistance to methicillin. Tn4291 was 
found on the β-lactamase plasmid pI524 (Trees and Iandolo 1988). These findings 
are considered controversial as they have never been confirmed (Chambers 1997). 
 
1.4.4.4.5 Tn1546 
The transposon Tn1546 originated in E. faecalis, is 10.8 kb in length with 
imperfect terminal IR of 38 bp and flanking DR of 5 bp. Tn1546 contains seven 
van genes and two transposases. The van gene cluster contains the genes required 
for the production and regulation of resistance to vancomycin and teicoplanin 
(Arthur et al. 1993). Tn1546 and Tn1546-like elements are found on conjugative 
plasmids of the pSK41/pGO1 family (Zhu et al. 2008). 
 
1.4.4.4.6 Tn5406 
The transposon Tn5406 is 5.4 kb in length with terminal repeats absent. Tn5406 
has 61-73% homology with Tn554, carries three transposase genes, the gene 
ermA, which encodes resistance to MLSB, spc, which encodes resistance to 
spectinomycin and vgaAv, which confers resistance to streptogramin A drugs 
except pristinamycin. Tn5406 is found on the chromosome, in the Tn554 specific 
insertion sites, and on plasmids (Haroche, Allignet, and El Solh 2002). 
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Table 1.7 Antimicrobial Resistance Transposons in S. aureus 
Element Size (kb) Associated Resistance 
Flanking 
IS 
Resistance 
Genes Location
Tn551 5.2 Macrolides, Lincomides, Streptogramin B (MLSB)
None ermB P 
Tn552, 
Tn3852, 
Tn4002, 
Tn4201 
6.5-
7.3 Penicillins None blaZ C,P 
Tn554 6.7 Macrolides,Lincosamides,Streptogramin B (MLSB)
None spc C 
Tn3854 4.5 Kanamycin, Neomycin, Streptomycin  
aphA-3 
aadE P 
Tn4001 4.7 Gentamicin, Kanamycin, Tobramycin IS256 (I) aacA-aphD C,P 
Tn4003 4.7 Trimethoprim IS431 (D) dfrA C,P 
Tn4004 6.4 Mercury IS431 (D) merA, merB P 
Tn4291 7.8 Methicillin  mecA C 
Tn5404 16 Kanamycin, Neomycin, Streptomycin none 
aphA-3 
aadE C 
Tn5405 12 Kanamycin, Neomycin Streptomycin IS1182 (I)
aphA-3 
aadE C 
Tn5406 5.4 Streptogramin B (MLSB)Spectinomycin  
ermA, spc 
vgaAv C,P 
Tn5801 28.5 Tetracycline  tet(M) C 
Tn1546 10.8 Vancomycin, Teicoplanin  vanA P 
Abbreviations: C, chromosome; (D), direct; (I), inverted; IS, insertion sequence; 
P, plasmid.  
This table is based on Firth, N and Skurry, R. (1998) 
 
 
1.4.5 Plasmids 
 
Plasmids are extra-chromosomal self replicating genetic elements that frequently 
carry antibiotic resistant genes. Plasmids are categorised into four classes 
according to their size and components. Classes II and III are comprised of 
integrated class I plasmids, transposons and transposon remnants. Class I plasmids 
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appear to be resistant to transposon insertion and encode single antibiotic 
resistance genes. Class IV plasmids are comprised of plasmids that don’t fit in the 
other three classes. There is a strong tendency for certain resistance markers to be 
associated with particular plasmid classes (Novick 1989). 
 
1.4.5.1 Class I Plasmids 
Class I plasmids are 1 – 5 kb, have a high copy number of 15 - 50 per cell, and 
replicate by the rolling circle mechanism (Novick 1989). Only a single antibiotic 
resistance is encoded on class I plasmids such as the plasmid pUB110, which 
encodes resistance to aminoglycosides. Class I plasmids are able to integrate into 
the chromosome or into large plasmids, by transposition or recombination, 
mediated by IS431/257 (Werckenthin, Schwarz, and Roberts 1996; Ito et al. 
2003b). Some class I plasmids can be mobilised by class III plasmids (Forbes and 
Schaberg 1983; Lyon and Skurray 1987). Common antibiotic resistances encoded 
by class I plasmids include tetracycline, neomycin, streptomycin, chloramphenicol 
and erythromycin (Novick 1989). Cryptic plasmids are class 1 plasmids with no 
known phenotype and they frequently contain only the genes for their own 
replication. Cryptic plasmids are less than 2 kb in size. 
 
1.4.5.2 Class II Plasmids 
Class II plasmids were the first S. aureus plasmids identified and characterised in 
the 1960s. Class II plasmids are 15 – 30 kb in size and have a low copy number of 
4 - 6 per cell. They contain resistance determinants integrated on transposable 
elements and replicate by the theta mechanism (Novick 1989; Ito et al. 2003b). 
Class II plasmids can be subdivided into the β-lactamase/heavy metal resistances 
and pSK1 plasmid families (Firth and Skurray 1998). Plasmids often contain β-
lactamase genes (blaZ, blaR1 and blaI) on Tn552-like transposons. Examples 
include plasmids pMW2 and pN315 which encode β-lactamase on transposon 
Tn552 (Rowland and Dyke 1990; Ito et al. 2003b). The plasmid pMU50, while 
not encoding β-lactamase, encodes an efflux-mediated antiseptic-resistance 
determinant (qacA) on transposon Tn4001. Tn4001 also encodes aminoglycoside 
resistance (aacA-aphD) and can be found on pSK1 related plasmids (Gillespie, 
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May, and Skurray 1986; Gillespie et al. 1987). Resistance determinants to 
trimethoprim have also being found on class II plasmids (Novick 1989). 
 
1.4.5.3 Class III Plasmids 
Class III plasmids or conjugative plasmids are much larger, 40 – 60 kb, and carry 
determinants for conjugative transfer (tra), transposable-resistance determinants 
and a number of IS-like sequences (Novick 1989; Ito et al. 2003b). Class III 
plasmids are the only class of plasmids that are self transmissible by conjugative 
transfer and they can mobilise some class I plasmids to facilitate horizontal gene 
transfer (Forbes and Schaberg 1983; Lyon and Skurray 1987). Class III plasmids 
replicate by the theta mechanism and can be subdivided by phenotypic and 
restriction patterns and by conjugative proficiency (Novick 1989). Class III 
plasmids can be multi-resistance plasmids and commonly carry resistance 
determinants for aminoglycosides and trimethoprim (Novick 1989). The insertion 
sequence IS431/257 has an important role in the accumulation and integration of 
genes, carried by transposons and smaller plasmids, into Class III plasmids which 
can contain as many as seven to nine copies of IS431/257 (Werckenthin, Schwarz, 
and Roberts 1996). An example of a class III plasmid is pJE1 which contains the 
integrated class I plasmid pUB110 (confers resistance to bleomycin), a Tn4003-
like transposon (confers resistance to trimethoprim), Tn4001-hybrid transposon 
(confers resistance to aminoglycosides) and genes for antiseptic and disinfectant 
resistance (smr) (Evans and Dyke 1988; Firth and Skurray 1998). 
 
1.4.5.4 Class IV Plasmids 
Class IV plasmids are classified if a plasmid doesn’t fit into the previous three 
well defined classes (Ito et al. 2003b). Class IV plasmids commonly encode 
resistance to fusidic acid (Novick 1989).  An example of a class IV plasmid is 
pUB101 which confers resistance to fusidic acid, β-lactamase and cadmium 
(O'Brien et al. 1998). 
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1.5 Staphylococcal Protein A 
 
Staphylococcal protein A was the first surface protein identified in S. aureus 
(Jensen 1958). The expression of surface proteins influences the adhesive and 
serum binding properties of staphylococci to human tissues causing abscesses at 
many anatomical sites (Flock 1999).  
 
The staphylococcal protein A spans the bacterial cell wall and is covalently linked 
to the peptidoglycan layer. It is encoded by the spa gene which is 2,150 bp in size 
and its structure is shown in Figure 1.2.  It is comprised of distinct regions 
characteristic of surface proteins – 
1. NH2-terminal signal sequence encoding a YSIRK type signal peptide that is 
cleaved during secretion across the cytoplasmic membrane.  
2. COOH-terminal region contains a LPXTG motif (Leu-Pro-X-Thr-Gly) 
which precedes a hydrophobic membrane region containing 15-22 amino 
acids followed by 5-12 amino acid residues that form a positively charged 
tail. During cell wall anchoring, the LPXTG sorting signal is 
proteolytically cleaved between the threonine and glycine residues with an 
amide bond forming between threonine and the pentaglycine crossbridge 
before final peptidoglycan cross-linking. The staphylococcal protein A is 
orientated with the NH2-terminus at the bacterial cell surface and the 
COOH-terminus anchoring the protein in the cell wall or membrane 
(Schneewind, Fowler, and Faull 1995). 
3. The Fc-Immunoglobulin binding region consists of five 160 bp domains 
displayed on the bacterial surface that interact with IgG antibodies and 
cause precipitation of the immunoglobulin (Jensen 1958; Mazmanian, 
Ton-That, and Schneewind 2001). 
4. The X region, situated between the Fc binding region and the LPXTG motif, 
is highly polymorphic and consists of a variable number of 24 bp repeats 
which have been used as a sequence-based marker in spa typing (Koreen 
et al. 2003). 
 
 
                                                                                        Literature Review  
 56
 
Fc Binding Region X Region
LKKKNIYSIRKLGVGIASVTLGTLLI
Signal Peptide
LPETGEENPFIGTTVFGGLSLALGAALLAGRRREL
Sorting Signal
Wall/Membrane 
Spanning Region
NH2-terminus COOH-terminus
 
 
Figure 1.2 Diagrammatic Representation of the spa Gene 
Abbreviations: Wr, repeats; Wc, non-repeats 
 
 
1.5.1 spa Typing 
 
Sequencing and analysis of the polymorphic X region to determine the spa type is 
a valuable typing tool to characterise S. aureus lineages and is complimentary to 
MLST and PFGE in epidemiological studies (Koreen et al. 2003). 
 
 
1.6 Staphylococcal Cassette Chromosome 
 mec 
 
1.6.1 Definition 
Methicillin resistance occurs with the chromosomal acquisition of a site-specific 
genomic resistance island known as the staphylococcal cassette chromosome mec 
or SCCmec (Ito, Katayama, and Hiramatsu 1999; Katayama, Ito, and Hiramatsu 
2000). The mecA gene, which confers resistance to methicillin, was found to be 
located on the chromosome in 1975 (Sjöström, Löfdahl, and Philipson 1975). 
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Soon after, in 1978, the mecA gene was mapped between the purA gene, which 
encodes a protein involved in the biosynthesis of purines, and the staphylococcus 
protein A (spa) gene (Kuhl, Pattee, and Baldwin 1978).  The SCCmec consists of 
the mec complex (Ito, Katayama, and Hiramatsu 1999), the cassette chromosome 
recombinase (ccr) genes (Katayama, Ito, and Hiramatsu 2000) and three variable 
regions known as the J or joining regions located at the ends of the SCCmec and 
between the mec complex and ccr genes (Ma et al. 2002; Oliveira and De 
Lencastre 2002). SCCmec(s) are typed according to the class of the mec complex 
and the type of ccr genes they encode. Eleven SCCmec types have been described, 
including types I, II, III (Ito et al. 2001) and type VI (Oliveira, Milheirico, and de 
Lencastre 2006), which are primarily associated with HA-MRSA, types IV (Ma et 
al. 2002) and V (Ito et al. 2004) primarily associated with CA-MRSA and, 
recently, types VII (Berglund et al. 2008), type VIII (Zhang et al. 2008), types IX 
and X (Li et al. 2011) and type XI (Garcia-Álvarez et al. 2011).    
 
 
1.6.2 SCCmec Elements 
 
The SCCmec is a large heterogeneous mobile, or once mobile, genetic element 
defined by the organisation of the mec complex and the ccr genes. Sub-types are 
defined by the genetic content of the J regions. Overtime the SCCmec structure is 
becoming more diverse between the various classes and sub-types, with elements 
and regions occurring in other SCCmec classes. The SCCmec structure is 
suggested to have been assembled outside the species of S. aureus and integrated 
into the chromosome. Environmental and adaptive pressure have given rise to the 
SCCmec allotypes that have been described to date, with sub-types and variants 
emerging through recombination and insertion events (Oliveira, Tomasz, and De 
Lencastre 2001; Milheiriço, Oliveira, and De Lencastre 2007). 
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Figure 1.3 Basic Structures of SCCmec Types 
The figure is according to the International Working Group on the Classification 
of Staphylococcal Cassette Chromosome elements (IWG-SCC) from 
www.sccmec.org. 
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1.6.2.1 The mec Complex Regions 
The mec complex region is composed of the structural resistance gene, mecA, with 
intact or truncated sets of the regulatory genes mecR1 and mecI and starts with the 
insertion sequence IS431 (IS431mec) at its left end  (Deurenberg and Stobberingh 
2008; Ito, Katayama, and Hiramatsu 1999). See Figure 1.4. 
 
1.6.2.2 The mecA Gene 
The mecA gene is 2.1 kb in length and encodes the modified penicillin-binding 
protein 2a/2' (PBP2a/2'), which has a low affinity for β-lactams due to a distorted 
active site (Deurenberg and Stobberingh 2008; Song et al. 1987). This confers 
resistance to methicillin and most β-lactam antibiotics. S. aureus possess four 
PBPs with PBP2 responsible for peptidoglycan synthesis with transpeptidase and 
transglycosylase activity (Pinho, De Lencastre, and Tomasz 2001). PBP2a/2' has a 
molecular mass of 78 kDa and contains a transpeptidase domain and a non-
penicillin-binding (n-PB) domain of unknown function (Berger-Bächi and Rohrer 
2002). Resistance to methicillin and the other β-lactam antibiotics occurs because 
the acylation action of β-lactams on the active sites of PBP2a/2' is reduced, thus 
enabling the synthesis of the bacterial cell wall in the presence of β-lactam 
antibiotics. Methicillin/β-lactam sensitive bacteria would bind to these sites and 
prevent acylation, interrupting cell-wall construction, resulting in the death of the 
cell (Goffin and Ghuysen 1998; Lim and Strynadka 2002) 
 
1.6.2.3 The mecA Regulatory Genes 
The mecA regulatory genes mecR1 and mecI are located upstream of mecA and are 
transcribed in the opposite direction to mecA (Tesch et al. 1990; Hiramatsu et al. 
1992). The molecular organisation, structure, function and mechanism of 
regulation by mecR1 and mecI are similar to that of the β-lactamase regulatory 
elements blaR1 and blaI (Tesch et al. 1990). 
 
The mecR1 gene is 1,758 bp in length, is comprised of 585 amino acids and has 
34% homology to blaR1 in S. aureus (Hiramatsu et al. 1992). The mecR1 gene is 
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comprised of two domains. The membrane-spanning domain, which is embedded 
in the plasma membrane, has zinc metalloprotease activity. The second domain is 
the penicillin-binding domain, which protrudes through the cell wall and contains 
site-specific receptors for the binding of β-lactam antimicrobials (Zhang et al. 
2001). mecR1 acts as a co-inducer of mecA (Hiramatsu et al. 1992). 
 
The mecI gene is 372 bp in length, is comprised of 123 amino acids and has 61% 
homology to blaI in S. aureus (Hiramatsu et al. 1992). The MecI protein represses 
the production of PBP2a/2' and the transcription of mecR1 when it binds as a 
homodimer to palindromic sites within the mecA promoter region (Zhang et al. 
2001). 
 
The MecR1 protein has a sensor-transducing function. When β-lactam 
antimicrobials bind to the penicillin-binding domain of MecR1, MecR1 is 
autocatalytically cleaved, activating the intracellular zinc metalloprotease of the 
membrane-spanning domain of mecR1. This protease cleaves the repressor MecI 
and enables transcription of the mecA gene (Zhang et al. 2001; Berger-Bächi and 
Rohrer 2002). 
 
The blaZ-blaR1-blaI β-lactamase complex is structurally and functionally very 
similar to the mecA-mecR1-mecI PBP2a/2' complex system (Hiramatsu et al. 
1992), with blaR1 and blaI able to regulate mecA, in cases when mecR1 and mecI 
are non-functioning (Hackbarth and Chambers 1993). The blaR1-blaI regulatory 
complex has been shown to be more efficient and faster than that of mecR1-mecI, 
with mecR1, although inducible by cefoxatin, less efficient and slower in the 
presence of methicillin and oxacillin (McKinney et al. 2001). blaI and mecI are 
both able to repress the transcription of mecA and blaZ, while their action together 
forms a more effective repression of mecA than when acting alone (Rosato et al. 
2003). 
 
1.6.2.4 The mec Complex Classes 
The mec complex classes are illustrated in Figure 1.4. The mec complex is 
structurally diverse and the expression of mecA is affected by this diversity. The 
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regulatory genes mecR1 and mecI in some classes have been found to be 
dysfunctional due to truncation with insertion sequences, or disabling mutations 
(Archer et al. 1994; Katayama, Ito, and Hiramatsu 2001). The mec complex is 
classified into classes according to these diversities (Ito et al. 2001). 
 
 
IS431  HVR                         mecA                         mecR1           mecI
Class A  mec Complex
Class D mec Complex
Class B mec Complex
IS431     HVR                          mecA                      ΔmecR1         IS1272
Class C mec Complex
IS431   HVR                        mecA               ΔmecR1 IS431
IS431      HVR                         mecA ΔmecR1
blaZ mecALGA251 mecR1LGA251 mecILGA251
Class mecC Complex
 
 
Figure 1.4 The mec Complex Regions 
Abbreviations: HVR, Hypervariable Region 
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1.6.2.4.1 Class A mec Complex 
The class A mec complex was first characterised in the MRSA isolate N315 and is 
comprised of mecA, mecR1 and mecI, with mecR1 containing both membrane-
spanning and penicillin-binding domains (Ito et al. 2001). 
 
Mutations and deletions in mecI have been described, with blaI taking its place 
functionally due to its high homology with mecI (Rosato et al. 2003).  
 
Subtypes of class A have been described with subtype A.3 found to have mecI 
truncated by IS1182. Subtype A.4 has IS1182 inserted into mecI (Shore et al. 
2005). See Table 1.8. 
 
Table 1.8 Descriptive Designations of Class A mec Complex Sub-Types 
Sub-Type Descriptive Designation 
Class A IS431-mecA-mecR1-mecI 
Class A.3 IS431-mecA-mecR1-ΔmecI-IS1182 
Class A.4 IS431-mecA-mecR1-ΔmecI-IS1182-ΔmecI 
 
 
1.6.2.4.2 Class B mec Complex 
Class B mec complex is commonly found in CA-MRSA (Okuma et al. 2002), 
however, it is also found in the epidemic UK EMRSA-15 clone (Oliveira and De 
Lencastre 2002). The class B mec complex is comprised of mecA, mecR1 
truncated by a partial copy of insertion sequence IS1272 and mecI completely 
absent. The remaining portion of mecR1 contains only the membrane-spanning 
domain (Ito et al. 2001; Katayama, Ito, and Hiramatsu 2001; Lim, Coombs, and 
Grubb 2002).  
 
A Class B mec complex subtype, B1 has been described containing a larger 
truncation of IS1272 into ΔmecR1 (Lim et al. 2003). The class B mec complex 
subtype B2 contains mecR1 truncated by the aminoglycoside-resistance 
transposon Tn4001 (Heusser et al. 2007). The B3 mec complex contains mecR1 
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truncated by the integration of a 1,014 bp ISSep1-like transposase (Berglund et al. 
2009). See Table 1.9. 
 
Table 1.9 Descriptive Designations of Class B mec Complex Sub-Types 
Sub-Type Descriptive Designation 
Class B IS431-mecA-∆mecR1-IS1272 
Class B1 IS431-mecA-∆mecR1-IS1272 
Class B2 IS431-mecA-∆mecR1-Tn4001 
Class B3 IS431-mecA-ΔmecR1-ISSep1-ΔIS1272 
 
 
1.6.2.4.3 Class C mec Complex 
Class C2 mec complexes are found in CA-MRSA and consist of mecA with the 
penicillin-binding domain of mecR1 and mecI truncated by IS431.  (Ito et al. 
2004). There are two subtypes of class C mec complex. Class C1 mec complex 
consists of ΔmecR1 containing only the membrane-spanning domain with IS431 
transcribed in the same direction as mecA. Class C2 mec complex consists of 
mecR1 with a greater truncation and contains only a small remnant of the 
membrane-spanning domain and IS431 is transcribed in the opposite direction to 
mecA (Katayama, Ito, and Hiramatsu 2000; Berglund et al. 2008). See Table 1.10. 
 
Table 1.10 Descriptive Designations of Class C mec Complex Sub-Types 
Sub-Type Descriptive Designation 
Class C1 IS431-mecA-∆mecR1-IS431 
Class C2 IS431-mecA-∆mecR1-IS431* 
Note: IS431* transcribes in the opposite direction to mecA 
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1.6.2.4.4 Class D mec Complex 
The class D mec complex consists of mecA and a truncated mecR1. The truncation 
occurs in the penicillin-binding domain. Neither IS431 nor IS1272 are present at 
this deletion site. This class of mec complex has been described in S. caprae 
(Katayama, Ito, and Hiramatsu 2001). See Table 1.11. 
 
Table 1.11 Descriptive Designation of the Class D mec Complex 
Sub-Type Descriptive Designation 
Class D IS431-mecA-∆mecR1 
 
 
1.6.2.4.5 mecC  Complex 
The mecC complex, which was formally class E, consists of a mecA homologue, 
mecALGA251, found in the S. aureus strain LGA251(Garcia-Álvarez et al. 2011). 
See Table 1.12 
 
Table 1.12 Descriptive Designation of the mecC Complex 
Sub-Type Descriptive Designation 
mecC blaZ-mecALGA251-mecR1LGA251-mecILGA251 
 
 
1.6.2.5 Cassette Chromosome Recombinase Genes 
 
The ccr genes control the precise excision, the orientation and the integration of 
the SCCmec element. The ccr genes encode proteins of the invertase-resolvase 
family (Ito et al. 2001; Deurenberg and Stobberingh 2008). They have been 
classified as ccrA, ccrB and ccrC. ccrA and ccrB are usually found as a pair 
together with surrounding ORFs of unknown function to form the ccrAB gene 
complex. The ccrC gene forms a ccr gene complex alone with three upstream and 
three downstream surrounding ORFs (IWG-SCC 2009). The ccrAB genes 
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transcribe in the same direction as mecA while ccrC transcribes in the opposite 
direction (Katayama, Ito, and Hiramatsu 2000; Ito et al. 2001; Ito et al. 2004). 
 
Occurrences of multiple ccr genes within one SCCmec have been reported in S. 
aureus (Boyle-Vavra et al. 2005). The occurrence of three ccr gene complexes has 
been reported in one S. epidermidis isolate studied (Hanssen and Sollid 2007). In 
these instances it is unclear as to which ccr gene(s) controls the SCCmec 
integration (Boyle-Vavra et al. 2005). 
 
Diversity exists between the ccr genes. Four allotypes have been described for the 
ccrAB genes (Ito et al. 2001; Oliveira, Tomasz, and De Lencastre 2001) with 60-
82% homology between the allotypes (Ito et al. 2004; IWG-SCC 2009). The ccrC 
gene consists of nine different alleles of ≥87% homology (Boyle-Vavra et al. 
2005; Higuchi et al. 2008; IWG-SCC 2009). ST59-MRSA-V (5C2&5), commonly 
known as the Taiwan Clone, contains two ccrC gene complexes of alleles 2 and 8. 
The ccrC1, allele 8 gene complex is found downstream of the mec complex, while 
the ccrC1, allele 2 gene complex is found upstream. Both these gene complexes 
consist of the ccrC gene and three accompanying ORFs flanking each side. Allele 
2 and allele 8 are 93% homologous with each other while the gene complexes 
with accompanying ORFs are 85% homologous. The gene complex of allele 8 is 
6.5 kb in size and found to have ≥97% homology with the ccrC gene complexes 
in SCCmecZH47, which carries ccrC1, allele 9, and in SCCmercury, which carries 
ccrC, allele 3. The ccrC1 gene complexes of allele 3, 8 and 9 are located 
downstream of the mec complex and have a homology of ≥97%. This gene 
complex with its accompanying ORFs is termed the ccrC carrying unit  (Higuchi 
et al. 2008). 
 
The ccr gene classes are summarised in Table 1.13 (Garcia-Álvarez et al. 2011; 
Ito et al. 2001; Ito et al. 2004; Oliveira et al. 2006; Li et al. 2011). 
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Table 1.13 ccr Gene Classes 
ccr Gene Complex Gene 
Class1 ccrA1 ccrB1 
Class 2 ccrA2 ccrB2 
Class 3 ccrA3 ccrB3 
Class 4 ccrA4 ccrB4 
Class 5 ccrC1 
Class 6 ccrA5ccrB3 
Class 7 ccrA1ccrB6 
Class 8 ccrA1ccrB3 
 
 
1.6.2.5.1 The Function of the ccr Gene Complex 
The site-specific excision and integration of the SCCmec element is dependent on 
a recombinase of the invertase/resolvase family, which is encoded by the ccrAB or 
ccrC genes located within the SCCmec element. The SCCmec integrates into the 
chromosome at a site-specific location, orfX. The orfX is located near the origin of 
replication, has an unknown function and is well conserved among clinical strains 
of S. aureus. The integration of SCCmec occurs specifically at the site designated 
attBSCC with the SCCmec element inserting into orfX resulting in a larger portion 
of orfX at the 5′ end of SCCmec and a smaller remnant of orfX at the 3′ end of 
SCCmec. 
 
The integration site is flanked by a pair of DR (DR-B and DR-SCC) 15 bp in 
length, and a pair of inverted terminal repeats 27 bp in length (IR-L and IR-R) 
(Ito, Katayama, and Hiramatsu 1999; Katayama, Ito, and Hiramatsu 2000). The 
inverted terminal repeats are absent in SCCmec type V, which carries the ccrC 
gene. The ccrC can only mediate integration of SCCmec carrying ccrC (Ito et al. 
2004). 
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1.6.2.6 The J Regions 
 
The J or joining regions of the SCCmec constitute the non-essential components 
of the SCCmec, but may carry additional antimicrobial-resistance determinants. 
The J regions are demonstrated (shaded in gray) in Figure 1.3. The J regions were 
previously termed junkyard regions and are comprised of three parts. The J1 
region is between ccr and the right hand end of the SCCmec, the J2 region is 
between mec and ccr and the J3 region is between orfX and mec. The J1 region is 
believed to reflect the original form of SCC into which the mec complex was 
integrated (Kondo et al. 2007). Plasmids, such as pUB110 and pT181, encoding 
antimicrobial-resistance genes may integrate into the J3 region due to the activity 
of the insertion sequence IS431. The occurrence of two copies of IS431 flanking 
integrated plasmids suggests they were accumulated by homologous 
recombination events (Ito et al. 2001). The presence or absence of resistance 
genes, polymorphisms, or variations in the J regions are used as markers to 
classify SCCmec elements into subtypes or variants (Oliveira, Tomasz, and De 
Lencastre 2001; Oliveira and De Lencastre 2002; Shore et al. 2005; Kondo et al. 
2007).  
 
 
1.6.3 The Direct Repeat Region 
 
The direct repeat (dru) region is a HVR (hyper variable region) that is located 
downstream of mecA within the mec region between IS431 and mecA, and 
contains direct repeat units (Ryffel et al. 1991). See Figure 1.4. These units are 
comprised of 40 bp repeated 2 to 11 times within 500 bp. Variations within the 
dru region result from deletion or addition of repeats and point mutations within a 
repeat. These variations allow for the determination of the dru region to be used in 
the typing of MRSA for epidemiological studies (Ryffel et al. 1991; Witte, 
Werner, and Cuny 2001). 
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1.6.4 Direct and Inverted Repeats 
 
Direct repeat (DR) and inverted repeat (IR) sequences are found flanking SCC 
and other transposable elements such as transposons. DR sequences are in the 
same direction while IR are opposite to each other. 
 
DR play a role in the replication process with one DR found at the left hand end of 
the integrated element and the other, found immediately outside the element at the 
right hand end (Recchia and Hall 1995; Stokes et al. 1997). DR sequences are site 
specific and are associated with an attachment site such as the attachment site attB 
of the SCCmec (Ito, Katayama, and Hiramatsu 1999). 
 
IR have a role in mobility and integration of DNA elements (Recchia and Hall 
1995; Stokes et al. 1997; Ito, Katayama, and Hiramatsu 1999). They can serve as 
primers in the replication process acting as assembly points of DNA (Mathews 
1995). They are important for genetic instability by promoting DNA re-
arrangement and prevent degradation of damaged DNA (Lin et al. 2001). 
 
1.6.5 The SCCmec and Virulence 
 
S. aureus can contain virulence factors that affect its ability to cause disease. The 
SCCmec is not normally associated with virulence, but is the location for the 
known virulence determinants encoded by the pls and pms genes (Savolainen et 
al. 2001; Queck et al. 2009). 
 
1.6.5.1 The pls Gene 
The pls gene encodes a surface-protein molecule Pls (plasmin sensitive), of 230 
kDa. The function of the Pls protein is to reduce adhesion to host proteins and 
cellular invasiveness, which may allow the spread of cells, but once the protein is 
cleaved by receptor-bound plasminogen on the bacterial surface, this may then aid 
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in adhesion to tissues and structures of the host  (Savolainen et al. 2001). The pls 
gene is a characteristic marker on SCCmec type I, although it has also been 
reported on SCCmec types II, III and IV (Werbick et al. 2007) and has recently 
been found encoded on S. aureus plasmid pWBG761 (GenBank Accession No. 
GQ900474). The pls gene is comprised of a number of regions typical of other 
surface proteins, beginning with a signal sequence, a constant region, three 
different regions of repeat sequences (R1, R2 and R3) and ending with a LPXTG 
cell wall attachment sequence. The size of the pls gene is approx. 4 kb however, it 
varies according to the size of the repeat regions (Savolainen et al. 2001). The pls 
surface protein covalently anchors to the cell wall peptidoglycan when sortase, the 
membrane-bound transpeptidase, cleaves the link between the threonine and 
glycine residues of the LPXTG motif (Ton-That et al. 1999). The preceding 
serine-aspartic acid SD repeat region (R3) acts as an arm spanning the 
peptidoglycan layer (Hartford et al. 1997). Pls is a member of the SD repeat 
containing family (SDr) of surface proteins with regions homologous to the 
accumulation-associated protein (Aap) of S. epidermidis, which is associated with 
biofilm formation (Savolainen et al. 2001; Hussain et al. 1997). Pls is cleaved in 
the presence of receptor-bound plasminogen on the S.aureus surface into 175 and 
68 kDa segments by proteolysis (Kuusela and Saksela 1990). Because of it size, 
Pls produces a steric hindrance to the adherence and invasiveness of MRSA to the 
host, but may allow the bacteria to multiply or be of another advantage to the host 
cell (Hussain et al. 2009). 
 
1.6.5.2 The psm Gene 
A recent study has shown a previously unknown occurrence of virulence 
determinants within the SCCmec. The staphylococcal cytolytic toxins, phenol-
soluble modulins (PSMs) encoded by the psm gene, contribute to neutrophil lysis, 
immune evasion and disease. A psm-mec gene was found encoded within the 
SCCmec rather than on the core genome suggesting for the first time a link with 
methicillin resistance and virulence factors. The psm-mec gene was found 
adjacent to the mec complex of SCCmec II and SCCmec III isolates (Queck et al. 
2009). 
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1.6.6 SCCmec Types 
 
The SCCmec is classified into sub-types or variants according to the content of the 
J regions and in some cases variations of the mec complexes and ccr gene 
complexes (Ito et al. 2001; Oliveira, Tomasz, and De Lencastre 2001). SCCmec 
types or allotypes are summarised in Table 1.14. 
 
1.6.6.1 SCCmec Type I 
Isolates containing SCCmec type I were found in the 1960s and 1970s and are 
known as the archaic clone (Ito et al. 2001). SCCmec type I carries a class B mec 
complex and type 1 ccr gene complex and is 34 kb in length. See Figure 1.3. The 
SCCmec type I carries the pls gene in the J1 region and the downstream constant 
segment (dcs) in the J3 region (Oliveira, Wu, and De Lencastre 2000). See Table 
1.14 for sub-types of SCCmec type I. 
 
Table 1.14 SCCmec Allotypes 
Feature 
SCCmec Allotypes 
I II III IV V VI VII VIII IX X XI 
Size (kb) 34 53 67 21-24 28 24 32 32 44 51 29 
mec  
complex B A A B C2 B C1 A C2 C1 mecC 
ccr 
complex A1B1 A2B2 A3B3 A2B2 C A4B4 C A4B4 A1B1 A1B6 A1B3 
IS431 (n) 1 2 4 1 2 1 2 1 2 2 0 
Tn554 (n) - 1 2 - - - - 1 - - - 
pUB110 - + - - - - - - - - - 
pT181 - - + - - - - - - - - 
p1258 - - + - - - - - - - - 
Other 
Resistance 
Genes 
None ermA ermA,tet(K)mer None None None None 
ermA, 
spc 
cadDX, 
arsRBC, 
arsDARBC 
cadDX, 
arsRBC
arsRBC, 
blaZ 
Abbreviations: n, number; kb, kilobases 
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1.6.6.2 SCCmec Type II 
SCCmec type II was first found in the strain N315 ST5-MRSA-II (2A) commonly 
known as New York/Japan (Ito, Katayama, and Hiramatsu 1999; Ito et al. 2001). 
It carries a class A mec complex and type 2 ccr gene complex, and is 53 kb in 
length. See Figure 1.3. The antimicrobial-resistance plasmid pUB110 is found 
integrated and flanked by IS431 in the J3 region together with the downstream 
constant sequence dcs. The kdp operon is characteristically found in the J1 region. 
The kdp operon encodes a potassium-dependent ATPase and its regulators. The J2 
region carries the transposon Tn554 (ermA and spc) encoding resistance to 
erythromycin and spectinomycin (Ito et al. 2001). See Table 1.15 for sub-types of 
SCCmec type II. 
 
1.6.6.3 SCCmec Type III 
The SCCmec type III was first described in HA-MRSA strain 85/2082 and carries 
a class A mec complex and type 3 ccr gene complex (Ito et al. 2001). See Figure 
1.3. SCCmec type III was originally considered to be the largest SCCmec type at 
66 kb but is actually comprised of a SCCmec of 34 kb and an adjacent SCC 
element, SCCmercury (SCCHg) of 32 kb. The SCCmec type III carries in the J2 
region, the pseudo-transposon ψTn554 containing cadA, which confers cadmium 
resistance. It has an integrated tetracycline-resistance plasmid, pT181, flanked by 
two copies of IS431 in the J3 region. The separate SCC element, SCCHg, found 
adjacent to the J3 region, contains the mer operon, encoding mercury resistance, 
flanked by two copies of IS431/257, a ccrC gene complex, a truncated hsdR gene 
(ΔhsdR) and Tn554, which encodes resistance to macrolide, lincosamide and 
streptogramin B (MLSB). DR sequences are found at each end of the SCCmec 
element with a third copy found between the plasmid pT181 and the mer operon 
of SCCHg (Ito et al. 2001; Ito et al. 2003a). See Table 1.15 for sub-types of 
SCCmec type III. 
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1.6.6.4 SCCmec Type IV 
SCCmec type IV was first described in CA-MRSA MW2 and carries a class B 
mec complex and a type 2 ccr gene complex (Ma et al. 2002). See Figure 1.3. At 
21-31 kb it is the smallest SCCmec type. The SCCmec type IV is most commonly 
found in CA-MRSA, however it has also been described in the epidemic HA-
MRSA, EMRSA-15 (Ma et al. 2002; Ito et al. 2003a). See Table 1.15 for sub-
types of SCCmec type IV. 
 
1.6.6.5 SCCmec Type V 
The first SCCmec type V was described in an Australian CA-MRSA strain WIS, 
ST45-MRSA-V (WBG 8318) (Ito et al. 2004). SCCmec type V carries a class C2 
mec complex, a type 5 or ccrC gene complex (5C2) and is 28.6 kb in size. See 
Figure 1.3. This SCCmec is commonly found in CA-MRSA. See Table 1.15 for 
sub-types of SCCmec type V. 
 
1.6.6.6 SCCmec Type VI 
SCCmec type VI was first detected in a MRSA from a paediatric hospital in 
Portugal in 1992 which became known as the “paediatric clone”. It carries a class 
B mec complex and type 4 ccr gene complex and is 23.3 kb in length (Oliveira, 
Milheirico, and de Lencastre 2006). See Figure 1.3 and Table 1.15 for SCCmec 
types. 
 
1.6.6.7 SCCmec Type VII 
SCCmec type VII (26.7 kb) was first detected in strain JCSC6082 from Sweden 
and  carries a class C1 mec complex characterised by IS431 transcribing in the 
same direction as mecA (opposite to class C2). See Figure 1.3. An SCC-like 
cassette (CC6082) is found adjacent to the J1 region. The J3 region has 99% 
homology to regions of the SCCHg of SCCmec III strain 85/2082 but with the 
mer operon and Tn554 absent (Berglund et al. 2008). See Table 1.15 for SCCmec 
types. 
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Table 1.15 SCCmec Types and Sub-Types 
SCCmec 
Type 
Sub-
Type 
Alternative 
Nomenclature 
mec 
Complex 
Class 
ccr Gene 
Complex J1 Region J2 Region J3 Region References 
I (1B) 
I 1B.1.1 (I.I.I) 
B ccrA1-ccrB1 
pls 
 
dcs 
Ito et al. 2001
IA 1B.1.2 (I.I.2) pUB110 dcs 
IB 1B.2.1 (I.2.1) pls absent I.2 J1 
pUB110 absent 
two IS431 present 
Han et al. 
2009 
Bergland et 
al. 2009 
II (2A) 
IIa 2A.1.1 (II.I.I) 
A 
ccrA2-
ccrB2 
kdp 
Tn554 
pUB110 
dcs Ito et al. 2001
Variant 2A.1.2 (II.1.2) pUB110 absent Cha et al. 2005 
IIb 2A.2 (II.2) kdp absent II.2 J1 dcs 
Hisata et al. 
2005 
IIA 2A.3.1 (II.3.1) A.4 IS1182 
kdp absent 
IVb J1 
pUB110 
dcs 
Shore et al. 
2005 
IIB 2A.3.2 (II.3.2) A Tn554 absent 
IIC 2A.3.3 (II.3.3) A.3 IS1182 
ΔTn554 
6 orfs absent 
short J2 
IID 2A.3.4 (II.3.4) A.4 IS1182 Tn554 
pUB110 absent 
IIE 2A.3.5 (II.3.5) A.3 IS1182 
Tn554 
short J2 
 2A.4.1 (II.4.1) 
A 
kdp absent 
Tn554 
pUB110 
dcs 
Kwon et 
al.2005 
 2A.5.1 (II.5.1) 
I.2 J1 pUB110 Han et al. 2009 
 2A.5.2 (II.5.2) 
Tn6012 
present 
Tn554 absent 
III (3A) 
III 3A.1.1 (III.1.1) 
A ccrA3-ccrB3 
Unique III 
ψTn554 
pT181, SCCHg-
p1258(mer 
operon), Tn554, 
ΔhsdR ccrC 
Ito et al. 2001
IIIA 3A.1.2  (III.1.2) 
III J1 
pT181 and region 
between pT181 and 
mer absent Oliveria & De 
Lencastre 
2002 
IIIB 3A.1.3 (III.1.3) 
pT181 absent 
IIIC 3A.1.4 (III.1.4) Chongtrakool et al. 2006 
novel 3A.1.5 (III.1.5) 
Elements of 
SCCHg absent 
including ccrC, 
ΔhsdR, Tn554 
Arakere et al. 
2009 
Unclassif
ied 
(Aus2) 
3A.N.N (III.N.N) Undetermined Undetermined mer operon absent Unpublished 
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Table 1.15 SCCmec Types and Sub-Types (Continued) 
SCCmec 
Type 
Sub-
Type 
Alternative 
Nomenclature 
mec 
Complex 
Class 
ccr Gene 
Complex J1 Region J2 Region J3 Region References 
IV (2B) 
IVa 2B.1 (IV.1) 
B 
ccrA2-ccrB-
2 
Unique IV  dcs Ma et al. 2002 
IVA 2B.N.2 (IV.N.2) IVc J1 Undetermined pUB110 dcs 
Oliveria & De 
Lencastre 
2002 
Park et al. 
2009 
IVA 
variant 
(Korean) 
2B.3 
B variant 
Tn20 with 
HVR and 
ugpQ 
absent 
IVc J1 
 
pUB110 
Mongkolratta
nothai et 
al.2004 
Park et al. 
2009 
IVb 2B.2.1 (IV.2.1) 
B 
Unique IVb  
Shore et al. 
2005 
IVc 2B.3.1 (IV.3.1) Unique IVc
Tn4001 with 
flanking IS256 
dcs 
IVc 2B.3.2 (IV.3.2) IVc J1 dcs 
IVd 2B.4 (IV.4) Unique IVd
dcs absent IVE 2B.3.3 (IV.3.3) IVc J1 
IVF 2B.2.2 (IV.2.2) IVb J1 
IVg 2B.5 (IV.5) Unique IVg
dcs 
Kwon et al. 
2005 
IVh 2B.6 (IV.6) Unique IVh Shore et al. 2005 
IVi 2B.7 (IV.7) B.3 ISSep1-like II.2 J1 
II.2 J2 
Tn554 absent 
Berglund et al 
2009 
IVj 2B.8 (IV.8) B I.2 J1  
ZH47 2B&5 
B2 
Tn4001 
ccrA2-
ccrB2 & 
ccrC1 allele 
9 
IVc J1 IVc J2 SCC carrying ccrC Heusser et al. 2007 
V (5C) 
V 5C.1 (V.1) 
C2 
ccrC1 Unique V Unique V Unique V Ito et al. 2004
VT 
(Taiwan) 5C2&5 (V.2.2) 
ccrC1 
alleles 2&8 Unique VT 
ISSau-4 like 
Transposase SCC carrying ccrC 
Boyle-Vavra 
et al. 2005 
VI (4B) Paediatric 4B (VI) B ccrA4-ccrB4 IVa J1  dcs 
Oliveira et al. 
2006 
VII (5C1) VII 5C1 (VII) C1 ccrC1 
SCC-like 
cassette 
(CC6082) 
 
Homologous to 
SCCHg mer, 
Tn554 absent 
Berglund et 
al. 2008 
VIII (4A) VIII 4A (VIII) A ccrA4-ccrB4  Tn554  
Zhang et al. 
2009 
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Table 1.15 SCCmec Types and Sub-Types (Continued) 
SCCmec 
Type 
Sub-
Type 
Alternative 
Nomenclature 
mec 
Complex 
Class 
ccr Gene 
Complex J1 Region 
J2 
Region 
J3 
Region References 
IX(1C2) XI 1C2(IX) C2 
ccrA1-
ccrB1 
cadDX, copB, 
arsRBC,arsDARBC 
  
Li et al. 
2011 
X(7C1) X 7C1(X) C1.2 
Type 7 
ccrA1-
ccrB6 
cadDX, copB, 
arsRBC, ISSha1 
 arsRBC 
Li et al. 
2011 
XI(8E) XI 
(XI) 
SCCmecLGA251 
mecC 
blaZ 
Type 8 
ccrA1-
ccrB3 
arsRBC  Absent 
Garcia-
Álvarez et 
al. 2011 
 
 
1.6.6.8 SCCmec Type VIII 
SCCmec type VIII (32.1 kb) was first described in 2003 in MRSA from a hospital 
in Canada and carries a class A mec complex and type 4 ccr gene complex (Zhang 
et al. 2008). See Figure 1.3. The J1 region has 100% homology to a region 
between DR-SCCpbp4 and IS431 of the SCC-CI element in ATCC 12228 (Zhang 
et al. 2003). The J2 region contains 19 ORFs with seven belonging to Tn554 
(Zhang et al. 2008). See Table 1.15 for SCCmec types. 
 
1.6.6.9 SCCmec Type IX 
SCCmec type IX ((43.7 kb) was first detected in strain JCSC6943 and carries a 
class C2 mec complex and type 1 ccr gene complex. The J1 region contains a 
cadDX operon encoding cadmium resistance, a copB gene and two operons, 
arsRBC and arsDARBC, encoding arsenate resistance (Li et al. 2011). 
 
1.6.6.10 SCCmec Type X 
SCCmec type X (50.8 kb) was first detected in strain JCSC6945 and carries a 
novel class C1-like mec complex (C1.2) and a type 7 ccr gene complex consisting 
of ccrA1-ccrB6 genes. The J1 region carries a cadDX operon, a copB gene, an 
arsRBC operon and a ISSha1 insertion sequence. The J3 region carries an arsRBC 
operon (Li et al. 2011). 
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1.6.6.11 SCCmec Type XI 
SCCmec type XI (29.4 kb) was first detected in S. aureus strain LGA251 that was 
isolated from bulk milk, and found to be phenotypically resistant to methicillin but 
negative for mecA. Type XI was determined to carry a novel mecA homologue, 
(mecALGA251) blaZ-mecALGA251-mecR1LGA251-mecILGA251, with the same organisation 
to that found in the plasmid, pMCCL2 (Baba et al. 2009), and a SCC-like element 
found in Macrococcus caseolyticus (Tsubakishita et al. 2010; Garcia-Álvarez et 
al. 2011). The mec region of the SCCmec XI has been designated mecC by the 
International Working Group (IWG) for the Classification of SCCmec (Peterson 
et al. 2012). SCCmec XI carries a type 8 ccr gene complex with ccrA1-ccrB3 
genes. The J1 region carries an arsRBC, membrane proteins, a lipase gene 
fragment, ABC transport genes, and an exported protein. The J2 region carries 
genes that encode exported and membrane proteins, while the J3 region is absent 
(Garcia-Álvarez et al. 2011). 
 
 
1.6.7 SCC Elements Without mecA 
 
SCC elements have been described that do not carry mecA. These elements, like 
SCCmec, carry a ccr gene complex, integrate into the staphylococcal chromosome 
at integration site sequence (ISS) and possess flanking DR sequences containing 
the ISS (IWG-SCC 2009). 
 
1.6.7.1 SCC-Composite Island (SCC-CI) 
The SCC-CI (57 kb) has been described in S. epidermidis strain ATCC12228 and 
is flanked by 28 bp SCC DR sequences. The SCC-CI contains a 19 kb SCC 
element SCCpbp4, together with a 38 kb element in tandem. The SCCpbp4 carries 
the pbp4 gene that encodes cell-wall biosynthesis proteins, the tagF gene, which 
encodes a teichoic acid biosynthesis protein, a type 2 ccr gene complex and a 
phage-resistance protein. SCCpbp4 is flanked by DR and IR sequences. Adjacent 
to SCCpbp4, the 38 kb element that completes the composite island contains a 
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second ccr gene complex (type 4), three IS431 elements, type 1 restriction 
modification genes (hsdR, hsdS), a CadR region encoding cadmium resistance and 
a MerR region encoding mercury resistance. This region is also flanked by DR 
and IR sequences (Mongkolrattanothai et al. 2004). This 38 kb element also 
contains the arginine-deiminase pathway gene cluster (arc) and is classed as an 
ACME II (arginine catabolic mobile element) as the oligopeptide-permease gene 
cluster (opp-3) which is present in ACME I, is absent (An Diep et al. 2006). 
 
1.6.7.2 SCCcap1 
SCCcap1 (27.4 kb) encodes 27 ORFs of which 15 are cap1 genes making up the 
cap1 operon (15.5 kb), which encodes the type 1 capsular polysaccharide. 
SCCcap1 carries a ccrB homologue with a nonsense mutation which renders the 
ccr incapable of an excision function. SCCcap1 has been found inserted into orfX 
at the same att site as SCCmec. A novel enterotoxin was found adjacent to the 
SCCcap1 site  (Luong et al. 2002). 
 
1.6.7.3 SCCfar or SCC476 
SCCfar or SCC476 (22.8 kb) was first found in the strain MSSA476. It encodes 18 
ORFs including the resistance determinant far1, which encodes resistance to 
fusidic acid. SCCfar also carries a type 1 ccr gene complex and a type 1 restriction 
modification system of hsdM, hsdS and hsdR (Holden et al. 2004). 
 
1.6.7.4 SCC12263 
SCC12263 (21.6 kb) found in S. hominis strain GIFU 12263 encodes 26 ORFs. 
SCC12263 carries a type 1 ccr gene complex and a cluster of restriction-
modification enzyme gene homologues in the right end. No antibiotic resistance 
genes or mobile elements were found in SCC12263 (Katayama et al. 2003). 
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1.6.7.5 SCCmercury or SCCHg 
SCCHg is found inserted adjacent to the J3 region of SCCmec type III, is flanked 
by DR sequences and contains the mer operon, which encodes resistance to 
mercury, a ccrC gene complex, a truncated restriction-modification gene (ΔhsdR) 
and Tn554 (Ito et al. 2001). See Figure 1.3. 
 
 
1.6.8 SCC-like Cassette Chromosome Elements 
 
SCC-like elements do not carry mecA or a ccr gene complex and are reliant on 
neighbouring ccr gene complexes for their incision and excision. These elements 
are flanked by DR sequences and are often found at the 3' end of a SCCmec 
element (Ito et al. 2003a). It is thought that SCC-like elements are remnants of 
something that was previously active (Ito et al. 2003a; Berglund et al. 2008). 
 
1.6.8.1 Arginine Catabolic Mobile Element (ACME) 
The arginine catabolic mobile element (ACME) was first described in the S. 
aureus strain USA300. This mobile element is 30.9 kb in size and carries a 
characteristic cluster of six genes including the arc gene cluster, which encodes an 
arginine-deiminase pathway and an Opp-3 operon, which encodes a putative 
oligopeptide-permease system. ACME, like other SCC elements integrates into 
orfX and is flanked by characteristic DR (15 bp) and IR (26 bp). ACME does not 
have ccrA/ccrB recombinase genes and relies on adjacent recombinase genes to 
catalyse integration and excision. The presence of ACME possibly has a role 
enhancing the capacity of USA300 to grow and survive in its host (An Diep et al. 
2008). ACME is classified into two allotypes with allotype I being found in 
USA300 and allotype II, differing by the absence of the Opp-3 operon found in S. 
epidermidis ATCC12228 (An Diep et al. 2006). 
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1.6.8.2 CC6082 
CC6082 (5.6 kb) is found at the right extremity of the SCCmec adjacent to the J1 
region of SCCmec type VII strain JCSC6082, is flanked by DR sequences, typical 
of SCC-like cassettes, and contains five ORFs, three encoding hypothetical 
proteins, a hsdM gene encoding a type 1 restriction-modification system DNA 
methylase, a membrane protein homologue gene and a gene encoding a 
hypothetical protein similar to a reverse transcriptase (Berglund et al. 2008). 
 
1.6.8.3 CCV14 
CCV14 is found at the right extremity of the SCCmec adjacent to the J1 region of a 
novel SCCmec type III strain, V14, isolated in India. CCV14 is flanked by DR 
sequences (Arakere et al. 2009). 
 
1.6.8.4 IE25932 
IE25932 (5.8kb) was first described in the MSSA strain ATCC25932 which was 
isolated in 1945. The IE25932 element was found in orfX, at the same site utilised 
by SCCmec, and is flanked by incomplete IR and DR (15bp) sequences. IE25932 
carries no drug-resistance genes or any ORFs with inferable function or ccr genes, 
suggesting it is a remnant of SCC or SCCmec (Ito et al. 2001). The IE25932 SCC-
like element has more recently been described in the SCCmec subtype IVc strain 
81/108 where it is found at the right extremity adjacent to the J1 region (Ito et al. 
2003a). 
 
These SCC-like elements CC6082, CCV14, and IE25932 have been found at the 
right extremity of SCCmec suggesting that they previously existed in MSSA 
strains and that a mobile SCCmec element has inserted itself between orfX and the 
SCC-like element at the same att site. 
 
 
 
 
                                                                                              Materials and Methods 
 80
Chapter Two 
Materials and Methods 
 
Materials 
 
 
2.1 Bacterial Strains 
 
The strains used in this study were prototypes of CA-MRSA lineages isolated in 
WA between the years 2003-2006. They were provided by ACCESS (formally 
known as GPBTRU) at PathWest laboratories, Royal Perth Hospital (RPH), Perth, 
WA. ACCESS Typing and Research Unit is a joint collaboration with Curtin 
University, School of Biomedical Sciences, Molecular Genetics Research Unit, 
Medical Research Foundation, RPH, Perth, WA. The strains were partially 
characterised and are listed in Table 2.1. 
 
 
2.2 Media 
 
The media used in this project included trypticase soy broth (TSB), Mueller-
Hinton Agar (MHA), Mueller-Hinton broth (MHB), blood agar (BA), brain-heart 
infusion agar (BHIA) and, brain-heart infusion broth (BHIB). All media were 
supplied by Oxoid Ltd (Hampshire, UK) and prepared by PathWest Laboratory 
Medicine WA, Media (Mt Claremont, WA).  
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Table 2.1 Panel of WA CA-MRSA  
Name Resistance Profile Urea
COAG PCR-
RFLP PFGE MLST SCCmec ccr 
mec 
com-
plex 
Clonal 
Complex 
WA MRSA-1 Ery, Fus POS 20 WA 1 ST1 IVa 2 B 1 
WA MRSA-2 Ery POS 258 8 ST255 IVa 2 B 88 
WA MRSA-3 Ery POS 36 12sub ST5 IVa 2 B 5 
WA MRSA-4 Fully S POS DNC 9sub ST45 V 5 C2 45 
WA MRSA-5 Tet POS 18 1sub ST8 IVa 2 B 8 
WA MRSA-6 Tet POS 18 WA 6 ST8 IVa 2 B 8 
WA MRSA-7 
Qld Clone Fully S POS 32 
nmMRSA 
A ST93 IVa 2 B Singleton 
WA MRSA-8 Fully S POS DNAmp nmMRSA F ST75 IVa 2 B 75 
WA MRSA-9 
Taiwan Clone Ery, Tet POS 40 WA 9 ST59 VT 5 C2 59 
WA MRSA-10 Trim POS 34 WA 10 ST573 V 5 C2 1 
WA MRSA-11 Gent POS 34 26 ST5 V 5 C2 5 
WA MRSA-12/ 
USA300 Tet POS 18 
nmMRSA 
D ST8 IVc 2 B 8 
WA MRSA-13 Ery POS 32 WA 13 ST834 IVc 2 B 9 
WA MRSA-14 Tet, Trim, Fus POS 40 WA 14 ST5 V 5 C2 5 
WA MRSA-15 Fully S POS 40 WA 15 ST59 IVa 2 B 59 
WA MRSA-16 Gent, Ery, Cip, Mup NEG 18 WA 16 ST8 Novel 4 A 8 
WA MRSA-17 Tet, Fus POS DNC WA 17 ST583 IVc 2 B 80 
WA MRSA-18 Fully S POS 36 WA 18 ST5 Novel NT B 5 
WA MRSA-19 Ery, Gent, Cip, Fus, Mup NEG 18 WA 19 ST609 IVb 2 B 8 
WA MRSA-20 Gent, Tet, Trim, Rif POS DNC WA 20 ST612 IVd 2 B 8 
WA MRSA-21 Fully S POS 34 WA 21 ST5 Novel NT B 5 
WA MRSA-22 Ery POS 42 WA 22 ST577 V 5 C2 121 
WA MRSA-23 Fully S POS/NEG 22 WA 23 ST45 IVc 2 B 45 
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Table 2.1 Panel of WA CA-MRSA (Cont.) 
Name Resistance Profile Urea
COAG PCR-
RFLP PFGE MLST SCCmec ccr 
mec com-
plex 
Clonal 
Complex 
WA MRSA-24 Ery POS 40 WA 24 ST87 IVb 2 B 59 
WA MRSA-25 Fully S POS DNC WA 25 ST575 IVa 2 B 5 
WA MRSA-26 Fully S POS 40 WA 26 ST59 Novel 5 B 59 
WA MRSA-27 Ery, Cip POS 36 WA 27 ST5 Novel 2 C2 5 
WA MRSA-28 Tet POS 18 WA 28 ST361 Novel 4 C2 361 
WA MRSA-29 Cip POS 18 WA 29 ST672 IVa 2 B 672 
WA MRSA-30 Fully S POS DNC WA 30 ST728 IVc 2 B 80 
WA MRSA-31 Fully S POS 18 WA 31 ST576 IVv 2 B 8 
European Clone Tet, Fus POS DNC WA 32 ST80 IVc 2 B 80 
WA MRSA-33 Ery POS 32 WA 33 ST733 IV 2 B Singleton 
WA MRSA-34 Fully S NEG 36 WA 34 ST5 V 5 C2 5 
WA MRSA-35 Ery, Tet, Cip, Fus POS 36 WA 35 ST5 V 5 C2 5 
WA MRSA-36 Ery, Cip NEG 17 WA 36 ST8 Novel NT B 8 
WA MRSA-37 Fully S POS 40 WA 37 ST732 IV 2 B Un- determined
WA MRSA-38 Gent, Ery, Cip, Trim, Rif POS 22 WA 38 ST188 IVa 2 B 188 
WA MRSA-39 Ery, Fus POS 18 WA 39 ST526 IVv 2 B 5 
WA MRSA-40 Cip POS 36 WA 40 ST835 Novel 5&2 C2 5 
WA MRSA-41 Fully S POS 32 WA 41 ST834 IV 2 B 9 
WA MRSA-42 Ery POS 40 WA 42 ST87 Novel NT B 59 
WA MRSA-43 Cip POS 36 WA 43 ST835 V 5 C2 5 
WA MRSA-44 Trim POS 40 WA 44 ST72 IVa 2 B 72 
WA MRSA-45 Ery, Fus, Trim, Mup POS DNAmp WA 45 ST872 IVa 2 B 1 
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Abbreviations for Table 2.1: Cip, Ciprofloxacin; DNAmp, Did Not Amplify; 
DNC, Did Not Cut; Ery, Erythromycin; Fully S, Fully sensitive; Fus, Fusidic 
Acid; Gent, Gentamicin; NT, Not Typable; Tet, Tetracycline; Mup, Mupirocin; 
RFLP, restriction fragment length polymorphism; Rif, Rifampicin; Trim, 
Trimethoprim 
 
The bacterial strains were stored at -20ºC in 15% glycerol in BHIB. 
 
 
2.3 Antimicrobial Agents 
 
Antimicrobial agents and concentrations are presented in Table 2.2. All antibiotic 
discs were supplied by Oxoid. The heavy metal discs were prepared as previously 
published (Townsend, Grubb, and Ashdown 1983). 
 
Table 2.2 Antimicrobial Agents 
Antimicrobial Agent Antimicrobial Abbreviation Concentration/Disc 
Gentamicin Gent 10µg 
Erythromycin Ery 15µg 
Tetracycline Tet 10µg 
Ciprofloxacin Cip 5µg 
Fusidic Acid Fus 10µg 
Rifampicin Rif 2µg 
Mupirocin Mup 5µg 
Trimethoprim Trim 25µg 
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Table 2.2 Antimicrobial Agents (Cont.) 
Antimicrobial Agent Antimicrobial Abbreviation Concentration/Disc 
Heavy Metals 
Cadmium acetate Cd 0.1M 
Phenylmercuric acetate Pma 0.17% w/v 
Mercuric chloride Mc 0.4g 
Propamidine isethionate Pi 1.0% w/v 
Sodium arsenate Asa 0.2µM 
Ethidium bromide Eb 15µg 
 
 
 
2.4 Buffers, Reagents and Chemicals 
 
2.4.1 High Pure (HP) Water 
 
Water was purified with an ELGA Labwater System (Veolia Water System Pty 
Ltd), with conductivity at 18.2 MΩ. 
 
2.4.2 Injectable Water 
Injectable water was supplied by Pfizer Australia in 20ml Steriamp® ampoules. 
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2.4.3 Lysis Solution 
Lysozyme   250U 
Lysostaphin  25U 
EDTA   1mM 
Tris pH 8   10mM 
Triton X   1.2% 
 
 
2.4.4 Gel Electrophoresis 
Ethidium Bromide  1mg/ml 
 
2.4.4.1 TAE Buffer (40x) 
 Tris    1.6M 
 Sodium acetate  0.8M 
 EDTA   40mM 
 pH to 7.2 with glacial acetic acid. 
  
 
2.4.4.2 Tracking Dye 
 Bromophenol blue 0.25% 
 Xylene cyanol FF 0.25% 
Ficol    15% 
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2.4.5 PCR Primers 
 
The primers generated in this study were designed using MacVector 7.2 software 
(Accelrys, Cambridge UK). 
 
 
Table 2.3 Primers for spa Typing 
Primer 
Name Primer Sequence (5' to 3') Gene Reference 
spaF TAAAGACGATCCTTCGGTGAGC
spa 
Shopsin et al. 
1999 
spaF2 GAACAACGTAACGGCTTCATCC Koreen et al. 2004 
spaF3 CTAAAAGATGACCCAAGCC This Study 
spaR CAGCAGTAGTGCCGTTTGCTT Shopsin et al. 1999 
 
 
Table 2.4 Primers for Sequencing the Regions of Ciprofloxacin Resistance (grlAB 
and gyrAB) 
Primer 
Name Primer Sequence (5' to 3') Gene Reference 
grlAF ACTTGAAGATGTTTTAGGTGAT 
grl 
Schmitz F-J 
et al. 1998 
grlAR TTAGGAAATCTTGATGGCAA 
grlBF CGATTAAAGCACAACAAGCAAG
grlBR CATCAGTCATAATAATTACTC 
gyrAF AATGAAGAAGGTATGACACC 
gyr 
gyrAR TACGCGCTTCAGTATAACGC 
gyrBF CAGCGTTAGATGTAGCAAGC 
gyrBR CCGATTCCTGTACCAAATGC 
 
 
                                                                                              Materials and Methods 
 87
Table 2.5 Primers for Typing the SCCmec 
PCR 
Name 
Primer 
Name Primer Sequence (5' to 3') Target Reference
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
De 
Lencastre 
Multiplex 
Primer 
Set 
CIF2 F2 TTCGAGTTGCTGATGAAGAAGG 
SCCmec 
I 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oliveira & 
de 
Lencastre 
2002 
CIF2 R2 ATTTACCACAAGGACTACCAGA 
KDP F1 AATCATCTGCCATTGGTGATGC 
SCCmec 
II 
KDP R1 CGAATGAAGTGAAAGAAAGTGG 
MEC1 
P2 ATCAAGACTTGCATTCAGGC SCCmec 
II, III MEC1 
P3 GCGGTTTCAATTCACTTGTC 
DCS F2 CATCCTATGATAGCTTGGTC 
SCCmec 
I, II, IV 
DCS R1 CTAAATCATAGCCATGACCG 
RIF4 F3 GTGATTGTTCGAGATATGTGG 
SCCmec 
III 
 
 
 
 
 
 
 
 
RIF4 R9 CGCTTTATCTGTATCTATCGC 
 
 
 
 
 
 
 
 
 
RIF5 
F10 TTCTTAAGTACACGCTGAATCG SCCmec 
III RIF5 
R13 GTCACAGTAATTCCATCAATGC 
IS431 P4 CAGGTCTCTTCAGATCTACG 
SCCmec 
IA pUB110 
R1 GAGCCATAAACACCAATAGCC 
IS431 P4 CAGGTCTCTTCAGATCTACG 
SCCmec 
IIIA pT181 
R1 GAAGAATGGGGAAAGCTTCAC 
MECA 
P4 TCCAGATTACAACTTCACCAGG 
mecA 
MECA 
P7 CCACTTCATATCTTGTAACG 
 
mec 
Complex 
MRA1 GTCTCCACGTTAATTCCATT mecR1 
MS 
domain 
 
 
Hiramatsu 
et al.1992 
 
 
MRA2 GTCGTTCATTAAGATATGACG 
MRB1 AAGCACCGTTACTATCTGCACA 
mecR1 
PB 
mecR1 
PB 
domain 
MRB2 GAGTAAATTTTGGTCGAATGCC 
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Table 2.5 Primers for Typing the SCCmec (Continued) 
PCR 
Name 
Primer 
Name Primer Sequence (5' to 3') Target Reference
mec 
Complex 
mA ACCAAACCCGACAACTACAAC mecA Archer et al. 1994 
Rorf2 GGACAACTTAAGCCAGGGTA IS1272 Lim et al. 2003 
IS-1 ACATTAGATATTTGGTTGCGT 
IS431/257 
Barbaris-
Maino et 
al. 1987 IS-2 TGAGGTTATTCAGATATTTCGATGT
m15 GACTGGAGTCCAAAAACCATTCG 
mecI Lim et al. 2003 
m16 AAGACAAGTGAATTGAAACCGCC 
 
 
 
 
 
ccr Gene 
Complex 
 
 
 
 
 
 
 
CB ATTGCCTTGATAATAGCCTTCT ccrB 
Ito et al. 
2001 
cA1 AACCTATATCATCAATCAGTACGT ccrA1 
cA2 TAAAGGCATCAATGCACAAACACT ccrA2 
cA3 AGCTCAAAAGCAAGCAATAGAAT ccrA3 
C1 TGAAGAAGCACAAGAAGAGCGGC ccrA4 Lim et al. 
2003 
 Lim et al. 
2003 C2 CTGCACCACATTTTGGGCAC ccrB4 
c5 F CGTCTATTACAAGATGTTAAG 
ccrC Ito et al. 2004 
c5 R CCTTTATAGACTGGATTATTC 
 
 
Zhang 
Multiplex 
Primer 
Set 
 
 
Type I 
F GCTTTAAAGAGTGTCGTTACAGG 
SCCmec I 
 
Zhang et 
al. 2005 
 
Type I 
R GTTCTCTCATAGTATGACGTCC 
Type II 
F CGTTGAAGATGATGAAGCG SCCmec 
II Type II 
R CGAAATCAATGGTTAATGGACC 
Type 
III F CCATATTGTGTACGATGCG SCCmec 
III Type 
III R CCTTAGTTGTCGTAACAGATCG 
Type 
IVa F GCCTTATTCGAAGAAACCG 
SCCmec 
IVa 
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Table 2.5 Primers for Typing the SCCmec (Continued) 
PCR 
Name 
Primer 
Name Primer Sequence (5' to 3') Target Reference
Zhang 
Multiplex 
Primer 
Set 
 
Type IVa 
R CTACTCTTCTGAAAAGCGTCG 
SCCmec 
IVa 
Zhang et 
al. 2005 
 
 
 
Type IVb 
F TCTGGAATTACTTCAGCTGC SCCmec 
IVb Type IVb 
R AAACAATATTGCTCTCCCTC 
Type IVc 
F ACAATATTTGTATTATCGGAGAGC SCCmec 
IVc Type IVc 
R TTGGTATGAGGTATTGCTGG 
Type IVd 
F5 CTCAAAATACGGACCCCAATACA SCCmec 
IVd Type IVd 
R6 TGCTCCAGTAATTGCTAAAG 
Type V F GAACATTGTTACTTAAATGAGCG 
SCCmec 
V 
Type V R TGAAAGTTGTACCCTTGACACC 
MecA147 
F GTGAGGATATACCAAGTGATT 
mecA 
MecA147 
R ATGCGCTATAGATTGAAAGGAT 
 
 
Table 2.6 Primers for Sequencing the SCCmec of WA MRSA-40 
 
PCR 
Name 
Primer 
Name Primer Sequence (5' to 3') Target Reference
 
SCCmec 
junction-
ccrC1 
Allele 8 
 
 
P127 
(orf3orf51F) CGTGTTATTTTAGAAGCGACTATG 
orf3-
orf5  
 
This 
Study 
 
P133 
(orf3orf52F) TGTCTACCAAGAAGGAGAG 
P140 
(orf3orf53F) GCGTTTATTGGGCTTTCAG 
P134 
(orf3orf52R) CGTTTCTCACTACCATTTGGAC 
P128 
(orf3orf51R) CGTATGTTGGACTGCTTTAGG 
P109 
(TCccrC1F) GACAAAACACAGCAATGGC 
 
orf5-
ccrC 
 
 
P129 
(orf5ccrC1F) TACAATGGTTGGATGCGGTCAGCC 
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Table 2.6 Primers for Sequencing the SCCmec of WA MRSA-40 (Continued) 
PCR 
Name 
Primer 
Name Primer Sequence (5' to 3') Target Reference
SCCmec 
junction-
ccrC1 
Allele 8 
 
 
P135 
(orf5ccrC2F) CGTTAGATGCGTTTGGAGG 
orf5-
ccrC 
 
This 
Study 
 
P141 
(orf5ccrC3F) GCTTGAAGGTCGTTTTGAC 
P130 
(orf5ccrC1R) TTAGATTATTGCTACAGACTATCGG 
P89 
(ccrC8R) GGTTGTAATGGCTTTGAGG ccrC1 
Allele 
8 
Higuchi et 
al. 2008 
P10 
 (RIF5 R13) GTCACAGTAATTCCATCAATGC 
Oliveira 
& De 
Lencastre 
2002 
 
 
 
 
 
 
 
 
 
ccrC1 
Allele8-
mecA 
 
 
 
 
 
 
 
 
P17 
(Fdru1F) AATCTGCCAAGGGACGAAG 
ccrC-
dru 
This 
Study 
P23 
(Fdru2F) CCGCATTATGATGGCATTC 
P24 
(Fdru2R) GATGTTATCACTGTAGCCGTTG 
P18 
(Fdru1R) GGGAATAGTATGTGCGAGAGAC 
P9  
(dru F) GTTAGCATATTACCTCTCCTTGC 
dru Larsen et al. 2008 P11 
 (dru R) GCCGATTGTGCTTGATGAG 
P1 
(drumec1F) CTCCATAATCAATACGAATC dru-
mecA 
This 
Study P2 
(drumec1R) GCTACAATCCCAAAATCTCAGG 
P3  
(MECA P4) TCCAGATTACAACTTCACCAGG 
mecA 
Oliveira 
& De 
Lencastre 
2002 
P7  
(MECA P7) CCACTTCATATCTTGTAACG 
 
mecA-
ccrC1 
Allele 2 
 
P15 
(mecF1F) CAACGATTGTGACACGATAG 
mecA-
Zhang 
V 
This 
Study 
P21 
(mecF2F) CCCAATCTAACTTCCACATACC 
P80 
(mecZh4R) TCTGAAGAGACCTGCGGTTC 
P72 
(mecZh3F) AGAACCGCAGGTCTCTTCAG 
P68 
(mecZh3R) ACCACCATTTTTCCCTGG 
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Table 2.6 Primers for Sequencing the SCCmec of WA MRSA-40 (Continued) 
PCR 
Name 
Primer 
Name Primer Sequence (5' to 3') Target Reference
mecA- 
ccrC1- 
Allele 
2 
P65 
(mecFZh2R) CACTCCACAGGTAGCCTTTC mecA- 
Zhang 
V 
This 
Study P37 
(mecFZh1R) CATAGAAAAAACACCTCCGC 
P13  
(Zhang VF) GAACATTGTTACTTAAATGAGCG 
Zhang 
V 
Zhang et 
al. 2005 
P19  
(ZhF1F) GACGACAAGGATAGGTAAACC 
Zhang 
V-
ccrC1 
Allele 2 
This 
Study 
P25  
(ZhF2F) TCATTCCTCGCTAAAGTCTG 
P32 
 (ZhF3F) GCATCCATTACCAAAGTCAG 
P34  
(ZhF4F) TTGGGAGCAGATTAGCGAG 
P49 
 (ZhF5F) GGAAGAGAGCAACATTATCCTG 
P60 
 (ZhF6F) TTGGCACACGAACACATCGG 
P50 
 (ZhF5R) GCTGTGCTACATTTTGTGC 
P35 
 (ZhF4R) CCGTTGATTTCTGTATGCCATC 
P33 
 (ZhF3F) ACACGCTTTCTGATGTGC 
P26 
 (ZhF2R) AGTTGTTCCTGCTCCTTTTC 
P20 
 (ZhF1R) TTACCACTTCTTCGCTGAAC 
P14  
(RIF5 F10) TTCTTAAGTACACGCTGAATCG 
ccrC1 
Allele 2 
Oliveira 
& De 
Lencastre 
2002 
 
ccrC1 
Allele 
2- 
hsd 
 
P66 
(Zh49hsd2F) GCGTCAAGTGTGATAGAAGAACTG 
ccrC1 
Allele2-
hsd  
 
This 
Study 
 
P78 
(Zh49hsd3F) GTGGCTGAAGATGTATTACCTG 
P79 
(Zh49hsd3R) TCGCATAAGCACCATAGGC 
P67 
(Zh49hsd2R) GGTATCTAAGCGTTTCTCTGAG 
P61 
(Zh49hsd1R) GATAAACCGATGAAAGGGC 
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Table 2.6 Primers for Sequencing the SCCmec of WA MRSA-40 (Continued) 
PCR 
Name 
Primer 
Name Primer Sequence (5' to 3') Target Reference
 
 
 
 
 
hsd 
 
 
 
 
 
 
P54 
(VO21R) GAACCTGAACAAAACGAAACGACC 
hsdR 
This 
Study 
 
P52 
(VO21F) CCGCTTTATCTGTATCTATTGCCG 
P70 
(hsdRM2F) GCATTCGGTAAAGCATCTC  
 
hsdR-
hsdM 
 
 
 
hsdR-
hsdM 
P76 
(hsdRM3F) CAATCACTACGATAGGCAAGC 
P77 
(hsdRM3R) TCTACAGGGAGTGCTAATCAAG 
P69 
(hsdRM2R) GGACAACTCTTTTACTCAACCC 
P64 
(hsdRM1R) TGTGTTAGGTCGTGTGTATGAG 
P53 
(VO23R) TTGAGAGGAAGTATGGATGCTGC hsdM 
VO22F ATCCTGCTTTTCCTCCAG 
hsdS 
VO22R GCGGCATTTCTAACGATG 
P55 
(VO23F) TACCCCCTGAACCACAACAAGG hsdM 
 
 
 
 
 
 
 
hsd-
Right 
hand 
end 
 
 
 
 
 
 
 
 
 
 
P81 
(hsdorfY1F) GGTGGATGGTGTTACAAATG  
 
 
 
 
 
 
hsd-
orfY 
 
 
 
 
 
 
 
 
 
 
P83 
(hsdorfY2F) GTCAATAAAATCTGGGTGGG 
P87 
(hsdorfY3F) GGCTCATCTACATCCTACTATGC 
P91 
(hsdorfY4F) CACAAATGACAGTTGGAATG 
P94 
(hsdorfY5F) GATTACCCATTCATTCTCAC 
P96 
(hsdorfY6F) TCAGGGTTTAGAAAGGGGGC 
P104 
(hsdorfY7F) CGTATCACACCAGCAAAAC 
P97 
(hsdorfY6R) GGAAGTGCCGAATAAAGG 
P95 
(hsdorfY5R) GCTCCAGCGTCATTTTCTAC 
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Table 2.6 Primers for Sequencing the SCCmec of WA MRSA-40 (Continued) 
PCR 
Name 
Primer 
Name Primer Sequence (5' to 3') Target Reference
hsd- 
Right 
hand 
end 
P92 
(hsdorfY4R) ACTTCGCTTTCAGTCGTATG 
hsd- 
orfY This 
Study 
P88 
(hsdorfY3R) TTGTTCTTTTGAAACTTC 
P84 
(hsdorfY2R) TTCCTGTGGATGTCCTTGG 
P82 
(hsdorfY1R) GCCAACTCTATTCCATTTCC 
P62  
(orfY) GCGAACACACAAGCAAAG 
Taiwan 
Clone 
orfY 
 
ccrC 
 
 
ccrC8F GCATGGGTACTCAATCCA 
ccrC8  
Higuchi et 
al.2008 
 
 
ccrC8R GGTTGTAATGGCTTTGAGG 
ccrC2F ATAAGTTAAAAGCACGACTCA 
ccrC2 
ccrC2R TTCAATCCTATTTTTCTTTGTG 
 
 
Table 2.7 Primers for Sequencing ΨSCCpls 
PCR Name Primer Name Primer Sequence (5' to 3') Target Reference
 
 
 
ΨSCCpls 
orfX-hsd 
 
 
P158 
(OSorfXF) CCAGCAGCGATGTTTGTATTAG 
orfX 
 
 
 
This 
 Study 
 
P57 
(orfXF) CCGCCAATGACGAATACAAAGTC 
P28  
(orfXR) GTTCCAGACGAAAAAGCACCAG 
orfX-pls 
P71 
(orfXdru1F) GCGATGTAACGAAGATGCTAAC 
P74 
(orfXdru2F) GTTCCATTTTCTCGCCTC 
P137 
(orfXpls1R) CGCCTTTAGTTCCTGTATC 
P126 
(plsR) ACAATAACATCAGGTGAGCC 
P138 
(plsHP1F) GGTCAAAATGCCCTAAATAC 
 
pls-HP 
 
 
P144 
(plsHP2F) AAAAGCAGGCGAACCAGAGG 
 
                                                                                              Materials and Methods 
 94
Table 2.7 Primers for Sequencing ΨSCCpls (Continued) 
PCR Name Primer Name Primer Sequence (5' to 3') Target Reference
ΨSCCpls 
orfX-hsd 
 
P160 
(pls1F) AGGCTCACCTGATGTTATTG 
pls-HP 
 
This 
 Study 
 
P161 
( pls2F) 
GGAAGTAACGAAAGAACCAATA
GAC 
P162 
(pls2R) TCAAGCCATCTTTACCTGG 
P148 
(plsHP3R) GAGCATCATTACCAGTATCC 
P145 
(plsHP2R) CTCTTTAGTAGTATTATCTGGTCG 
P139 
(plsHP1R) CCTTTAGCCACTTTCTGAGC 
 
 
 
 
HP-hsd 
 
 
 
 
P146 
(HPF1) GACACTCTTCTTCTACTTATGC 
P151 
(HPhsdF1) AAGCGAAAGATACGGGTC 
P153 
(HPhsd2F) AGCATCTTGAATCTCAGCAC 
P156 
(HPhsd3F) 
CCTTCAGGAGTGTAATAATGTTC
AC 
P159 
(HPhsd4F) GTCGTCAACAGTGAAGTTTTG 
P157 
(HPhsd3R) CGCCAAACAAAATACAAG 
P154 
(HPhsd2R) GCTGAAGGTAAAGAGGACAATG 
P152 
(HPhsd1R) GCCGTTCCATTAGCAGTAAC 
P117 
(orfXhsd2R) ACATACTCATTATTATTAGG 
hsd/ 
SCCsorbitol 
P111 
(orfXhsd1R) TAACTCAATCTGGCGGTCG 
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Table 2.8 Primers for Sequencing SCCsorbitol 
PCR Name Primer Name Primer Sequence (5' to 3') Target Reference
 
 
 
 
 
 
 
 
 
 
  
hsd- 
SCCmec 
junction  
 
 
 
 
 
 
 
 
 
 
 
 
P28 
 (orfXR) GTTCCAGACGAAAAAGCACCAG 
 
 
 
 
 
hsd-
ccrA2B2 
 
 
 
 
 
 
 
This 
 Study 
 
 
P98 
(CIccr21F) ATAGCAGGTATGACACAG 
P102 
(CIccr22F) ATGAAAGCGAGCCCAAGAC 
P105 
(CIccr23F) CTCTCTGATTCATCTAATAAATG 
P107 
(CIccr24F) CATCATAGGGACAACTGGG 
P114 
(CIccr26F) ATTAAAGCATCCCTCACCG 
P110 
(CIccr25R) ATGTGATGCTTTTGCCAG 
P108 
(CIccr24R) CACCAACATTTATCACGGG 
P106 
(CIccr23R) CGACTCAAAGCATTGTATCTATCAG 
P103 
(CIccr22R) CAAGTCAGTCAAAAACCCC 
P99 
(CIccr21R) GGTAAATCTATGAACAGACCTGAG 
P41  
(CA2) TAAAGGCATCAATGCACAAACACT 
ccrA2B2 Ito et al. 2001 P40 
(CB) ATTGCCTTGATAATAGCCTTCT 
P112 
(ccr2orf31F) TGATAAAAGTCTCGGCACAC 
 
 
ccrA2B2
-orf3 
 
 
 
 
This 
Study 
 
P115 
(ccr2orf32F) CCACTACGATTATCTTTGCG 
P118 
(ccr2orf33F) TAGTTGTTTGGCGTCCACGGTCAG 
P120 
(ccr2orf34F) AACCTTCAAGTGCGTTACG 
P124 
(ccr2orf35F) AGCAATCACCTCCTTTCG 
P131 
(ccr2orf36F) GAAAAGAGGTAAATAAAGTG 
P142 
(ccr2orf37F) TTGTAAGTGAGAACCAAAAG 
P149 
(ccr2orf38F) GTGATTTTCATAAGCGTG 
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Table 2.8 Primers for Sequencing SCCsorbitol (Continued) 
PCR Name Primer Name Primer Sequence (5' to 3') Target Reference
hsd- 
SCCmec 
junction  
 
 
P155 
(ccr2orf39F) CATCTTTGAATGCCTCTGC 
ccrA2B2
-orf3 
 
This 
 Study 
 
P150 
(ccr2orf38R) CGGATGGGTAACTGATTTCACAAC 
P143 
(ccr2orf37R) GAAAAAAATACCATCGCC 
P132 
(ccr2orf36R) GATTTTGTTACAGAAAGTG 
P125 
(ccr2orf35R) GAGCAACATTTCTTGATG 
P121 
(ccr2orf34R) TTCTATGTCAGTAAAGGATGTC 
P119 
(ccr2orf33R) TTCCAAAGAAGAACATCCTG 
P116 
(ccr2orf32R) ATGACGCAGAATGTAAGAGC 
P113 
(ccr2orf31R) TCATAATCTGGTAAGGACGG 
P51  
(TC1R) CCTTACAACTTTTACCGTCG 
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2.4.6 DNA Size Marker 
 
The 1 kb Plus DNA ladder (Invitrogen™ Australia Pty Ltd) was used to estimate 
the size of PCR products. See Figure 2.1. 
 
 
 
 
 
Figure 2.1 The Increments of the 1 kb Plus DNA Ladder. Figure from 
Invitrogen™ 1kb Plus DNA ladder catalogue documentation. 
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2.5 Suppliers of Reagents and Chemicals 
 
Table 2.9 Suppliers of PCR Primers, Reagents and Chemicals  
Reagents/Chemicals Suppliers 
Abbott Abbott Australia Pty Ltd Cronulla, NSW, Australia 
Ajax Chemicals APS Chemicals Ltd Seven Hills, NSW, Australia 
Applied Biosystems/Life 
Technologies 
Applied Biosystems/Life Technologies 
Mulgrave Vic, Australia 
BBL® 
Becton, Dickinson and Company 
Macquarie University, Research Park, 
North Ryde, NSW, Australia 
BDH Chemicals Merck Pyt Ltd Kilsyth, Vic, Australia 
Bio-Rad Laboratories Bio-Rad Laboratories Reagents Park, NSW, Australia 
ELGA Labwater System Veolia Water System Pty Ltd Pyrmont, NSW, Australia 
GeneWorks GeneWorks Ltd, Thebarton, SA, Australia 
GlaxoSmithKline 
GlaxoSmithKline 
Pharmaceuticals Division 
Baronia, Vic, Australia 
Invitrogen™ Australia Invitrogen™ Australia Pty Ltd Mt Waverley, Vic, Australia 
KodakTM Kodak Australia Coburg, Vic, Australia 
Merck Merck Pty Ltd Kilsyth, Vic, Australia 
Mo Bio Laboratories GeneWorks Ltd Thebarton, SA, Australia 
Oxoid Oxoid Australia Pty Ltd Melbourne, Vic, Australia 
Pfizer Pfizer Australia West Ryde, NSW, Australia 
Promega Promega Corp Annandale, NSW, Australia 
QBiogene MP Biomedicals Australasia Seven Hills, NSW, Australia 
Roche Diagnostics Roche Diagnostics Australia Pty Ltd Castle Hill, NSW, Australia 
Sigma Chemical Company Sigma-Aldrich Pty Ltd Castle Hill, NSW, Australia 
Ultra-Violet Products Ltd Ultra-Violet Products Ltd Cambridge, UK 
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Methods 
 
 
2.6 Antimicrobial Sensitivity Testing 
 
Antimicrobial sensitivity testing was performed according to the Clinical and 
Laboratory Standards Institute (CLSI) guidelines (CLSI 2006). CLSI was 
formally the National Committee for Clinical Laboratory Standards (NCCLS) 
 
 
2.7 Chromosomal DNA Extraction 
 
DNA was extracted using the Invitrogen PureLinkTM Genomic DNA Purification 
Kit, as recommended by the supplier, with the addition of lysostaphin for lysis of 
the S. aureus cell wall. 
 
The strains were grown in 5ml TSB overnight at 35ºC. 700µl of culture was 
transferred into a 1.5ml Eppendorf tube and centrifuged at 13,000g for 3 min. The 
supernatant was discarded and the cell pellet was resuspended with 180µl lysis 
buffer and 20µl proteinase K. The tubes were then incubated for 30 min at 37ºC. 
After incubation 20µl RNAse was added. The tubes were left to stand for 2 min at 
room temperature. After mixing with a vortex mixer, 200µl binding buffer was 
added before further vortexing and incubated for 30 min at 70ºC. After incubation, 
200µl ethanol was added followed by further mixing by vortexing. The contents 
of each tube were then transferred to an extraction column and centrifuged for 1 
min at 12,000g. After centrifugation, 500µl wash buffer was added to the column 
which was centrifuged for 30 sec at 12,000g. This was followed by the addition of 
500µl wash buffer with ethanol and a further 30 sec centrifugation at 12,000g. 
The flow through and tube were discarded as required and replaced with a sterile 
tube for elution. DNA was eluted following the addition of 200µl sterile HP water 
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into the column, incubation for 1 min at room temperature and then centrifugation 
for 1.5 min at 12,000g. The DNA extracts were stored at -20ºC for future use. 
 
2.8 Agarose Gel Electrophoresis 
 
Amplified DNA from PCR products were viewed following gel electrophoresis. A 
1% PCR grade agarose gel made in TAE buffer was used. See Table 2.10 for 
electrophoresis times and voltages.  
 
Table 2.10 Gel Electrophoresis Times and Voltages 
PCR Reaction Voltage Time (Min) 
spa 60 40 
Ciprofloxacin 
gyrAB/grlAB 60 40 
dru 60 40 
SCCmec 
22 960 
60 40 
Long Range PCR 
22 960 
80 150 
 
 
The ethidium bromide (1μg/ml) was either mixed directly (5µl) with the 1% gel 
during preparation or the gel was stained post-electrophoresis in an ethidium 
bromide bath, consisting of 300μl ethidium bromide and 600ml HP water. DNA 
in the agarose gels was visualised using the Bio-Rad Scanner Fluor-S™ 
MultiImager and Bio-Rad Quantity One 4.6.3 1-D Analysis Software. 
 
                                                                                              Materials and Methods 
 101
2.9 PCR Clean-Up 
 
PCR products required a purification or clean-up process prior to DNA 
sequencing to remove any unwanted components of the PCR reaction such as 
primers, dNTPs, polymerase and buffer constituents. One of two methods was 
used according to the size of the PCR product. For a product size of ≤ 5 kb, the 
UltraClean™ PCR Clean-up Kit (MO BIO Laboratories, Inc) was used, and for a 
product size of > 5 kb the GENECLEAN® Turbo Kit (QBIOgene) was used. Both 
methods were performed according to the manufacturers recommendations with 
the final elution using injectable water according to the DNA concentration 
estimated from the band intensity on gel electrophoresis. If required, samples were 
further diluted with injectable water before sequencing to attain the required DNA 
concentration for PCR products of 50-10,000 bp length of approximately 
0.02ng/µl/bp of sequence. 
 
2.10 DNA Sequencing 
 
DNA sequencing was performed by capillary electrophoresis on a 3730 (48 
capillary) DNA Analyser (Applied Biosystems/Life Technologies) by the 
Department of Clinical Immunology and Immunogenetics, Royal Perth Hospital, 
Perth WA 
 
2.11 Bioinformatic Analysis 
 
DNA sequence analysis for relevant sections of this project was performed using 
the following software programmes: 
 AssemblyLIGN™ 1.0.9 (Oxford Molecular Group) 
MacVector 7.2 (Accelrys, Cambridge UK) 
BioEdit Sequence Alignment Editor 7.0.9 – 
 www.mbio.ncsu.edu/bioedit.bioedit.html 
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 RidomTraceEdit - www.ridom.de 
spa analysis – www.spaserver.ridom.de 
dru analysis – druID from www.dru-typing.org  
 
  
2.12 Staphylococcal Protein A (spa) 
 Typing 
 
Staphylococcal protein A (spa) region is a polymorphic region of the S. aureus 
chromosome characterised by a variable number of 24 bp repeats that are used for 
strain typing. 
 
PCR for amplification of spa repeats was performed as previously published 
(Koreen et al. 2003). 
 
Amplification was performed using an iCycler, version 1.259, 96 well 0.2 ml 
Reaction Module (Bio-Rad Laboratories). The cycler programme consisted of one 
cycle at 95ºC for 10 min; 30 cycles of 30 sec at 95ºC, 30 sec at 60ºC and 45 sec at 
72ºC; final extension at 72ºC for 10 min. 
 
PCR products were viewed following gel electrophoresis in a 1% agarose gel 
containing ethidium bromide. PCR products were then sequenced following PCR 
clean-up. 
 
spa sequences were analysed for repeat segments, 24 bp in length, that were then 
each assigned a Kreiswirth ID code (Koreen et al. 2003) and a Ridom Repeat 
Succession ID code (Harmsen et al. 2003). The web-site www.spaserver.ridom.de 
was used for the designation of the spa type. Sequences of unknown spa types 
were submitted online at this web-site following the instructions provided. 
 
                                                                                              Materials and Methods 
 103
spa sequences can be further analysed using the BioNumerics software program 
(version 6.5; Applied Maths, Ghent, Belgium), to generate a minimum spanning 
tree with spa types that are ≥97% similar being considered closely related and 
assigned to the same lineage (Benson 1997; Tenover et al. 2012). 
 
 
2.13 Investigation of Ciprofloxacin 
 Resistance 
 
Ciprofloxacin resistance in S. aureus results from base pair mutation in the gyrase 
(gyrA/B) and topoisomerase (grlA/B) genes. The genes were amplified by PCR 
and sequenced to detect any mutations. 
 
PCR for S. aureus gyrA/B and grlA/B genes amplifications were performed as 
previously published (Schmitz, Jones, et al. 1998). 
 
Amplification was performed using an iCycler, version 1.259, 96 well 0.2 ml 
Reaction Module (Bio-Rad Laboratories). The cycler programme consisted of one 
cycle at 94ºC for 10 min; 25 cycles of 20 sec at 94ºC, 20 sec at 55ºC and 50 sec at 
72ºC; final extension at 72ºC for 5 min. 
 
PCR products were viewed following gel electrophoresis in a 1% agarose gel 
containing ethidium bromide. PCR products were then sequenced following PCR 
clean-up 
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2.14 SCCmec Typing 
2.14.1 mec Complex 
Classes of the mec complex were detected using the following primer pairs in 
seven separate PCR reactions: MRA1 and MRA2 (class A-membrane-spanning 
domain), MRB1 and MRB2 (class A-penicillin-binding domain), mA and RORF2 
(class B), M15 and M16 (class A-mecI), mA and IS-2 (class C2) and mA and IS-1 
(class C1). 
 
PCR amplification was performed as previously published (Lim et al. 2003). 
 
PCR amplification was performed using an iCycler (Bio-Rad Laboratories). The 
iCycler program consisted of one cycle of 94ºC for 5 min; 10 cycles of 94ºC for 
45 sec, 65ºC for 45 sec and 72ºC for 1 min 30 sec; 25 cycles 94ºC for 45 sec, 55ºC 
for 45 sec and 72ºC for 1 min 30 sec; final extension at 72ºC for 10 min. 
 
2.14.2 ccr Gene Complex 
2.14.2.1 Multiplex PCR for ccr Types 1, 2 and 3 
A multiplex was performed to determine ccr gene complexes 1-3. The final 
reaction volume was 25µl with 2µl chromosomal DNA used as the template. PCR 
amplification was performed as previously published (Lim et al. 2003). 
 
The iCycler program (Bio-Rad Laboratories)  consisted of one cycle of 94ºC for 5 
min; 10 cycles of 94ºC for 45 sec, 65ºC for 45 sec and 72ºC for 1 min 30 sec; 25 
cycles 94ºC for 45 sec, 55ºC for 45 sec and 72ºC for 1 min 30 sec; final extension 
at 72ºC for 10 min (Lim et al. 2003). 
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2.14.2.2 PCR for ccr Types 4 and 5 
PCR was performed to determine ccr gene complexes ccr4 and 5 (ccrC). The final 
reaction for each was 25µl using 1µl chromosomal DNA and was performed as 
previously published (Lim et al. 2003). 
 
The iCycler program (Bio-Rad Laboratories)  consisted of one cycle of 95ºC for 5 
min; 25 cycles of 95ºC for 1 min, 60ºC for 1 min, 72ºC for 1 min; final extension 
72ºC for 5 min (Lim et al. 2003). 
 
2.14.2.3 Multiplex PCR for ccr Types 1, 2, 3, 4 and 5 
A multiplex PCR was also used to confirm the ccr gene complex. This enabled the 
determination of ccr 1-5 in one PCR reaction. The final reaction volume was 50µl 
with 2µl chromosomal DNA used in the template and was performed as 
previously published (Kondo et al. 2007). 
 
PCR amplification was performed using an iCycler (Bio-Rad Laboratories). The 
iCycler program consisted of one cycle of 94ºC for 5 min; 30 cycles of 94ºC for 2 
min, 57ºC for 1 min, 72ºC for 2 min; final extension 72ºC for 7 min (Kondo et al. 
2007). 
 
 
2.14.3 Structural Elements 
2.14.3.1 SCCmec Typing Utilising the Method of Oliveira, 
D.  and de Lencastre, H. (2002) 
The multiplex PCR was performed using a final volume of 50µl and 2 µl DNA. 
 
PCR amplification was performed using an iCycler (Bio-Rad Laboratories). The 
iCycler program consisted of one cycle of 94ºC for 4 min; 30 cycles of 94ºC for 
30 sec, 53ºC for 30 sec and 72ºC for 1 min; final extension at 72ºC for 1 min 
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(Oliveira and De Lencastre 2002). See Table 2.11 for the location and size (bp) of 
loci A-H and the mecA control used in the multiplex PCR. 
  
Table 2.11 Loci Locations and Amplicon Sizes for the Multiplex PCR of the 
SCCmec (Oliveira, D and de Lencastre, H. 2002) 
Locus Amplicon Size (bp) Location SCCmec Type 
A 495 Downstream of pls gene I 
B 284 Within kdp operon II 
C 209 Within mecI II, III 
D 342 Within dcs I, II, III 
E 243 Between plasmid pI258 and Tn554 III 
F 414 Between Tn554 and orfX III 
G 381 Between IS431 and pUB110 IA 
H 303 Between IS431 and pT181 IIIA 
mecA 162 mecA All SCCmec Types 
 
 
2.14.3.2 SCCmec Typing Utilising the Method of Zhang, 
K. et al. (2005) 
This multiplex PCR was performed to detect structural components in the J 
regions of the SCCmec. The final reaction volume of the reaction mix was 25µl 
with 1µl chromosomal DNA and PCR amplification was performed using an 
iCycler (Bio-Rad Laboratories). The iCycler program consisted of one cycle of 
94ºC for 5 min; 10 cycles of 94ºC for 45 sec, 65ºC for 45 sec, 75ºC for 1 min 30 
sec; 25 cycles 94ºC for 45 sec, 55ºC for 45 sec, 75ºC for 1 min 30 sec; final 
extension at 72ºC for 10 min (Zhang et al. 2005). See Table 2.12 for the primer 
names and amplicons sizes (bp) of the SCCmec types detected.  
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Table 2.12 Amplicon Sizes of the Multiplex PCR Utilising the Method of Zhang, 
K. et al. (2005)  
SCCmec Type/ Primer Name Amplicon Size (bp) 
I 613 
II 398 
III 280 
IVa 776 
IVb 493 
IVc 200 
IVd 881 
V 325 
mecA Control 146 
 
 
 
2.15 Long Range PCR 
 
Long Range PCR was performed using the Expand Long Range dNTPack 
(Roche) according to recommendations of the manufacturer. The final reaction 
volume was 50µl with 4µl chromosomal DNA as the template. The reaction mix 
contained 1x Expand Long Range buffer with 12.5 mM MgCl2, 500µM PCR 
Nucleotide mix (10nM each dNTP), 0.3 µM primers, 2.6% DMSO and 3.5U/µl 
Expand Long Range Enzyme mix. PCR amplification was performed using an 
iCycler (Bio-Rad Laboratories). The iCycler program consisted of one cycle of 
92ºC for 2 min; 10 cycles of 92ºC for 10 sec, 52ºC for 15 sec, 68ºC for 60 sec/kb 
expected product size; 20 cycles of 92ºC for 10 sec, 52ºC for 15 sec, 68ºC for 60 
sec/kb expected product size + 20 sec for each successive cycle; final extension of 
68ºC for 7 min. PCR products were viewed by gel electrophoresis using 1% 
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agarose gel and stained with ethidium bromide (1mg/ml). PCR products were 
sequenced following PCR clean-up using Ultra Clean DNA PCR Clean Up Kit 
(Mo Bio Laboratories) for PCR products < 5 kb. For PCR products ≥5 kb, 
GeneClean PCR Clean-Up Kit (QBiogene) was used.  
 
 
2.16 dru Typing 
 
The dru region was amplified as previously published (Larsen et al. 2008) and 
typed according to Goering, et al (2008). The final reaction volume was 25µl with 
1µl of chromosomal DNA used in the template. 
 
PCR amplification was performed using an iCycler (Bio-Rad Laboratories). The 
iCycler program consisted of one cycle of 94ºC for 5 min; 10 cycles of 94ºC for 
45 sec, 65ºC for 45 sec and 72ºC for 1 min 30 sec; 25 cycles 94ºC for 45 sec, 55ºC 
for 45 sec and 72ºC for 1 min 30 sec; final extension at 72ºC for 10 min (Larsen et 
al. 2008). dru sequences were analysed using the druID software from www.dru-
typing.org.  
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Chapter Three 
Results 
 
3.1 Staphylococcal Protein A Typing 
 
To determine the usefulness of staphylococcal protein A typing, or spa typing, as 
a typing tool for CA-MRSA, spa typing was performed on all CA-MRSA in this 
study. The results are presented in Table 3.1. 
 
Table 3.1 spa Types of CA-MRSA in this Study 
Isolate spa Type Ridom Repeat Succession ID Kreiswirth ID 
WA MRSA-1 t127 07-23-21-16-34-33-13 UJFKBPE 
WA MRSA-2 t186 07-12-21-17-13-13-34-34-33-34 UGFMEEBBPB 
WA MRSA-3 t002 26-23-17-34-17-20-17-12-17-16 TJMBMDMGMK 
WA MRSA-4 t123 09-02-16-34-13-16-34-16-34 A2AKBEKBKB 
WA MRSA-5 t008 11-19-12-21-17-34-24-34-22-25 YHGFMBQBLO 
WA MRSA-6 t008 11-19-12-21-17-34-24-34-22-25 YHGFMBQBLO 
WA MRSA-7 
(Qld Clone) t202 11-17-23-17-17-16-16-25 YMJMMKKO 
WA MRSA-8 NT 259-31-17-17-17-23-17-17-23-17-22 [r259]NMMMJMMJML
WA MRSA-9 
(Taiwan Clone) t437 04-20-17-20-17-25-34 ZDMDMOB 
WA MRSA-10 t5073 26-23-13-21-17-34-34-34-33-02-02-34 TJEFMBBBPAAB 
WA MRSA-11 t045 26-17-20-17-12-17-16 TMDMGMK 
WA MRSA-12 
(USA300) t008 11-19-12-21-17-34-24-34-22-25 YHGFMBQBLO 
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Table 3.1 spa Types of CA-MRSA in this Study (Continued) 
Isolate spa Type Ridom Repeat Succession ID Kreiswirth ID 
WA MRSA-13 t3029 15-12-17-20-17-12-17-16 WGMDMGMK 
WA MRSA-14 t442 35-17-34-17-20-17-12-17-16 C3MBMDMGMK 
WA MRSA-15 t976 04-20-17-20-31-16-34 ZDMDNKB 
WA MRSA-16 t024 11-12-21-17-34-24-34-22-25-28 YGFMBQBLO 
WA MRSA-17 t044 07-23-12-34-34-33-34 UJGBBPB 
WA MRSA-18 t002 26-23-17-34-17-20-17-12-17-16 TJMBMDMGMK 
WA MRSA-19 t064 11-19-12-05-17-34-24-34-22-25 YHGCMBQBLO 
WA MRSA-20 t064 11-19-12-05-17-34-24-34-22-25 YHGCMBQBLO 
WA MRSA-21 t002 26-23-17-34-17-20-17-12-17-16 TJMBMDMGMK 
WA MRSA-22 t3025 14-51-12-17-23-18-17 I2P2GMJH2M 
WA MRSA-23 t1575 08-16-02-16-34-17-34 XKAKBMB 
WA MRSA-24 t216 04-20-17-20-17-31-16-34 ZDMDMNKB 
WA MRSA-25 t002 26-23-17-34-17-20-17-12-17-16 TJMBMDMGMK 
WA MRSA-26 t976 04-20-17-20-31-16-34 ZDMDNKB 
WA MRSA-27 t002 26-23-17-34-17-20-17-12-17-16 TJMBMDMGMK 
WA MRSA-28 t315 26-22-17-20-17-12-17-17-16 TLMDMGMMK 
WA MRSA-29 t1309 26-22-17-20-17-12-17-17-16-16 TLMDMGMMKK 
WA MRSA-30 t044 07-23-12-34-34-33-34 UJGBBPB 
WA MRSA-31 t334 11-12-21-17-34-22-25 YGFMBLO 
European cMRSA t044 07-23-12-34-34-33-34 UJGBBPB 
WA MRSA-33 t3029 15-12-17-20-17-12-17-16 WGMDMGMK 
WA MRSA-34 t458 26 T1 
 
                                                                                                         Results 
 111
Table 3.1 spa Types of CA-MRSA in this Study (Continued) 
Isolate spa Type Ridom Repeat Succession ID Kreiswirth ID 
WA MRSA-35 t688 26-23-17-34-17-16 TJMBMK 
WA MRSA-36 t190 11-17-34-24-34-22-25 YMBQBLO 
WA MRSA-37 t528 4 Z1 
WA MRSA-38 t189 07-23-12-21-17-34 UJGFMB 
WA MRSA-39 t4065 26-23-23-17-20-17-12-17-16 TJJMDMGMK 
WA MRSA-40 t002 26-23-17-34-17-20-17-12-17-16 TJMBMDMGMK 
WA MRSA-41 t3029 15-17-20-17-12-17-16 WMDMGMK 
WA MRSA-42 t216 04-20-17-20-17-31-16-34 ZDMDMNKB 
WA MRSA-43 t002 26-23-17-34-17-20-17-12-17-16 TJMBMDMGMK 
WA MRSA-44 t791 07-23-12-21-12-17-20-17-12-17-17 UJGFGMDMGMM 
WA MRSA-45 t127 07-23-21-16-34-33-13 UJFKBPE 
Abbreviations: NT, not typable 
 
spa types are also arranged according to their clonal complex to indicate the 
association between spa type and MLST/clonal complex. These results are 
presented in Table 3.2. 
 
WA MRSA-8 was not typable. This isolate did not amplify by the standard or 
modified PCR protocols. A new forward primer (spa F3), was designed upstream 
of the existing spa F and the alternative spa F2 primer sites. spa F3 primer yielded 
a PCR product, however, the resulting sequence was not considered of high 
enough quality to be assigned a new spa type by the Ridom database curator. 
Analysis of a consensus sequence however, enabled the designation of a Ridom 
repeat succession ID and a Kreiswirth ID. The Ridom number for the repeat 
sequence, r259 was used as the start number for the Kreiswirth ID for WA 
MRSA-8 as no Kreiswirth nomenclature has been assigned for this repeat 
sequence. See Table 3.1. 
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Table 3.2 CA-MRSA Grouped into Clonal Complexes 
Clonal 
Complex Isolate 
spa 
Type 
Ridom 
Repeat Succession ID Kreiswirth ID 
CC1 
WA MRSA-1 t127 07-23-21-16-34-33-13 UJFKBPE 
WA MRSA-10 t5073 26-23-13-21-17-34-34-34-33-02-02-34 TJEFMBBBPAAB
WA MRSA-45 t127 07-23-21-16-34-33-13 UJFKBPE 
CC5 
WA MRSA-3 t002 26-23-17-34-17-20-17-12-17-16 TJMBMDMGMK
WA MRSA-11 t045 26-17-20-17-12-17-16 TMDMGMK 
WA MRSA-14 t442 35-17-34-17-20-17-12-17-16 C3MBMDMGMK
WA MRSA-18 t002 26-23-17-34-17-20-17-12-17-16 TJMBMDMGMK
WA MRSA-21 t002 26-23-17-34-17-20-17-12-17-16 TJMBMDMGMK
WA MRSA-25 t002 26-23-17-34-17-20-17-12-17-16 TJMBMDMGMK
WA MRSA-27 t002 26-23-17-34-17-20-17-12-17-16 TJMBMDMGMK
WA MRSA-34 t458 26 T1 
WA MRSA-35 t688 26-23-17-34-17-16 TJMBMK 
WA MRSA-39 t4065 26-23-23-17-20-17-12-17-16 TJJMDMGMK 
WA MRSA-40 t002 26-23-17-34-17-20-17-12-17-16 TJMBMDMGMK
WA MRSA-43 t002 26-23-17-34-17-20-17-12-17-16 TJMBMDMGMK
CC8 
WA MRSA-5 t008 11-19-12-21-17-34-24-34-22-25 YHGFMBQBLO 
WA MRSA-6 t008 11-19-12-21-17-34-24-34-22-25 YHGFMBQBLO 
WA MRSA-12 
(USA300) 
t008 11-19-12-21-17-34-24-34-22-25 YHGFMBQBLO 
WA MRSA-16 t024 11-12-21-17-34-24-34-22-25-28 YGFMBQBLO 
WA MRSA-19 t064 11-19-12-05-17-34-24-34-22-25 YHGCMBQBLO 
WA MRSA-20 t064 11-19-12-05-17-34-24-34-22-25 YHGCMBQBLO 
WA MRSA-31 t334 11-12-21-17-34-22-25 YGFMBLO 
WA MRSA-36 t190 11-17-34-24-34-22-25 YMBQBLO 
 
                                                                                                         Results 
 113
Table 3.2 CA-MRSA Grouped into Clonal Complexes (Continued) 
Clonal 
Complex Isolate 
spa 
Type 
Ridom 
Repeat Succession ID Kreiswirth ID 
CC9 
WA MRSA-13 t3029 15-12-17-20-17-12-17-16 WGMDMGMK 
WA MRSA-41 t3029 15-17-20-17-12-17-16 WMDMGMK 
CC45 
WA MRSA-4 t123 09-02-16-34-13-16-34-16-34 A2AKBEKBKB 
WA MRSA-23 t1575 08-16-02-16-34-17-34 XKAKBMB 
CC59 
WA MRSA-15 t976 04-20-17-20-31-16-34 ZDMDNKB 
WA MRSA-24 t216 04-20-17-20-17-31-16-34 ZDMDMNKB 
WA MRSA-26 t976 04-20-17-20-31-16-34 ZDMDNKB 
WA MRSA-42 t216 04-20-17-20-17-31-16-34 ZDMDMNKB 
WA MRSA-9 
(Taiwan Clone) 
t437 04-20-17-20-17-25-34 ZDMDMOB 
CC72 WA MRSA-44 t791 07-23-12-21-12-17-20-17-12-17-17 UJGFGMDMGMM 
CC75 WA MRSA-8 NT 259-31-17-17-17-23-17-17-23-17-22 [r259]NMMMJMMJML
CC80 
WA MRSA-17 t044 07-23-12-34-34-33-34 UJGBBPB 
WA MRSA-30 t044 07-23-12-34-34-33-34 UJGBBPB 
European cMRSA t044 07-23-12-34-34-33-34 UJGBBPB 
CC88 WA MRSA-2 t186 07-12-21-17-13-13-34-34-33-34 UGFMEEBBPB 
CC93 
WA MRSA-7 
(Qld Clone) 
t202 11-17-23-17-17-16-16-25 YMJMMKKO 
CC121 WA MRSA-22 t3025 14-51-12-17-23-18-17 I2P2GMJH2M 
CC188 WA MRSA-38 t189 07-23-12-21-17-34 UJGFMB 
CC361 WA MRSA-28 t315 26-22-17-20-17-12-17-17-16 TLMDMGMMK 
CC672 WA MRSA-29 t1309 26-22-17-20-17-12-17-17-16-16 TLMDMGMMKK 
Singleton WA MRSA-33 t3029 15-12-17-20-17-12-17-16 WGMDMGMK 
Undetermined WA MRSA-37 t528 4 Z1 
Abbreviations: NT, not typable 
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3.2 Ciprofloxacin Resistance in WA  
CA-MRSA 
 
A subset of ciprofloxacin-resistant CA-MRSA isolates was analysed for 
chromosomal mutations within the DNA gyrase and topoisomerase IV genes. The 
isolates analysed were WA MRSA-16, WA MRSA-19, WA MRSA-27, WA 
MRSA-29, WA MRSA-35, WA MRSA-38, WA MRSA-40 and WA MRSA-43. 
 
Previously defined regions of the ciprofloxacin-resistance associated genes, gyrA, 
gyrB, grlA and grlB were amplified by PCR and sequenced. The sequences were 
then compared to the ciprofloxacin sensitive reference strain S. aureus NCTC 
8325, GenBank Accession No. CP000253, and analysed for single point mutations 
using BioEdit 7.0.9 Sequence Alignment Editor. The corresponding codon 
locations for the detected mutations and the resulting amino acid changes are 
displayed in Table 3.3. 
 
Table 3.3 Mutations and Amino Acid Changes Within the grlA, grlB, gyrA and 
gyrB Genes in Eight Ciprofloxacin Resistant WA CA-MRSA 
Isolate 
grlA grlB gyrA gyrB
Codon 80 
nt 239 
Codon 84 
nt 251 
Codon 126 
nt 376 
Codon 471 
nt 1412 
Codon 84 
nt 251  
WA MRSA-16 Ser→Phe TCC→TTC 
Glu→Val 
GAA→GTA   
Ser→Leu 
TCA→TTA  
WA MRSA-19 Ser→Phe TCC→TTC   
Glu→Lys 
GAA→GGA 
Ser→Leu 
TCA→TTA  
WA MRSA-27 Ser→Tyr TCC→TAC
Glu→Gly 
GAA→GGA
Leu→Leu 
TTA→CTA  
Ser→Leu 
TCA→TTA  
WA MRSA-29 Ser→Phe TCC→TTC    
Ser→Leu 
TCA→TTA  
WA MRSA-35 Ser→Phe TCC→TTC    
Ser→Leu 
TCA→TTA  
WA MRSA-38 Ser→Phe TCC→TTC    
Ser→Leu 
TCA→TTA  
WA MRSA-40 Ser→Phe TCC→TTC    
Ser→Leu 
TCA→TTA  
WA MRSA-43 Ser→Phe TCC→TTC    
Ser→Leu 
TCA→TTA  
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Abbreviations (for Table 3.3): Glu, Glutamine; Gly, Glycine; Leu, Leucine; nt, 
nucleotide; Phe, Phenylalanine; Ser, Serine; Tyr, Tyrosine; Val, Valine 
All isolates possessed mutations in the grlA and gyrA genes. 
 
WA MRSA-16 possessed two resistance mutations in grlA, one at codon 80 of 
C→T resulting in a Ser→Phe amino acid change and one at codon 84 of A→T 
resulting in a Glu→Val amino acid change. In the gyrA gene a C→T change was 
detected at codon 84 resulting in an amino acid change of Ser→Leu. No 
mutations were detected in grlB or gyrB genes. 
 
WA MRSA-19 possessed a C→T mutation in the grlA gene at codon 80 resulting 
in an amino acid change of Ser→Phe. The grlB gene showed a mutation at codon 
471 of A→G resulting in an amino acid change of Glu→Lys. The gyrA gene 
showed a mutation at codon 84 of C→T resulting in an amino acid change of 
Ser→Leu, while no mutations were detected in the gyrB gene. 
 
WA MRSA-27 possessed four mutations. The gyrA gene contained three 
mutations, with the first at codon 80 of C→T resulting in an amino acid change of 
Ser→Tyr. The second mutation was at codon 84 with a change of A→G resulting 
in an amino acid change of Glu→Gly with the third mutation at codon 126 of 
T→C, not resulting in an amino acid change (Leu→Leu). The gyrA gene showed 
a mutation at codon 84 of C→T resulting in an amino acid change of Ser→Leu. 
No mutations were detected in grlB or gyrB. 
 
WA MRSA-29, WA MRSA-35, WA MRSA-38, WA MRSA-40 and WA MRSA-
43 all showed the same combination of mutations, with a C→T mutation in the 
grlA gene at codon 80 resulting in an amino acid change of Ser→Phe and a 
mutation in the gyrA gene at codon 84 of C→T resulting in an amino acid change 
of Ser→Leu. No mutations were detected in grlB or gyrB. 
 
In this study, three previously unreported amino acid changes in the S. aureus 
ciprofloxacin-resistance region were reported. The WA MRSA-19 mutation in 
grlB at codon 471, the WA MRSA-27 mutation at codon 84 of grlA and the silent 
mutation at codon 126 (Leu→Leu). 
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3.3 Novel SCCmecs  
 
Another subset of eight isolates was selected for SCCmec investigation in this 
study because their SCCmecs were classed as novel following previous testing 
(See Table 2.1). The class of mec complex and type of ccr gene complex was 
determined together with relevant structural elements present in the J regions.  
 
3.3.1 The mec Complex 
Results are presented in Table 3.4. 
 
WA MRSA-16, -27 and -28 were found to possess the membrane-spanning and 
penicillin-binding domains of mecR1 indicating an intact mecR1 gene. The 
presence of mecI and absence of IS1272 resulted in the SCCmecs of WA MRSA-
16, -27 and -28 being classified with class A mec complexes.  
 
The SCCmecs of WA MRSA-18, -21, -26 and -42 were found to possess only the 
membrane-spanning domain of mecR1, with the penicillin-binding domain and 
mecI truncated by the insertion of IS1272. The mec complexes of these MRSA 
were therefore classified as class B.  
 
The SCCmec of WA MRSA-40 was found to have a class C2 mec complex with 
mecI and the membrane-spanning domain of mecR1 truncated by IS431.  
 
Class A is positive for both the membrane-spanning and penicillin-binding 
domains of mecR1 and positive for mecI. 
 
Class B is positive for the membrane-spanning domain and negative for the 
penicillin-binding domain of mecR1 and mecI. Class B is positive for IS1272 
while Class A is negative for IS1272. 
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Table 3.4 Components of the mec Complexes of CA-MRSA with Novel SCCmecs 
Isolates 
Components mec 
Complex mecR1(MS) mecR1(PB) mecI IS1272 IS431 
WA MRSA-
16 POS POS POS neg NoTest A 
WA MRSA-
18 POS neg neg POS NoTest B 
WA MRSA-
21 POS neg neg POS NoTest B 
WA MRSA-
26 POS neg neg POS NoTest B 
WA MRSA-
27 POS POS POS neg neg A 
WA MRSA-
28 POS POS POS neg neg A 
WA MRSA-
40 POS neg neg neg POS C2 
WA MRSA-
42 POS neg neg POS neg B 
 
Abbreviations: MS, membrane-spanning domain; neg, negative; NoTest, not 
tested; PB, penicillin-binding domain; POS, positive. 
 
 
3.3.2 The ccr Gene Complex 
Results are presented in Table 3.5. 
 
The SCCmecs of WA MRSA-16 and -28 encoded the ccrA4B4 gene complex. 
 
The SCCmecs of WA MRSA-26, -27 and -42 encoded the ccrA2B2 gene 
complex.  
 
The SCCmec of WA MRSA-40 encoded both a ccrA2B2 and ccr5 (ccrC).  
 
The SCCmecs of WA MRSA-18 and -21 were both negative for all ccr PCR 
reactions, and were classified as not typable. 
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Table 3.5 Results for the ccr Gene Complexes 
Isolates 
ccr Gene Complex 
ccr Result 
1 2 3 4 5/C 
WA MRSA-16 neg neg neg POS neg 4 
WA MRSA-18 neg neg neg neg neg Not Typable 
WA MRSA-21 neg neg neg neg neg Not Typable 
WA MRSA-26 neg POS neg neg neg 2 
WA MRSA-27 neg POS neg neg neg 2 
WA MRSA-28 neg neg neg POS neg 4 
WA MRSA-40 neg POS neg neg WEAK POS 2 and 5/C 
WA MRSA-42 neg POS neg neg neg 2 
 
 
3.3.3 Structural Elements 
 
Two multiplex strategies were employed to determine the structural sub-types of 
the CA-MRSA. 
 
3.3.3.1 SCCmec Typing Utilising the Multiplex PCR 
Method of Oliveira, D and de Lencastre, H (2002) 
This multiplex PCR was used to differentiate structural elements within the 
SCCmec. Nine loci (A to H and mecA) were targeted. See Table 2.11 in Chapter 2. 
Structural heterogeneity of the J regions of the SCCmecs was demonstrated. 
While the reaction was useful to identify regions of sequence it was not 
informative as a SCCmec typing technique for the novel SCCmecs in this study. 
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This multiplex PCR was developed in 2002 and designed to detect SCCmec type’s 
I-IV. SCCmec type V, however, is not detected with this method (Oliveira and De 
Lencastre 2002). An update of this method has now been described with improved 
characterisation for SCCmec type IV subtypes and also including the detection of 
SCCmec type V (Milheiriço, Oliveira, and De Lencastre 2007). 
 
Results are presented in Figure 3.1 and Table 3.6. All isolates were positive for 
mecA. 
 
The SCCmec of WA MRSA-16 encoded locus A indicating a region with 
homology with SCCmec type I, locus C, which indicates the presence of mecI and 
thus a class A mec complex, and locus D, indicating the presence of the dcs 
region.  
 
The SCCmec of WA MRSA-18 was not positive for any of the loci detected by 
this multiplex PCR.  
 
The SCCmec of WA MRSA-21 was positive for locus A, indicating a region with 
homology to the SCCmec type I J1 region.  
 
The SCCmec of WA MRSA-26 was positive for locus D, indicating the presence 
of the dcs region, locus E, indicating homology for the region between pI258 and 
Tn554 of the type III SCCmec and locus F, indicating a region with homology 
with the region between Tn554 and orfX for SCCmec type III. 
 
The SCCmec of WA MRSA-27 was positive for locus B, indicating the presence 
of the kdp operon specific for SCCmec type II, locus C, which indicated the 
presence of mecI and locus G, which indicated a region with homology to the 
region between IS431 and pUB110 of SCCmec variant IA.  
 
The SCCmec of WA MRSA-28 was positive for locus A, indicating a region with 
homology with SCCmec type I and locus C, indicating the presence of mecI and 
therefore a class A mec complex. 
 
                                                                                                         Results 
 120
 
 
                                        
                          
 
Figure 3.1 Gel of Multiplex PCR SCCmec Typing Utilising the Method of 
Oliveira, D and de Lencastre, H (2002) 
 
 
Lane 1  1 Kb Plus DNA Ladder 
Lane 2  Control SCCmec I 
Lane 3  Control SCCmec II 
Lane 4  Control SCCmec III 
Lane 5  Control SCCmec IV 
Lane 6  WA MRSA-16 
Lane 7  WA MRSA-18 
Lane 8  WA MRSA-21 
Lane 9  WA MRSA-26 
Lane 10 WA MRSA-27 
Lane 11 WA MRSA-28 
Lane 12 WA MRSA-40 
Lane 13 WA MRSA-42 
 
 
2,000 bp 
1,000 bp 
500 bp 
300 bp 
Lane 1   2       3      4       5       6       7       8       9      10     11    12     13 
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The SCCmec of WA MRSA-40 was positive for locus E, indicating a region with 
homology with the region between pI258 and Tn554, and locus F, indicating a 
region with similar specificity for the region between Tn554 and orfX. Both loci E 
and F were previously considered to be specific for SCCmec III. 
 
The SCCmec of WA MRSA-42 was found to contain locus D only, indicating the 
presence of the dcs region found in SCCmec types I, II and IV. 
 
 
Table 3.6 SCCmec Typing Utilising the Multiplex PCR Method of Oliveira, D 
and de Lencastre, H (2002) 
Isolates 
PCR Loci SCCmec
Type A B C D E F G H mecA 
WA MRSA-16 POS neg POS POS neg neg neg neg POS I, II 
WA MRSA-18 neg neg neg neg neg neg neg neg POS 
Not 
Typable
WA MRSA-21 POS neg neg neg neg neg neg neg POS I 
WA MRSA-26 neg neg neg POS POS POS neg neg POS IV, III 
WA MRSA-27 neg POS POS neg neg neg POS neg POS I, II 
WA MRSA-28 POS neg POS neg neg neg neg neg POS I, II 
WA MRSA-40 neg neg neg neg POS POS neg neg POS III 
WA MRSA-42 neg neg neg POS neg neg neg neg POS I, II, IV
 
 
3.3.3.2 SCCmec Typing Utilising the Multiplex PCR 
Method of Zhang, K et al. (2005) 
This PCR Multiplex detects structural elements of SCCmec types I to V and 
allows for the differentiation of SCCmec IV subtypes a-d (Zhang et al. 2005). 
Further sub-typing of SCCmec type IV has been described with subtypes IVg and 
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IVh now classified (Berglund et al. 2008). Following primer analysis during this 
study it was determined that the sub-type IVc primers published for this reaction 
were not amplifying any region within the subtype IVc (Accession No. 
AB096217) but actually an element adjacent to the SCCmec (IE25923). 
 
Differentiation of SCCmec types by this method is determined by amplicon size. 
Results are presented in Figure 3.2 and Table 3.7. 
 
The SCCmec of WA MRSA-16 encoded structural elements for SCCmec types 
IVa and V, with bands of 776 and 325 bp respectively. 
 
The SCCmecs of WA MRSA-18, -26, -28 and -42 encoded structural elements for 
SCCmec type IVa, with a single band of 776 bp. 
 
The SCCmec of WA MRSA 21 encoded structural elements for SCCmec types 
IVa and III with bands of 776 and 280 bp respectively. 
 
The SCCmec of WA MRSA-27 encoded structural elements for SCCmec type II, 
with a band of 398 bp. 
 
The SCCmec of WA MRSA-40 amplified a band of 1600 bp, which didn’t 
correspond to the guideline of this multiplex. Sequencing of the product revealed 
the presence of an ISSau4-like element inserted into the SCCmec type V specific 
ORF (V011) (GenBank Accession No. AB121219) (results not shown).  
 
The multiplex PCR utilising the method of Zhang, K et al, (2005) also gave 
anomalous typing results, probably due to the heterogeneity of the J regions. 
Eventually the SCCmecs were typed according to the class of mec complex and 
type of ccr complex. 
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Figure 3.2 Gel of Multiplex PCR of the J Regions for SCCmec Typing  
(Zhang, K et al. 2005) 
 
 
Lane 1    1 Kb Plus DNA Ladder   
Lane 2     Control SCCmec type I    (613 bp) 
Lane 3  Control SCCmec type II   (398 bp) 
Lane 4  Control SCCmec type III  (280 bp) 
Lane 5  Control SCCmec type IVa  (776 bp) 
Lane 6     Control SCCmec type V   (325 bp) 
Lane 7  WA MRSA-16 
Lane 8     WA MRSA-18 
Lane 9  WA MRSA-21 
Lane 10  WA MRSA-26 
Lane 11   WA MRSA-27 
Lane 12   WA MRSA-28  
Lane 13   WA MRSA-40 (1600 bp) 
Lane 14   WA MRSA-42 
Lane 15   1 Kb Plus DNA Ladder 
 
 
2,000 bp 
1,000 bp 
500 bp 
300 bp 
 Lane 1     2      3      4      5       6       7      8      9      10     11     12     13    14     15 
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Table 3.7 Multiplex PCR of the J Regions for SCCmec Typing (Zhang, K et al. 
2005) 
Isolates 
PCR Loci Preliminary 
SCCmec 
Results I 
(613bp) 
II 
(398bp) 
III 
(280bp) 
IVa 
(776bp) 
IVb 
(493bp) 
IVc 
(200bp) 
IVd 
(881bp) 
V 
(325bp) 
WA 
MRSA-
16 
neg neg neg POS neg neg neg POS IVa, V 
WA 
MRSA-
18 
neg neg neg POS neg neg neg neg IVa 
WA 
MRSA-
21 
neg neg POS POS neg neg neg neg III, IVa 
WA 
MRSA-
26 
neg neg neg POS neg neg neg neg IVa 
WA 
MRSA-
27 
neg POS neg neg neg neg neg neg II 
WA 
MRSA-
28 
neg neg neg POS neg neg neg neg IVa 
WA 
MRSA-
40 
neg neg neg neg neg neg neg POS (1600bp) V variant 
WA 
MRSA-
42 
neg neg neg POS neg neg neg neg IVa 
 
 
The SCCmec results of the eight CA-MRSA with novel SCCmecs are summarised 
in Table 3.8 
 
Table 3.8 A Summary of the SCCmec Results of the Eight CA-MRSA with 
Previously Novel SCCmecs 
Isolate mec Complex ccr Gene Complex SCCmec Type 
WA MRSA-16 A 4 VIII 
WA MRSA-18 B Not Typable Novel 
WA MRSA-21 B Not Typable Novel 
WA MRSA-26 B 2 IV variant 
WA MRSA-27 A 2 II 
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Table 3.8 A Summary of the SCCmec Results of the Eight CA-MRSA with 
Previously Novel SCCmecs (Continued) 
Isolate mec Complex ccr Gene Complex SCCmec Type 
WA MRSA-28 A 4 VIII 
WA MRSA-40 C2 2 and C1 Novel 
WA MRSA-42 B 2 IVa 
 
 
3.4 SCCmec Region of WA MRSA-40 
 
WA MRSA-40 remained unclassified following SCCmec typing, due to the 
presence of two different ccr gene complexes, ccrC and ccrA2B2. To classify the 
SCCmec of WA MRSA-40, the entire SCCmec element was sequenced and 
analysed. 
 
A summary of SCCmec results of WA MRSA-40 is presented in Table 3.9. 
 
Table 3.9 SCCmec Results for WA MRSA-40 
PCR Reaction Result 
mec Complex Class C2 
ccr Gene Complex ccrA2B2 and ccrC 
Oliveira, D and de Lancastre, H. (2002) 
Multiplex PCR Loci E and F 
Zhang, K et al. (2005) Multiplex PCR *Type V (1600bp product) 
 
*The multiplex PCR utilising the method of Zhang, K et al. 2005, produced a 
PCR product of 1,600 bp due to the presence of an ISsau4-like element within the 
target ORF.  
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The multiplex PCR utilising the method of Oliveira, D and de Lencastre, H. 
(2002), which determines structural elements of SCCmec was positive for loci E 
and F, which are present in SCCmec III. Locus E was designed to detect the 
region between the integrated plasmid pI258 and transposon Tn554, while Locus 
F was designed to detect the region between Tn554 and the chromosomal junction 
orfX. PCR amplicons of WA MRSA-40 of these locus points were sequenced and 
showed homology with a restriction modification system (hsd) at locus E and 
homology with a ccrC gene at locus F. These results demonstrate that in this 
instance, these two locus points are not specific for only SCCmec III. 
 
 
3.4.1 Strategy for Sequencing the SCCmec of  
WA MRSA-40 
 
A long range PCR kit (Roche Diagnostics) capable of amplifying a product up to 
25,000 bp was used to amplify PCR products between known loci as presented in 
Figure 3.3. These loci were based on previous PCR typing results and were used 
as terminals to amplify larger products using the long range PCR kit. These loci 
were F locus/ccrC, dru, mecA, Zhang V primer site, hsdR, hsdM with the right 
hand end located using the locus orfY, which is located outside the SCCmec. 
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Left end       F(ccrC)               dru     mecA Zhang V           F(ccrC) hsd         Right end   orfY
Left end                F
F                     dru
dru mecA
mecA Zhang V
Zhang V       F
F                 hsd
hsd         orfY
9,000 bp
4,000 bp
3,000 bp
5,000 bp
7,000 bp
5,000 bp
10,000 bp  
 
Figure 3.3 Long Range PCR Products Covering the SCCmec of WA MRSA-40 
(Not drawn to scale) 
 
A technique of primer walking was then used to fully sequence the SCCmec of 
WA MRSA-40, because the resultant amplicons from the long range PCR 
reactions were too large for a single sequence read. 
 
The primer walking technique can be summarised as follows and is presented in 
Figure 3.4 
 Long Range PCR reaction, with a product that is too large to be sequenced 
in a single sequence read. 
 New forward and reverse primers were designed toward the ends of each of 
the forward and reverse sequences respectively. 
 The resultant PCR product was sequenced again, this time with the new 
primers. 
 The sequences were analysed with sequence assembly software. 
 New forward and reverse primers were again designed toward the ends of 
the sequences. 
 The PCR product was sequenced again with the next set of primers. 
 The sequences were analysed with sequence assembly software. 
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This process was continued until these short-sequence segments overlapped and 
the DNA fragment was completely sequenced. 
 
 
 
 
 Figure 3.4 Primer Walking Strategy 
 
Figure 3.5 presents an example of the long range PCR reactions. The PCR 
products of this long range PCR reaction of WA MRSA-40 used the primers for 
mecA (MECA P4 and MECA P7) and the F locus (RIF5 F10 and RIF5 R13). The 
forward and reverse primers for each of these loci were used in all possible 
combinations to ensure that the correct orientation of these genes could be 
determined. 
 
The PCR reactions revealed three products (see Figure 3.5), a 6,000 bp product in 
lane 3, a 12,000 bp product in lane 4 and a 4,000 bp product in lane 5. This lead to 
the postulation, that WA MRSA-40 possibly encoded multiple copies of the F 
locus, which is specific for the ccrC gene complex. One copy approx. 6,000 bp 
downstream of mecA and another copy approx. 12,000 bp upstream of mecA. The 
gel picture indicated a third location of a ccrC gene complex, also upstream of the 
mecA gene, with a 4,000 bp product (lane 5). This was later found to be 
misleading as sequencing revealed that this product was generated by non-specific 
primer binding. 
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Figure 3.5 WA MRSA-40 Long Range PCR using mecA – F Locus Primers 
 
 
Lane 1  1 Kb DNA Ladder 
Lane 2         mecAR (MECA P4) – F Locus R (RIF F10) 
Lane 3  mecAR (MECA P4) – F Locus F (RIF R13) 
Lane 4  mecAF (MECA P7) – F Locus R (RIF F10) 
Lane 5  mecAF (MECA P7) – F Locus F (RIF R13)  
 
 
 
 
 
 
 
 
12,000bp 
5,000bp 
2,000bp 
Lane 1      2          3          4          5
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3.4.2 The Structure of the SCCmec of  
WA MRSA-40 
 
The nucleotide sequence of the SCCmec of WA MRSA-40 was determined to be 
41,289 bp flanked by imperfect DR sequences of 15 bp and imperfect IR of 24 bp 
in length. See Table 3.14 and Figure 3.18. The SCCmec of  WA MRSA-40 has a 
G+C content of 30.7% which is lower than the 32.8-32.9% for S. aureus (Kuroda 
et al. 2001), indicating that it originally came from a species other than S. aureus. 
 
The SCCmec of WA MRSA-40 contained 36 ORFs, which could be divided into 
the regions of mec and ccr gene complexes and their surrounding regions J1, J2 
and J3. See Table 3.13 and Figure 3.12. 
 
The right hand (RH) end was integrated into the SCCmec insertion site in the orfX 
gene however, the left hand (LH) insertion site could not initially be determined. 
Further sequencing revealed two SCC-like elements inserted at the orfX 
integration site adjacent to the left hand end of the SCCmec of WA MRSA-40. 
The three elements formed a SCCmec-Composite Island (SCCmec-CI) with a total 
size of 72,522 bp. See Figure 3.18.  
 
The sequence of the SCCmec-CI of WA MRSA-40 has been named as 
SCCmecWA MRSA-40-CI and has been deposited in the NCBI GenBank public 
database under Accession number JQ746621. 
 
3.4.3 The mec Complex of WA MRSA-40 
 
WA MRSA-40 was found to have a class C2 mec complex consisting of a 
truncated mecR1, and the mecI gene completely deleted due to the insertion of 
IS431 at nucleotide (nt) 93 of mecR1. Sequences of IS431L (left/downstream of 
mecA) and IS431R (right/upstream of mecA) truncating mecR1, were analysed and 
compared with equivalent IS431 elements of two SCCmec type V isolates, WIS 
CA-MRSA (V[5C2]) and the Taiwan CA-MRSA (VT[5C2&5]) strain PM1 with 
                                                                                                         Results 
 131
GenBank Accession Nos AB121219 and AB462393 respectively. See Table 3.10 
and Figures 3.6 and 3.7. 
 
Table 3.10 Polymorphisms with Base-Pair Substitutions in IS431L and IS431R of 
the SCCmec of WA MRSA-40 
Nucleotide 
Position IS431 IS431L IS431R Stop Codon 
73 A→G   
93 A→G   
134 C→T C→T  
144 C→G C→G TAG 
150 G→A G→A TGA 
168 A→G A→G  
174 G→A G→A  
260 G→A G→A  
283 G→A G→A  
344 C→T C→T  
345 G→A G→A  
400 C→T C→T TAG 
420 A→C   
435 A→C   
457 G→C   
 
ClustalW alignment using MacVectorTM 7.2 (Accelrys Inc) of the IS431 gene, 
consisting of 481 nucleotides, revealed WA MRSA-40 to have 15 nucleotide 
polymorphisms in IS431L and 10 nucleotide polymorphisms in IS431R when 
compared with IS431L and IS431R of the prototypical type V SCCmec from WIS. 
See Table 3.10 for the nucleotide positions, base-pair substitutions and consequent 
stop codon formations. 
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A further comparison of IS431L and IS431R sequences of the three isolates 
analysed revealed IS431L and IS431R for WA MRSA-40 contained the same 
premature stop codons, resulting in truncated IS431 left and right transposase 
genes which would inactivate both transposases and stabilise the mec complex. 
The analysis showed the IS431L transposase gene for Taiwan CA-MRSA to be 
intact with no premature stop codons, however the IS431R transposase gene was 
identical to that of WA MRSA-40, IS431L and IS431R; IS431 transposase genes 
for WIS CA-MRSA were both intact. See Figures 3.6 and 3.7. 
 
WA 40     1 ATGAACTATTTCAGATATAAACAATTTAACAAGGATGTTATCACTGTAGC  50 
Taiwan    1 ATGAACTATTTCAGATATAAACAATTTAACAAGGATGTTATCACTGTAGC  50 
WIS       1 ATGAACTATTTCAGATATAAACAATTTAACAAGGATGTTATCACTGTAGC  50 
            ************************************************** 
 
WA 40    51 CGTTGGCTACTATCTAAGATATGCATTGAGTTATCGTGATATGTCTGAAA 100 
Taiwan   51 CGTTGGCTACTATCTAAGATATACATTGAGTTATCGTGATATATCTGAAA 100 
WIS      51 CGTTGGCTACTATCTAAGATATACATTGAGTTATCGTGATATATCTGAAA 100 
            ********************** ******************* ******* 
 
WA 40   101 TATTAAGGGAACGTGGTGTAAACGTTCATCATTTAACGGTCTAGCGTTGA 150 
Taiwan  101 TATTAAGGGAACGTGGTGTAAACGTTCATCATTCAACGGTCTACCGTTGG 150 
WIS     101 TATTAAGGGAACGTGGTGTAAACGTTCATCATTCAACGGTCTACCGTTGG 150 
            ********************************* ********* *****  
 
WA 40   151 GTTCAAGAATATGCCCCGATTTTATATCAAATTTGGAAGAAAAAGCATAA 200 
Taiwan  151 GTTCAAGAATATGCCCCAATTTTGTATCAAATTTGGAAGAAAAAGCATAA 200 
WIS     151 GTTCAAGAATATGCCCCAATTTTGTATCAAATTTGGAAGAAAAAGCATAA 200 
            ***************** ***** ************************** 
 
WA 40   201 AAAAGCTTATTACAAATGGCGTATTGATGAGACGTACATCAAAATAAAAG 250 
Taiwan  201 AAAAGCTTATTACAAATGGCGTATTGATGAGACGTACATCAAAATAAAAG 250 
WIS     201 AAAAGCTTATTACAAATGGCGTATTGATGAGACGTACATCAAAATAAAAG 250 
            ************************************************** 
 
WA 40   251 GAAAATGGAACTATTTATATCGTGCCATTGATACAGAGGGACATACATTA 300 
Taiwan  251 GAAAATGGAGCTATTTATATCGTGCCATTGATGCAGAGGGACATACATTA 300 
WIS     251 GAAAATGGAGCTATTTATATCGTGCCATTGATGCAGAGGGACATACATTA 300 
            ********* ********************** ***************** 
 
WA 40   301 GATATTTGGTTGCGTAAGCAACGAGATAATCATTCAGCATATGTATTTAT 350 
Taiwan  301 GATATTTGGTTGCGTAAGCAACGAGATAATCATTCAGCATATGCGTTTAT 350 
WIS     301 GATATTTGGTTGCGTAAGCAACGAGATAATCATTCAGCATATGCGTTTAT 350 
            *******************************************  ***** 
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WA 40   351 CAAACGTCTCATTAAACAATTTGGTAAACCTCAAAAGGTAATTACAGATT 400 
Taiwan  351 CAAACGTCTCATTAAACAATTTGGTAAACCTCAAAAGGTAATTACAGATC 400 
WIS     351 CAAACGTCTCATTAAACAATTTGGTAAACCTCAAAAGGTAATTACAGATC 400 
            *************************************************  
 
WA 40   401 AGGCACCTTCAACGAAGGTCGCAATGGCTAAAGTCATTAAAGCTTTTAAA 450 
Taiwan  401 AGGCACCTTCAACGAAGGTAGCAATGGCTAAAGTAATTAAAGCTTTTAAA 450 
WIS     401 AGGCACCTTCAACGAAGGTAGCAATGGCTAAAGTAATTAAAGCTTTTAAA 450 
            ******************* ************** *************** 
 
WA 40   451 CTTAAACCTGACTGTCATTGTACATCGAAAT 481           
Taiwan  451 CTTAAACCTGACTGTCATTGTACATCGAAAT 481 
WIS     451 CTTAAAGCTGACTGTCATTGTACATCGAAAT 481 
            ****** ************************ 
 
Figure 3.6 ClustalW Alignment of 481 Nucleotides of IS431L Gene, of WA 
MRSA-40, the Taiwan clone and WIS CA-MRSA. Nucleotide positions are 
numbered on the ends of the lines and identical nucleotides are indicated by 
asterisks beneath the alignment. Premature stop codons are boxed. 
 
WA 40     1 ATGAACTATTTCAGATATAAACAATTTAACAAGGATGTTATCACTGTAGC  50 
Taiwan    1 ATGAACTATTTCAGATATAAACAATTTAACAAGGATGTTATCACTGTAGC  50 
WIS       1 ATGAACTATTTCAGATATAAACAATTTAACAAGGATGTTATCACTGTAGC  50 
            ************************************************** 
 
WA 40    51 CGTTGGCTACTATCTAAGATATGCATTGAGTTATCGTGATATGTCTGAAA 100 
Taiwan   51 CGTTGGCTACTATCTAAGATATGCATTGAGTTATCGTGATATGTCTGAAA 100 
WIS      51 CGTTGGCTACTATCTAAGATATGCATTGAGTTATCGTGATATGTCTGAAA 100 
            ************************************************** 
 
WA 40   101 TATTAAGGGAACGTGGTGTAAACGTTCATCATTTAACGGTCTAGCGTTGA 150 
Taiwan  101 TATTAAGGGAACGTGGTGTAAACGTTCATCATTTAACGGTCTAGCGTTGA 150 
WIS     101 TATTAAGGGAACGTGGTGTAAACGTTCATCATTCAACGGTCTACCGTTGG 150 
            ********************************* ********* *****  
 
WA 40   151 GTTCAAGAATATGCCCCGATTTTATATCAAATTTGGAAGAAAAAGCATAA 200 
Taiwan  151 GTTCAAGAATATGCCCCGATTTTATATCAAATTTGGAAGAAAAAGCATAA 200 
WIS     151 GTTCAAGAATATGCCCCAATTTTGTATCAAATTTGGAAGAAAAAGCATAA 200 
            ***************** ***** ************************** 
 
WA 40   201 AAAAGCTTATTACAAATGGCGTATTGATGAGACGTACATCAAAATAAAAG 250 
Taiwan  201 AAAAGCTTATTACAAATGGCGTATTGATGAGACGTACATCAAAATAAAAG 250 
WIS     201 AAAAGCTTATTACAAATGGCGTATTGATGAGACGTACATCAAAATAAAAG 250 
            ************************************************** 
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WA 40   251 GAAAATGGAACTATTTATATCGTGCCATTGATACAGAGGGACATACATTA 300 
Taiwan  251 GAAAATGGAACTATTTATATCGTGCCATTGATACAGAGGGACATACATTA 300 
WIS     251 GAAAATGGAGCTATTTATATCGTGCCATTGATGCAGAGGGACATACATTA 300 
            ********* ********************** ***************** 
 
WA 40   301 GATATTTGGTTGCGTAAGCAACGAGATAATCATTCAGCATATGTATTTAT 350 
Taiwan  301 GATATTTGGTTGCGTAAGCAACGAGATAATCATTCAGCATATGTATTTAT 350 
WIS     301 GATATTTGGTTGCGTAAGCAACGAGATAATCATTCAGCATATGCGTTTAT 350 
            *******************************************  ***** 
 
WA 40   351 CAAACGTCTCATTAAACAATTTGGTAAACCTCAAAAGGTAATTACAGATT 400 
Taiwan  351 CAAACGTCTCATTAAACAATTTGGTAAACCTCAAAAGGTAATTACAGATT 400 
WIS     351 CAAACGTCTCATTAAACAATTTGGTAAACCTCAAAAGGTAATTACAGATC 400 
            *************************************************  
 
WA 40   401 AGGCACCTTCAACGAAGGTCGCAATGGCTAAAGTCATTAAAGCTTTTAAA 450 
Taiwan  401 AGGCACCTTCAACGAAGGTCGCAATGGCTAAAGTCATTAAAGCTTTTAAA 450 
WIS     401 AGGCACCTTCAACGAAGGTCGCAATGGCTAAAGTCATTAAAGCTTTTAAA 450 
            ************************************************** 
 
WA 40   451 CTTAAACCTGACTGTCATTGTACATCGAAAT 481 
Taiwan  451 CTTAAACCTGACTGTCATTGTACATCGAAAT 481 
WIS     451 CTTAAACCTGACTGTCATTGTACATCGAAAT 481 
            ******************************* 
 
Figure 3.7 ClustalW Alignment of 481 Nucleotides of IS431R Gene of WA 
MRSA-40, the Taiwan clone and WIS. Nucleotide positions are numbered on the 
ends of the lines and identical nucleotides are indicated by asterisks beneath the 
alignment. Premature stop codons are boxed. 
 
3.4.4 dru Typing 
 
The direct repeat unit (dru) region is the hyper-variable region (HVR) of the 
SCCmec adjacent to IS431L within the mec region (Figure 1.4), and is useful for 
typing purposes when further differentiation is required for SCCmec evolutionary 
studies. The repeat sequences are 40 bp in length. The dru type designations are 
assigned according to the number of repeat sequences present and indicate the 
different arrangements of specific repeats with regard to divergence from the 
consensus (Ryffel et al. 1991; Goering et al. 2008). Figure 3.8 presents the 
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sequence of the dru repeats of WA MRSA-40 including 5' and 3' signature 
flanking sequences. The sequence was submitted to http://www.dru-typing.org 
where it was analysed by druID software. 
 
5' TCTTACTGAGATTATACTA 
ATAAGAGGAA TAGTAAAAGC AATTCTAAGT AAAATTGCAG 
ATAAGAGGTT TGTTAAAAGC AGTTCTAAGT AAAATTGCAG 
ATAAGAGGTT TGTTAAAAGC AGTTCTCAGT AAAATTACAG 
ATAAGAGGTA CGTTAAAAGC AGTTCTAAGT AAAATTGCAG 
ATAAGAGGTT TGTTAAAAGC AGTTCTAAGT AAAATTGCAG 
ATAAGAGGTA CGTTAAAAGC AATTCCATGC AAAATTGCTG 
ATAAGGGGTA AGTTAAAAGC AGTTCTCAGT AAAATTGCAG 
ATAAGAGGTA CGTTAAAAGC AGTTCTAGGC AAAATTGCAG 
ATAAGAGGTG CGTTAAAAGC AGTTCTAAGT AAAATTGCTG 
ATAAGGGGTA AGTTAAAAGC AATCCTAAGT AAAATTGCAG 
ATAAGAGGTA AGTTAAAAGC AATCCTAAGT AAAATTGCAG 
ATAAGGGGTACAGAAAAAC 3' 
 
Figure 3.8 Sequence of the dru Region of WA MRSA-40 
Note: Flanking sequences are in bold type 
 
The dru repeats were designated: 5a-2d-4a-0-2d-5b-3a-2g-2h-4e-3e which is 
characteristic of dru type:  dt 11p (Goering et al. 2008). 
 
 
3.4.5 ccrC Analysis of WA MRSA-40 
 
WA MRSA-40 was found to carry a ccrC gene complex by PCR typing. See 
Table 3.5. Sequencing the SCCmec of WA MRSA-40 however, actually revealed 
the presence of two ccrC gene complexes, one situated upstream of mecA, initially 
designated ccrCL (left) and the other situated downstream of mecA, designated 
ccrCR (right). See Figure 3.9. 
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The sequences of the two ccrC genes of WA MRSA-40 were classified by 
phylogenetic analysis using MacVectorTM. ccrC reference sequences from 
GenBank that were used in the comparison are presented in Table 3.11. 
 
WA MRSA-40 ccrCL showed 100% homology with ccrC8 by phylogenetic 
analysis, which was confirmed by nucleotide blast search 
(http://blast.ncbi.nlm.nih.gov). WA MRSA-40 ccrCR showed 100% homology 
with ccrC2 by phylogenetic analysis which was confirmed by nucleotide blast 
search. See Figure 3.9. 
 
The International Working Group on the Classification of Staphylococcal Cassette 
Chromosome elements (IWG-SCC 2009) currently recognises one ccrC allotype 
with all ccrC variants to date shown to have ≥87% nucleotide similarity. These 
variants are designated as alleles of the ccrC1 allotype (IWG-SCC 2009). 
Consequently the ccrC alleles of WA MRSA-40 were designated as ccrC1, allele 
8 and ccrC1, allele 2. 
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Method: Neighbor Joining; Best Tree; tie breaking = Systematic
Distance: Tamura-Nei; Gamma correction = Off
Gaps distributed proportionally
ccrC9
ccrC3
ccrC7
WA40 ccrC L
ccrC8
ccrC6
WA40 ccrC R
ccrC2
ccrC5
ccrC1
ccrC4
0.01
0.009
0.019
0.01
0.016
0.009
0.011
0.009
0.017
0.013
0.014
0.057
0.013
0.072
 
Figure 3.9 Phylogenetic Analysis of ccrC Allelic Gene Sequences 
Note: Phylogenetic distance is indicated below the figure. 
 
 
A multiplex PCR using primers ccrC2F, ccrC2R, ccrC8F and ccrC8R which 
differentiate ccrC1, alleles 2 and 8 was devised and performed. Figure 3.10 
presents PCR confirmation of WA MRSA-40 containing ccrC1, allele 8 and 
ccrC1, allele 2 gene complexes. The Taiwan CA-MRSA was the positive control 
for both ccrC gene complexes, while SCCmecZH47 was the negative control 
because it carries ccrC1, allele 9 (Higuchi et al. 2008). See Figure 3.10. 
 
 
 
 
 
 
Phylogenetic distance 
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Table 3.11 Reference ccrC Sequences Used for Phylogenetic Analysis of the ccrC 
of WA MRSA-40 
Alleles of ccrC1 Accession No. SCC element/ Organism Strain Name 
1 AB121219 SCCmec V (WIS) JCSC3624 
2 AY894416 SCCmec V (Taiwan) 
3 AB037671 SCCmercury 85/2082 
4 U10927 SCCcap 
S. aureus M Type 
1 capsular gene 
cluster 
5 AP006716 S. haemolyticus JCSC1435 
6 EF190467 S. haemolyticus 25-60 
7 EF190468 S. epidermidis 13-48 
8 AB462393 SCCmec V (Taiwan) PM1 
9 AM292304 SCCmecZH47 ZH47 
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Figure 3.10 ccrC Multiplex PCR to Detect ccrC1, Alleles 2 and 8 
 
 
Lane 1    1 Kb DNA Ladder 
Lane 2    Taiwan CA-MRSA 
Lane 3    WA MRSA-40 
Lane 4    SCCmecZH47 
 
 
 
 
 
 
 
 
 
 
 
2,000 bp 
1,000 bp 
500 bp 
100 bp 
Lane 1              2                   3                   4 
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The ccrC1, allele 8 gene complex of WA MRSA-40 was found to consist of the 
ccrC gene together with three flanking ORFs on each side. Upstream of ccrC1, 
allele 8 the three ORFs are identified as hypothetical proteins with ORF M04 a 
homologue of the DNA polymerase family A and ORF M06 a homologue of a 
primase of the P4 family, C-terminal domain. Downstream, three ORFs were 
identified as encoding hypothetical proteins with domains of unknown functions 
(DUF) of 950, 960 and 1643 bp respectively. See Table 3.13. This conserved ccrC 
region, designated the ccrC-carrying unit, downstream of mecA has been 
described in Taiwan CA-MRSA and SCCmercury and SCCmecZH47 (Higuchi et al. 
2008). See Figure 3.11. 
 
 
 
Figure 3.11 Diagram of the ccrC1, Allele 8 Carrying Unit of WA MRSA-40 
Abbreviations: DUF, Domain of Unknown Function; nt, nucleotide. 
 
 
The PCR, sequencing and phylogenetic analysis of the two ccr gene complexes of 
WA MRSA-40 has characterised it as carrying ccrC gene complexes of two 
different alleles, ccrC1, allele 8 and ccrC1, allele 2. 
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3.4.6 J Regions of WA MRSA-40 
 
3.4.6.1 J1 Region 
The J1 Region of WA MRSA-40 is located between the right hand end (attR) of 
the SCCmec and the ccrC1, allele 2 gene complex. It is 13,602 bp in size and 
encodes 7 ORFs. See Table 3.13. Contained in this region is a type 1 restriction-
modification system (hsdR, hsdS, and hsdM). The J1 region of WA MRSA-40 was 
100% homologous with the J1 region of the Taiwan CA-MRSA, except for three 
nucleotide polymorphisms. These three polymorphisms occurred in a non-coding 
region between ORF M29 and hsdR. See Table 3.12. 
 
Table 3.12 Polymorphisms with Base Pair Changes in the J1 Region of WA 
MRSA-40 when Compared with the J1 Region of the Taiwan CA-MRSA 
Position (nt) Base Pair Change 
59,408 C→T 
59,410 T→A 
59,414 C→A 
 
 
3.4.6.2 J2 Region 
The J2 region of WA MRSA-40 is located between the mec region and the ccrC1, 
allele 2 gene complex. This region is 5,056 bp in size and encodes 6 ORFs. This 
region also contains the insertion sequence ISSau4-like element inserted into ORF 
M20. See Figure 3.12. The ISSau4-like sequence is 1,269 bp in size and 97% 
homologous with ISSau4 (Accession No. DQ680163). It contains two ORFs, an 
ORF encoding a hypothetical protein and a transposase gene of 843 bp. See Table 
3.13. The ISSau4-like element is flanked by IR of 38 bp. These repeats indicate 
that the transposase inserted via an active transposition event. See Table 3.14 for 
IR sequences.  
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Homology between WA MRSA-40 and the Taiwan CA-MRSA in the J2 region is 
99-100% with a polymorphism seen in ORF M23 of WA MRSA-40 at nt 53,982 
with the addition of an extra A causing the amino acid change from threonine 
(Thr) to asparagine (Asn) and a premature stop codon to the ORF at nt 987 (of the 
ORF), whereas the equivalent ORF of the Taiwan CA-MRSA ends at nt 1110 and 
the ORF is presumably intact.  
 
3.4.6.3 J3 Region 
The J3 region is located between the SCCmec left hand end and the mec region, 
and includes the ccrC1, allele8 gene complex. This region is 13,602 bp in size and 
encodes 10 ORFs. See Table 3.13. The J3 region of WA MRSA-40 is 100% 
homologous with the J3 region of the Taiwan CA-MRSA. See Figure 3.12. 
 
 
Table 3.13 The Open Reading Frames of the SCCmec of WA MRSA-40 
Genetic 
Region 
ORF 
Name Position (nt) 
Size 
(bp) 
Identity 
(%) Homology Information 
Repeat 
Region 
DR-3 31,695-31,709 15 93% NCTC 8325 Direct Repeat SCCmecL 
IR-5 31,700-31,722 23   Inverted Repeat SCCmecL 
J3 
 
ORF M01 31,959-32,264 306 100 ORF2 Taiwan (PM1) 
Hypothetical protein, predicted 
restriction endonuclease (COG 
3183) 
ORF M02 32,463-33,326 864 100 ORF3 Taiwan (PM1) 
Hypothetical protein (COG 
3680) 
ORF M03 33,410-34,909 1500 100 ORF4 Taiwan (PM1) Hypothetical protein 
ccrC 
Gene 
Complex 
ORF M04 35,135-36,235 1101 100 ORF5 Taiwan (PM1) 
Hypothetical protein, DNA 
polymerase family A 
ORF M05 36,228-36,599 372 100 ORF6 Taiwan (PM1) Hypothetical protein 
ORF M06 36,596-38,239 1644 100 ORF7 Taiwan (PM1) 
Hypothetical protein,  primase-
Cterm: phage/plasmid primase, 
P4 family, C-terminal domain 
ORFM07/ 
ccrC 38,465-40,141 1677 100 
ccrC8 Taiwan 
(PM1) 
Cassette chromosome 
recombinase C1, Allele 8 
ORF M08 40,247-40,585 339 100 ORF9 Taiwan (PM1) 
Hypothetical protein (DUF 
950) 
ORF M09 40,681-40,992 312 100 ORF10 Taiwan (PM1) 
Hypothetical protein (DUF 
960) 
ORF M10 41,008-41,514 507 100 ORF11 Taiwan (PM1) 
Hypothetical protein (DUF 
1643) 
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Table 3.13 The Open Reading Frames of the SCCmec WA MRSA-40 (Continued) 
Genetic 
Region 
ORF 
Name Position (nt) 
Size 
(bp) 
Identity 
(%) Homology Information 
 
mec 
Region 
IS431 41,604-42,393 790 99 Taiwan (PM1) Mobile Element: IS431L 
Insertion sequence 
IRIS431 41,604-41,619 15 100 Taiwan (PM1) Inverted repeat of IS431L 
ORF 
M11/ 
IS431 
Complement 
42,194-42,337 144 99 Taiwan (PM1) 
Truncated transposase for 
IS431 
IRIS431 42,378-42,393 15 100 Taiwan (PM1) Inverted repeat of IS431L 
ORF 
M12/ 
ugpQ 
43,679-44,422 744 99-100 All SCCmec types 
Glycerophosphoryl diester 
phosphodiesterase 
ORF M13 44,519-44,947 429 99 ORF15 Taiwan (PM1) 
MaoC domain protein 
dehydratase 
ORF 
M14/  
mecA 
Complement 
44,993-47,002 2010 99-100 
All SCCmec 
types 
Penicillin-binding protein 
PBP2a/2' 
ORF 
M15/ 
ΔmecR1 
47,099-47,209 111 100 ORF17 Taiwan (PM1) 
Truncated signal transducer 
protein MecR1 
IS431 47,191-47,981 790 100 Taiwan (PM1) Mobile Element: IS431R Insertion sequence 
IRIS431 
 47,191-47,206 15 100 Taiwan (PM1) Inverted repeat of IS431R 
ORF 
M16/ 
IS431 
47,247-47,390 144 100 ORF 18 Taiwan (PM1) 
Truncated transposase for 
IS431 
IRIS431 47,966-47,981 15 100 Taiwan(PM1)  Inverted repeat of IS431R 
 
J2 
ORF M17 Complement 47,981-48,409 429 100 
ORF19 Taiwan 
(PM1) Hypothetical protein 
ORF M18 48,457-49419 963 100 ORF20 Taiwan  (PM1) Hypothetical protein 
ORF M19 49,581-50,063 483 100 ORF21 Taiwan (PM1) Hypothetical protein 
ISSau4-
like 
Element 
50,046-51,315 1269 100 Taiwan (PM1)  Mobile element: ISSau4-like Element 
IRISSau4-like 
L 50,047-50,084 38 100 Taiwan (PM1)  
Inverted repeat of ISSau4-like 
Element L 
ORF M20 50,131-50,445 315 100 ORF22 Taiwan (PM1) Hypothetical protein 
ORF M21 50,430-51,272 843 100 ORF23 Taiwan (PM1) 
Transposase for ISSau4-like 
Element 
IRISSau-4 like 
R 51,278-51,315 38 100 Taiwan (PM1) 
Inverted repeat of ISSau4-like 
Element R 
ORF M22 51,279-52,844 1566 100 ORF24 Taiwan (PM1) Hypothetical protein 
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Table 3.13 The Open Reading Frames of the SCCmec WA MRSA-40 (Continued) 
Genetic 
Region 
ORF 
Name Position (nt) 
Size 
(bp) 
Identity 
(%) Homology Information 
ccrC 
Gene 
Complex 
 
 
ORF M23 53,039-54,025 987 99 ORF25 Taiwan (PM1) 
Hypothetical protein, DNA 
polymerase family A 
ORF M24 54,142-54,510 369 100 ORF26 Taiwan(PM1) Hypothetical protein 
ORF M25 54,510-56,126 1617 100 ORF27 Taiwan (PM1) 
Hypothetical protein,  primase-
Cterm: phage/plasmid primase, 
P4 family, C-terminal domain 
ORF 
M26/ 
ccrC 
56,351-58,030 1680 100 ORF28 ccrC2 Taiwan (PM1) 
Cassette chromosome 
recombinase C1, Allele 2 
ORF M27 58,083-58,457 375 100 ORF29 Taiwan (PM1) 
Hypothetical protein (DUF 
950) 
ORF M28 58,536-58,862 327 100 ORF30 Taiwan (PM1) 
Hypothetical protein (DUF 
960) 
ORF M29 58,868-59,380 513 100 ORF31 Taiwan (PM1) 
Hypothetical protein (DUF 
1643) 
J1 
hsdR Complement 59,690-62,812 3123 100 
ORF32 Taiwan 
(PM1) 
Type 1 restriction-modification 
system endonuclease 
homologue 
hsdS Complement 62,793-64,094 1302 100 
ORF33 Taiwan 
(PM1) 
Type 1 restriction-modification 
system specificity subunit 
hsdM Complement 64,084-65,607 1524 100 
ORF34 Taiwan 
(PM1) 
Type 1 restriction-modification 
system DNA methylase 
ORF M33 66,007-68,103 2097 100 ORF35 Taiwan (PM1) 
Hypothetical protein, predicted 
ATP-dependent endonuclease 
of the OLD family (COG 
3593) 
ORF M34 68,078-69,853 1776 100 ORF36 Taiwan (PM1) 
Hypothetical protein, UvrD 
Superfamily I DNA and RNA 
helicases (COG 0210) 
ORF M35 Complement 70,313-71,737 1425 100 
ORF37 Taiwan 
(PM1) 
Hypothetical protein, DOPA 
decarboxylase family 
ORF M36 Complement 71,820-72,146 327 100 
ORF38 Taiwan 
(PM1) 
Hypothetical protein (DUF 
1958) 
Repeat 
Region 
IR-6 72,960-72,982 23   Inverted Repeat 
DR-4 72,984-72,998 15 100 NCTC 8325 Direct Repeat SCCmecR 
 
Abbreviations: COG, Cluster of orthologous groups of proteins; DUF, Domain of 
Unknown Function; L, left repeat; R, right repeat; SCCmecL, SCCmec left end; 
SCCmecR, SCCmec right end. Accession Nos: Taiwain CA-MRSA PM1, 
AB462393; ISSau4-like Element, DQ680163; NCTC 8325, CP000253 
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3.4.7 Repeat Sequences of the SCCmec of  
WA MRSA-40 
 
Repeat regions of sequence flanking genetic elements indicate incision, excision 
and genetic recombination events. The following table (Table 3.14) presents the 
DR and IR sequences of the SCCmec of WA MRSA-40. 
 
Table 3.14 Repeat Sequences of the SCCmec of WA MRSA-40 
Genetic 
Region 
Repeat 
Type Sequence 
Size 
bp Position 
SCCmec 
Left end 
Direct 
DR-3 AGAGGCtTATCATAA 15 
31,695-
31,709 
SCCmec 
Right end 
Direct 
DR-4 AGAGGCgTATCATAA 15 
72,984-
72,998 
SCCmec 
Left end 
Inverted 
IR-5 CtTATCAtaaATaaaaCTAAAAA 23 
31,700-
31,722 
SCCmec 
Right end 
Inverted 
IR-6 TTTTTAGcaaaATcacTGATAgG 23 
72,960-
72,982 
IS431L 
Inverted GGTTCTGTTGCAAAGT 15 41,604-41,619 
Inverted ACTTTGCAACAGAACC 15 42,378-42,393 
IS431R 
Inverted GGTTCTGtTGCAAAGT 15 47,191-47,206 
Inverted ACTTTGCAgCAGAACC 15 47,966-47,981 
ISSau4-
like 
Inverted GgACTGACCCCaaTtAgtGGGAAtTatATAAAAACACT 38 50,047-50,084 
Inverted AGTGTTTTTATtaAgTTCCCgtTtAagGGGGTCAGTaC 38 51,278-51,315 
 
Figure 3.14 demonstrates the similarities between the DR and the flanking 
sequences at the SCCmec junctions of reference SCCmec types I, II, III, IV, V and 
VT and relevant SCC-like elements. Note: Non-complementary nt are in lower 
case and bold type 
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3.5 SCC and SCC-like Elements 
 
Previous PCR results indicated the presence of a ccrA2B2 gene complex but not 
the location. Several failed PCR reactions at the left hand end of the SCCmec of 
WA MRSA-40 led to the possibility of extra insertions between orfX and the 
SCCmec which were too large to amplify with the PCR conditions. A long range 
PCR reaction between orfX and ccrA2B2 amplified a 7,000 bp product between an 
hsd gene and ccrA2B2 gene complex with the orfX primer (P28) non-specifically 
binding to a semi-homologous region in an hsd gene. The P28 primer was 
homologous for 14 of its 22 bases with sequence of the hsdS gene at nt 12,699 to 
nt 12,720. An otherwise technical error was fortuitous. The primer walking 
technique was then used to sequence this SCC-like element. The following locus 
points were used for primer walking: orfX, pls, HP (hypothetical protein), hsd, 
ccrA2B2 and the SCCmec junction of WA MRSA-40. See Figure 3.13. 
 
 
orfX pls HP hsd ccrA2B2 SCCmec Junction    
orfX pls
pls HP
HP hsd
hsd ccrA2B2
ccrA2B2 SCCmec Junction 
2,000 bp
4,000 bp
6,000 bp
7,000 bp
12,000 bp  
 
Figure 3.13 Sites Along the SCC-like Element of WA MRSA-40 Used for Long 
Range PCR (Not drawn to scale). 
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The SCC-like element was 31,233 bp in length. Identification of DR and IR 
revealed that this region was actually comprised of two elements that have been 
named according to the IWG Classification of SCC elements that do not carry 
mecA (IWG-SCC 2009). The first element was homologous with the ∆J1 region of 
SCCmec type I, contained a pls gene and was designated pseudo SCCpls 
(ΨSCCpls). The second element was designated SCCsorbitol or SCCsrl and it 
contained a sorbitol operon, a ccrA2B2 complex and hsd genes. See Figure 3.18 
and Table 3.17. The entire region of DNA from the left hand end of the SCC-like 
element to the right hand end of the SCCmec has been designated as SCCmecWA 
MRSA-40-Composite Island (SCCmecWA MRSA-40-CI). 
 
DR and IR are presented in Table 3.15 and illustrated in Figures 3.14 and 3.18. 
The SCCmecWA MRSA-40-CI was flanked by 15 bp imperfect DR sequences, one at 
the orfX-CI (composite island) junction, designated DR-1, and the other at the 
right hand end of the SCCmec-chromosome junction, designated DR-4. Two 
similar 15 bp DRs were found within the composite island, with DR-2 found at 
the junction of ΨSCCpls and SCCsorbitol and DR-3 found at the junction of 
SCCsorbitol and the left hand end of the SCCmec. The DR at the right end of the 
SCCmec (DR-4) was 100% homologous with the DR sequence at the attB site in 
the orfX of the of S. aureus strain NCTC8325. The DR at the left end of the 
SCCmec (DR-3) had two base pairs dissimilar with those of NCTC8325. The DR 
at the junction of ΨSCCpls and SCCsorbitol (DR-2) had two base pairs dissimilar, 
while the left end of the ΨSCCpls element (DR-1) had three base pairs dissimilar. 
A maximum ambiguity of four base pairs is required for integration (Ito, 
Katayama, and Hiramatsu 1999). A unique occurrence in the SCCmecWA MRSA-40-
CI was identified with two additional DR sequences at the junction of the 
ΨSCCpls and SCCsorbitol (DR-5) and the junction of SCCsorbitol and the 
SCCmec (DR-6). These DR sequences, which flank the SCCsorbitol element, 
were imperfect (3 base pair differences from each other), 39 bp in size and 
contained the 15 bp SCCmec DR. 
 
 Imperfect IR sequences of 7 bp, were identified within DR-1 (IR-1), and 
immediately preceding DR-2 (IR-2). Imperfect IR of 24 bp were identified 
starting from within DR-2 at the ΨSCCpls/SCCsorbitol junction (IR-3) and 
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immediately preceding DR-3 at the SCCsorbitol/SCCmec junction (IR-4), and 
starting from within DR-3 at the left junction (IR-5) and immediately preceding 
the DR, DR-4 at the SCCmec right end (IR-6). At the junction between the 
ΨSCCpls and the SCCsorbitol, a large IR was found as previously described in 
the SCC-composite island of the S. epidermidis ATCC 12228 with a 13 bp perfect 
complementary IR separated by 29 nucleotides (including 13 bp DR) 
AAAAACCGCATCA-29nt-TGATGCGGTTTTT (IR-7 and IR-8) 
(Mongkolrattanothai et al. 2004).  
 
Table 3.15 Direct and Inverted Repeat Sequences of SCCmecWA MRSA-40-CI   
Repeat Sequence Size (bp) Location nt Position 
DR-1 AGAAGCgTAcCAcAA 15 orfX-ΨSCCpls (ΨSCCplsL) 462-476 
DR-2 AGAAGCaTAtCAtAA 15 
ΨSCCpls-
SCCsorbitol 
(ΨSCCplsR) 
12,198-12,212 
DR-3 AGAGGCtTATCATAA 15 SCCsorbitol-SCCmec (SCCmecL) 31,695-31,709 
DR-4 AGAGGCgTATCATAA 15 
SCCmec-
chromosome 
(SCCmecR) 
72,984-72,998 
DR-5 AAACCGCATCATTAtCtGATACGCAGAaGCaTATCATAA 39 
ΨSCCpls-
SCCsorbitol 
(SCCsorbitolL) 
12,174-12,212 
DR-6 AAACCGCATCATTAaCcGATACGCAGAgGCtTATCATAA 39 
SCCsorbitol-SCCmec 
(SCCsorbitolR) 31,671-31,709 
IR-1 GCGTAcC 7 orfX-ΨSCCpls (ΨSCCplsL) 466-472 
IR-2 GaTACGC 7 
ΨSCCpls-
SCCsorbitol 
(ΨSCCplsR) 
12,191-12,197 
IR-3 GCaTATCaTaAgTGATGCGGTTT 23 
ΨSCCpls-
SCCsorbitol 
(SCCsorbitolL) 
12,202-12,224 
IR-4 AAACCGCATCAtTaAccGATAcGC 24 SCCsorbitol-SCCmec (SCCsorbitolR) 31,671-31,694 
IR-5 CtTATCAtaaATaaaaCTAAAAA 23 SCCsorbitol-SCCmec (SCCmecL) 31,700-31,722 
IR-6 TTTTTAGcaaaATcacTGATAgG 23 
SCCmec-
chromosome 
(SCCmecR) 
72,960-72,982 
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Table 3.15 Direct and Inverted Repeat Sequences of SCCmecWA MRSA-40-CI 
(Continued) 
Repeat Sequence Size (bp) Location nt Position 
IR-7 AAAAACCGCATCA 13 
ΨSCCpls-
SCCsorbitol 
(SCCsorbitolL) 
12,172-12,184 
IR-8 TGATGCGGTTTTT 13 
ΨSCCpls-
SCCsorbitol 
(SCCsorbitolL) 
12,214-12,226 
IR-9 AGtTTTT 6 Sorbitol Operon L 25,085-25,091 
IR-10 AAAAcCT 6 Sorbitol Operon R 30,216-30,222 
   
Note: Non-complementary nucleotides are in lower case and bold type. 
 
 
 
Figure 3.14 (on the following page), compares the boundaries of SCCmec direct 
and inverted repeats of the SCC elements of WA MRSA-40, SCCmec types I-V 
and relevant SCC elements with MSSA strain NCTC 8325.  
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Figure 3.14 Boundaries of the SCCmec Types and SCC Elements 
The direct repeat sequences are in bold type and surrounded by a box. The inverted repeats are 
indicated by half arrows. IR-7 and IR-8 at the junction of the SCCsorbitol element are indicated as 
parallel lines with half arrows. WA MRSA-40-Composite Island elements are surrounded by a 
dashed box. 
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3.5.1 ΨSCCpls 
 
ΨSCCpls was 11,736 bp in length and comprised of eight ORFs. See Table 3.17. 
It is flanked by 15 bp imperfect DR (DR-1 and DR-2) that have three base pairs 
dissimilar and 7 bp imperfect IR (IR-1 and IR-2) that have one base pair 
difference. ΨSCCpls has high homology with a truncated J1 region of SCCmec 
type I. It contains a 4,473 bp gene designated ORF P03, homologous to the pls 
(plasmin-sensitive protein) gene, which is ORF CE010 of SCCmec I strain NCTC 
10442 (Accession No. AB033763.2) and ORF SACOL0051 of SCCmec I strain 
COL (Accession No CP000046.1). The pls genes of strains NCTC 10442 and 
COL are 5,097and 4,646 bp, respectively. 
 
The pls gene of WA MRSA-40 contained three regions of repeat sequences, R1, 
R2 and R3. See Figure 3.15. R3 was found to encode SD-dipeptide (serine-
aspartate) repeats that are characteristic of the Sdr protein family. The N-terminus 
encoded a characteristic YSIRK type signal peptide of 27 amino acid residues 
from nt 1,533 to nt 1,613 while the C-terminus encoded a wall spanning domain 
carrying the characteristic cell-wall sorting signal, the LPXTG motif from nt 
5,850 to nt 5,972 which was followed by hydrophobic amino acids and then 
positively charged residues. See Figure 3.15. 
 
 
Repeat Region
R1
Repeat Region
R2
Conserved  Region SD
Repeat Region
R3
PNKLNKYSIRRFTVGTASILVGSTLLF
Signal Peptide
LPDTGNDAQNNGTLFGSLFAALGGLFLVGRRRKNKNNEEK
Sorting Signal
Wall/Membrane 
Spanning Region
NH2 terminus –
Position nt 1,500
- COOH terminus
Position nt 5,972
 
 
Figure 3.15 Diagrammatic Representation of the pls Gene of WA MRSA-40 
Note: The YSIRK region of the signal peptide and LPXTG motif of the sorting signal are 
underlined and in bold type. 
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A conserved region, located between repeat regions R1 and R2 (see Figure 3.15) 
is homologous with the equivalent region of other surface proteins, such as the pls 
of SCCmec I, the aap (accumulation-associated protein) gene of S. epidermidis 
and sasG (Staphylococcus aureus surface protein G) gene (Hussain et al. 2009). 
 
The sequence from DR-1 at the integration site of nt 462 of orfX to the start of the 
pls gene at nt 1,500 has homology with several SCC and SCCmec entries in the 
NCBI database. This region was 100% homologous with a SCCmec-ACME-
composite island (CI) region of S. epidermidis strain BCM-HMP0060 from nt 
204,545 to nt 205,591 (Accession No. NZ_GG696727.1), 99% homologous with 
the truncated J1 SCCmec I element of the ACME-composite island strain 
M08/0126 at nt 13,026 to nt 14,313 (Accession No. FR753166.1), 100% 
homologous from nt 462 to nt 1,292 (the first 830 bp of ΨSCCpls) with SCCmec 
type II strain CCRI-9583 at nt 453 to nt 1,282 (Accession No. AY267384.1) and 
100% homologous from nt 462 to nt 903 (the first 441 bp of ΨSCCpls) with 
SCCmec type III strain V14 from nt 587 to nt 1,027 (Accession No. AB425427.1). 
See Figure 3.16. 
 
The sequence from the end of the pls gene at nt 5,973 to DR-2 at nt 12,198 was 
99% homologous with the sequences of SCCmec type I strain NCTC 10442 (nt 
4,485 to nt 10,730), SCCmec type I strain COL (nt 61,859 to nt 68,100), the 
truncated J1 SCCmec I element of the ACME-CI strain M08/0126 from nt 17,765-
24,006 and S. epidermidis strain BCM-HMP0060, from nt 207,630 to nt 213,869. 
 
The closest similarity was seen with the S. epidermidis strain BCM-HMP0060 
with only one base pair polymorphism in this region, resulting in both WA 
MRSA-40 and BCM-HMP0060 having the same ORF positions (start and stop) 
and sizes. See Table 3.17. A few more polymorphisms were seen in this region 
between the sequence of WA MRSA-40 and NCTC 10442, COL and ACME-CI 
M08/0126, which resulted in differences in ORF positions and sizes. 
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3.5.2 The Direct Repeats of ΨSCCpls 
 
Interestingly, it was noted that flanking the BCM-HMP0060 region, was a 15 bp 
sequence highly homologous to the SCC DR (attB site) within orfX. A nucleotide 
search of the NCBI database of the entire BCM-HMP0060 genome (Accession 
No. NZ_GG696727.1) revealed 15 matches of 11 bp or more, (including the DR 
sequences that flank the SCCmec-ACME-CI of BCM-HMP0060) with the 15 bp 
DR sequence of NCTC 8325 at the attB site. If a maximum ambiguity of four 
bases is required for integration (Ito, Katayama, and Hiramatsu 1999), these 15 
sites are potential DR and potential “hot spots” or recombination sites for SCC-
element formation. 
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3.5.3 SCCsorbitol 
 
The second SCC element was SCCsorbitol which contains a sorbitol operon, a 
ccrA2B2 ccr complex and a truncated type 1 restriction modification system. 
SCCsorbitol is 19,497 bp in length,  encodes 23 ORFs (see Table 3.17) and is 
flanked by 39 bp imperfect DR (DR-5 and DR-6) that have four base pair 
differences and 23 bp IR (IR-3 and IR-4) that have 5 base pair differences. See 
Table 3.15 and Figure 3.18. 
 
The type 1 restriction modification region of SCCsorbitol (nt 12,317 to nt 13,655) 
consists of an hsdS gene with a truncated hsdR gene of 144 bp. An hsdM 
component is absent. Type 1 restriction modification systems require three genes 
hsdR (restriction), hsdS (specificity) and hsdM (modification). Restriction 
modification systems encode endonucleases that cleave and then further degrade 
the double stranded DNA of foreign organisms such as bacteria or bacteriophages 
(Murray 2000). The hsdM of SCCsorbitol has probably been deleted by the 
insertion of a transposase, ORF S03 which immediately follows it. This 
transposase, 252 bp in size (at nt 13,659-13,910) is truncated and has 80% 
homology to IS1272 in S. haemolyticus strain Y176 (GenBank accession No. 
U35835.1). A copy of spermidine acetyltransferase follows (at nt 13,998-14,126), 
which is thought to have a role in the restriction modification system (Kaminska 
and Bujnicki 2008). See Table 3.17. 
 
SCCsorbitiol carries a ccrA2B2 gene complex. The IWG classify ccr genes with 
nucleotide identities of more than 85% as being assigned to the same allotype.  
Phylogenetic analysis shows the ccrAB complex of SCCsorbitol of WA MRSA-40 
to be allotype A2B2 (IWG-SCC 2009). The reference strains used in the 
phylogenetic analysis are listed in Table 3.16.  See Figure 3.17. 
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Method: Neighbor Joining; Best Tree; tie breaking = Systematic
Distance: Tamura-Nei; Gamma correction = Off
Gaps distributed proportionally
ccrA4(HDE288)
ccrA1(NCTC10442)
ccrA2(WA 40)
ccrA2(N315)
ccrA5(KM241)
ccrA3(85/2082)
ccrB7(STU33)
ccrB2(WA 40)
ccrB2(N315)
ccrB5(KM241)
ccrB3(85/2082)
ccrB6(ATCC15305)
ccrB1(NCTC10442)
ccrB4(HDE288)
0.2
0.17
0.17
0.096
0.773
0.129
0.155
0.143
0.103
0.146
0.111
0.103
Figure 3.17 Phylogenetic Analysis of the ccrAB Gene Sequence of SCCsorbitol. 
Note: The ccrA2B2 in SCCsorbitol of WA MRSA-40 is denoted as WA40 in the 
figure. Phylogenetic distance is indicated below the figure. 
 
SCCsorbitol is a mosaic structure that possesses homologies with regions found in 
the SCC-Composite Island (SCC-CI) of S.epidermidis ATCC 12228 (Accession 
No. AE015929), the ACME and SCCmec regions of S. aureus M1 type IV 
SCCmec (Accession No. HM030720), the ACME-CI of S. aureus M08/0126 
(Accession No. FR753166), and chromosomal regions of S. carnosus TM300 
(Accession No. AM295250.1), S. hominis C80 (Accession No. ACRM1000005.1) 
and   S. hominis SK119 (Accession No. (Accession No. NZ_ACLP01000020.1) 
(Sebastian et al. 2010; Mongkolrattanothai et al. 2004; Bartels et al. 2011; 
Rosenstein et al. 2009; Ward et al. 2010). Regions of homology are presented 
diagrammatically in Figure 3.16. Genetic regions, ORFs, positions, homologies 
and putative proteins are presented in Table 3.17. 
 
Phylogenetic Distance 
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Table 3.16 Reference Strains used in the Phylogenetic Tree Analysis of ccrA2B2 
of WA MRSA-40 
ccrAB Allotype Accession No. Strain Strain Name 
A1B1 AB033763 S. aureus NCTC10442 
A2B2 D56934 S. aureus N315 
A3B3 AB014436 S. aureus 85/2082 
A4B4 AF411935 S. aureus HDE288 
A5B5 AM904731 S. pseudintermedius KM241 
A1B6 NC_007350 S. saprophyticus ATCC15305 
A1B7 AB353724 S. saprophyticus STU33 
 
 
WA MRSA-40 SCCsorbitol possessed the most extensive homology with the S. 
epidermidis ATCC 12228 SCC-CI. There was 100% homology between 
SCCsorbitol nt 12,198 to nt 15,955 and ATCC 12228 SCC-CI up to their 
respective ccr complexes of ccrA2B2 and ccrA4B4 respectively. ATCC 12228 
carries an ISSep1-like transposase of 1014 bp at ORFSE51, which belongs to the 
Transposase 20 superfamily, although it is not annotated as such in the GenBank 
database. This transposase is 99.6% homologous to Tn20 found in the mec 
complex of ST72 MRSA-IV commonly known as the Korean clone (Park et al. 
2009) (not shown). The SCCsorbitol is absent of this ISSep1-like transposase. 
Upstream of the ccr complexes, the homology resumes with 90% homology 
between nt 20,979 to nt 22,772 of SCCsorbitol and nt 61,855 to nt 62,396 of 
ATCC 12228 SCC-CI. This region contains the 5' terminal of the SCCpbp4 
element of the ATCC 12228 SCC-CI. 
 
The ccr downstream region of SCCsorbitol, nt 12,198 to nt 17,745, also possessed 
between 100% and 87% homology with nt 1 to nt 5,024 of the ACME region of S. 
aureus ACME-CI strain M1. From nt 15,955 to nt 22,808 of SCCsorbitol there 
was 87-97% homology with the J1 and J2 regions of the SCC mec IVa (2B) of M1 
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at nt 40,175 to nt 47,028, with this region containing a ccrA2B2 gene complex. 
See Table 3.17 and Figure 3.16. 
There was 84-98% homology with the S. aureus ACME-composite island strain 
M08/0126 nt 34,551 to nt 43,406 (ORF C10-17) and nt 15,955 to nt 24,772 of 
SCCsorbitol. This region comprises the J1 and J2 regions of the SCCmec IVh 
subtype that is included in the composite island of M08/0126, and includes a 
ccrA2B2 gene complex.  See Figure 3.16 and Table 3.17. 
 
Upstream of the ccrA2B2 complex of SCCsorbitol (nt 25,092 to nt 30,212) is a 
sorbitol operon. This region is 5,120 bp in length and encodes six ORFs (ORF 
S17-ORF S22) that are flanked by 6 bp imperfect IR, IR9 and IR10. See Tables 
3.15 and 3.17. The sorbitol operon is a phosphotransferase system which transfers 
sorbitol into the bacterial cell. The operon consists of srlD, srlM, srlR, srlA, srlE 
and srlB genes. It was most homologous with the sorbitol operon of S. carnosus 
strain TM300, which encodes six ORFs (ORFSca2317-ORFSca2322) on a 
chromosomal region (not a SCC element), with nucleotide homology ranging 
between 81% and 69%. See Figure 3.16. 
 
Adjacent to the right hand end of the SCCsorbitol was a 276 bp ORF S23, with 
homologies of 83% (nt 30,918 to nt 31,659) and 91% (nt 30,749 to nt 30,906) 
with the nitrilotriacetate mono-oxidase component A genes of S. hominis C80 and 
S. hominis SK119 respectively. Given that the nitrilotriacetate mono-oxidase 
component A gene of S. hominis SK119 is 1,301 bp in size, ORF S23 probably 
represents a truncated form of the gene. 
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Table 3.17 The Open Reading Frames of ΨSCCpls and SCCsorbitol 
Genetic 
Region 
ORF 
Name Position (nt) 
Size 
(bp) 
Identity 
(%) Homology Information 
orfX ORF P01 1-480 480 99% S.aureus Conserved Hypothetical Protein orfX 
Repeat 
Region 
DR-1 462-476 15 
80% 
100% 
 
NCTC8325; 
M08/0126 
(∆J1SCCmecI) 
Direct Repeat ΨSCCplsL 
IR-1 466-472 7 100% M08/0126 (∆J1SCCmecI) Inverted Repeat ΨSCCplsL 
ΨSCCpls 
ORF P02 Complement 1,030-1,263 234 100% 
BCM-HMP0060;  
M08/0126 Hypothetical protein 
ORF P03/ 
pls 1,500-5,972 4473 
98% 
 
95% 
93% 
BCM-HMP0060 
ORF1721; 
M08/0126; 
NCTC10442/COL 
pls gene 
ORF P04 6,057-7,712 1656 
100% 
 
100% 
99% 
BCM-HMP0060 
ORF1722; 
M08/0126; 
NCTC10442/COL 
Hypothetical Protein 
ORF P05 Complement 7,872-9,383 1512 
100% 
 
99% 
99% 
BCM-HMP0060 
ORF1723; 
M08/0126; 
NCTC10442/COL 
Hypothetical Protein 
Glycosyltransferase 
(DUF1975); pfam09318 
ORF P06 Complement 9,406-11,064 1659 
100% 
 
100% 
99% 
BCM-HMP0060 
ORF1724; 
M08/0126; 
NCTC10442/COL 
Hypothetical Protein 
Mur ligase middle domain; 
pfam08245 
ORF P07 Complement 11,058-11,456 399 
100% 
 
99% 
99% 
BCM-HMP0060 
ORF1725; 
M08/0126; 
NCTC10442/COL 
Hypothetical Protein 
PRK11929 
ORF P08 11,744-11,866 123 100% 
BCM-HMP0060 
ORF1726; 
M08/0126; 
NCTC10442/COL 
Hypothetical Protein  
ORF P09 Complement 11,932-12,060 129 100% 
BCM-HMP0060 
ORF1727; 
M08/0126; 
NCTC10442/COL 
Hypothetical Protein 
Repeat 
Region 
IR-2 12,191-12,197 7   Inverted Repeat ΨSCCplsR 
IR-7 12,172-12,184 13 100% ATCC 12228 Inverted Repeat SCCsorbitol 
DR-5 12,174-12,212 39   Direct Repeat SCCsorbitolL 
DR-2 12,198-12,212 15 87% NCTC8325 Direct Repeat ΨSCCplsR 
IR-3 12,202-12,224 23   Inverted Repeat SCCsorbitolL 
IR-8 12,214-12,226 13 100% ATCC 12228 Inverted Repeat SCCsorbitol 
SCCsorbitol 
ORF S01/ 
hsdR 12,317-12,460 144 100% 
ATCC 12228 
SE0043; 
M1 
Type I Restriction Enzyme R 
Protein 
ORF S02/ 
hsdS 12,453-13,655 1203 100% 
ATCC 12228 
SE0044; 
M1 
Type I Restriction Enzyme S 
subunit  
ORF S03 Complement 13,659-13,910 252 100% 
ATCC 12228 
SE0045; 
M1 
Truncated transposase  
(80% homology with  
IS1272 of  S. haemolyticus) 
ORF S04 Complement 13,978-14,475 498 100% 
ATCC 12228 
SE0046 Spermidine acetyltransferase 
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Table 3.17 The Open Reading Frames of ΨSCCpls and SCCsorbitol (Continued) 
Genetic 
Region 
ORF 
Name Position (nt) 
Size 
(bp) 
Identity 
(%) Homology Information 
SCCsorbitol 
ORF S05 Complement 14,754-14,882 129 
100% 
 
100% 
98% 
ATCC 12228 
SE0047; 
M1; 
ATCC 12228 
SE0027 
Hypothetical Protein 
ORF S06 Complement 15,147-15,557 411 100% 
ATCC 12228 
SE0048; 
M1 
Hypothetical Protein 
pfam 11070  DUF 2871 
ORF S07 Complement 15,865-15970 108 100% 
ATCC 12228 
SE0049; 
M1 
Hypothetical Protein 
ORF S08 Complement 15,955-16,458 504 
99% 
 
99% 
 
99% 
88% 
ATCC 12228 
SE0030; 
ATCC 12228 
SE0052; 
M1; 
M08/0126 
ORFC10 
Hypothetical Protein 
 
 
 
 
 
 
 
 
ccr 
Gene 
Complex 
ORF S09 Complement 16,474-16,785 312 
100% 
  95% 
 
95% 
 
91% 
M1; 
ATCC 12228 
SE0031; 
ATCC 12228 
SE0053; 
M08/0126 
ORFC11 
Hypothetical Protein 
ORF S10 Complement 16,787-16,879 93 
100% 
  86% 
 
  86% 
M1; 
ATCC 12228 
SE0032; 
ATCC 12228 
SE0054 
Hypothetical Protein 
ORF S11 Complement 16,872-17,222 351 
87% 
  85% 
 
85% 
 
84% 
M1; 
ATCC 12228 
SE0033; 
ATCC12228 
SE0055; 
M08/126 
ORFC12 
Hypothetical Protein 
pfam 06106 DUF 950 
ORF S12/ 
ccrB2 
Complement 
17,746-19,395 1650 95-99% 
Various type II 
& IV SCCmecs 
Cassette chromosome 
recombinase B 
ccrB2 
ORF S13/ 
ccrA2 
Complement 
19,396-20,763 1368 95-99% 
Various type II 
& IV SCCmecs 
Cassette chromosome 
recombinase A 
ccrA2 
ORF S14 Complement 20,979-22,772 1794 
96% 
90% 
   
  90% 
 
90% 
M1; 
M08/0126 ORF 
C15; 
ATCC 12228 
SE0038; 
ATCC 12228 
SE0058 
Hypothetical Protein 
DUF 927 
ORF S15 Complement 22,766-23,077 312 
98% 
84% 
M08/0126 
ORFC16; 
ATCC 12228 
SE0039 
Hypothetical Protein 
ORF S16 Complement 23,234-24,772 1538 
95% 
92% 
SCCmec I COL 
M08/0126 
ORFC17 
Hypothetical Protein 
Repeat 
Region IR-9 25,085-25,091 6   
Inverted Repeat Sorbitol 
Operon L 
Sorbitol 
operon 
ORF S17 
srlB 
Complement 
25,092-25,445 354 69% TM300 Sca2322 
Putative sorbitol 
phosphotransferase system 
EIIA 
ORF S18 
srlE 
Complement 
25,461-26,486 1026 77% TM300 Sca2321 
Putative sorbitol 
phosphotransferase system 
EIIBC 
ORF S19 
srlA 
Complement 
26,498-27,145 648 80% TM300 Sca2320 
Putative sorbitol 
phosphotransferase system 
EIIC 
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Table 3.17 The Open Reading Frames of ΨSCCpls and SCCsorbitol (Continued) 
Genetic 
Region 
ORF 
Name Position (nt) 
Size 
(bp) 
Identity 
(%) Homology Information 
Sorbitol 
operonl 
ORF S20 
srlR 
Complement 
27,090-27,515 426 73% TM300 Sca2319 Sorbitol operon activator 
ORF S21 
srlM 
Complement 
27,508-29,052 1545 74% TM300 Sca2318 
Putative regulator of sorbitol 
operon 
ORF S22 
srlD 
Complement 
29,418-30,212 795 73% TM300 Sca2317 
Putative sorbitol-6-phosphate 
2- dehydrogenase 
Repeat 
Region IR-10 30,216-30,222 6   
Inverted Repeat Sorbitol 
Operon R 
SCCsorbitol ORF S23 Complement 30,667-30,942 276 81% 
C80 
SK119 ORF0518 
Nitrilotriacetate 
monooxygenase 
Repeat 
Region 
 
IR-4 31,671-31,694 24   Inverted Repeats SCCsorbitolR 
DR-6 31,671-31,709 39   Direct Repeat SCCsorbitolR 
DR-4 72,984-72,998 15    Direct Repeat SCCmecR 
DR-3 31,695-31,709 15 93% NCTC8325 Direct Repeat SCCmecL 
IR-5 31,700-31,722 23   Inverted Repeat SCCmecL 
 
 
Abbreviations: DUF, Domain of unknown function; L, left repeat; R, right repeat; 
Accession Numbers: S. epidermidis BCM-HMP0060, NZ_GG696727.1; S. 
epidermidis ATCC 12228, AE015929; ACME composite island SCCmec IVh 
strain M08/0126, FR753166.1; ACME-SCCmec IVa strain M1, HM030720.1; S. 
carnosus strain TM300, AM295250.1; S. hominis strain C80, ACRM1000005.1; 
S. hominis strain SK119, NZ_ACLP01000020.1. 
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Chapter Four 
Discussion 
 
4.1 Staphylococcal Protein A Typing 
 
Staphylococcal protein A or, spa, typing was found to be useful for typing WA 
CA-MRSA and has consequently been established as a routine typing technique 
by the ACCESS Typing and Research Unit. 
 
The spa gene is 2,150 bp in length and is comprised of distinct regions 
characteristic of surface proteins, including a starting signal peptide, regions of 
repeats and a LPXTG motif in the membrane-spanning region of the C-terminus. 
The polymorphic X region, which is embedded in the cell wall, consists of a 
variable number of 24 bp repeats. The diversity of this short-sequence repeat 
(SSR) region occurs as a result of deletion or duplication of repetitive units and by 
point mutation. Sequence analysis of the repeat region of the spa gene is 
considered a valuable typing technique and has been found to be comparable to 
the traditional methods of MLST and PFGE (Shopsin et al. 1999). 
 
The spa typing results for the CA-MRSA in this study revealed significant 
diversity with 28 different spa types seen among the 45 clones. spa type t002 was 
the most prevalent (7/45). One isolate, WA MRSA-8 (ST75), was considered not 
typable due to poor sequence quality. This isolate belongs to the clonal complex 
75 lineage and is believed to have its origins in the remote Indigenous 
communities in the northern regions of the Northern Territory of Australia. The 
strain is considered to be a phylogenetically distinct subspecies of S. aureus and is 
awaiting formal classification under taxonomic guidelines (Ng et al. 2009). MLST 
of CC75 strains has revealed a high degree of sequence divergence of the MLST 
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loci (Moneke, Slickers, and Ehricht 2008; Monecke et al. 2010) and this study 
now shows that the spa locus is also divergent. 
 
An association with spa type and lineage was demonstrated and is presented in 
Table 3.2, where MLST types and clonal complex groups coincided with spa 
identities. This is especially apparent when comparing the spa types using the 
Kreiswirth letter codes or the Ridom Number codes. 
 
Typing the spa gene provided useful information about the S. aureus lineages and 
possessed significant advantages over existing molecular typing procedures, such 
as MLST and PFGE. These advantages include increased speed, ease of 
performance, ease of interpretation, ability to create a database, ability to classify 
isolates into clonal complexes because of a correlation with MLST, and a high 
degree of reproducibility. Detection of the micro-variation provided by spa typing 
could be useful in outbreak situations, as with PFGE, and could be useful in 
phylogenetic population analysis, as with MLST (Koreen et al. 2003). 
 
 
4.2 Ciprofloxacin Resistance in WA  
CA-MRSA 
 
At the initiation of this study it was unusual to find ciprofloxacin resistance in 
CA-MRSA. Ciprofloxacin is a fluoroquinolone with broad-spectrum activity. 
Resistance to ciprofloxacin in S. aureus thus far has been due to chromosomal 
mutations within the DNA gyrase genes (gyrA and gyrB) and/or topoisomerase IV 
genes (grlA and grlB). This resistance occurs in a stepwise manner resulting from 
the combination of single point mutations within the grlA, grlB and gyrA genes 
(Schmitz, Jones, et al. 1998). 
 
A subset of eight isolates that were tested in this study were phenotypically high-
level ciprofloxacin resistant. Sequence analysis of mutations in the four genes 
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associated with ciprofloxacin resistance revealed that all eight isolates contained 
the amino acid changes Ser→Phe (C→T) or Ser→Tyr (C→A) at codon 80 in grlA 
and Ser→Leu (C→T) at codon 84 in gyrA. This combination of chromosomal 
mutations is known to result in high-level ciprofloxacin resistance (Schmitz, 
Jones, et al. 1998). Additional mutations seen in WA MRSA-19 at codon 471 
(Glu→Lys) and WA MRSA-27 at codon 84 (Glu→Gly) have not been reported to 
be responsible for high-level ciprofloxacin resistance but could possibly result in 
low-level resistance when not in combination with the grlA codon 80 and gyrA 
codon 84 base pair mutations. WA MRSA-19 and -27, are probably showing 
evidence of the stepwise process to ciprofloxacin resistance that results when an 
isolate first develops low-level resistance and then, high-level resistance due to 
continuing selective pressures or burdens (Schmitz, Hofmann, et al. 1998). 
 
In this study three previously unreported point mutations resulting in putative 
amino acid changes were found, two of which are possibly associated with 
ciprofloxacin resistance. These were a mutation of Glu→Lys at codon 471 in grlB 
and Glu→Gly at codon 84 in WA MRSA-19. The silent mutation of Leu→Leu at 
codon 126 of grlA of WA MRSA-27 is unlikely to be associated with 
ciprofloxacin resistance. 
 
WA MRSA-27 contained the most mutations with a total of four. This isolate was 
subsequently found to be the HA-MRSA, ST5-MRSA-II New York/Japan clone. 
The increased number of mutations found in this isolate may be due to frequent 
exposure to ciprofloxacin or other fluoroquinolones. 
 
Use of ciprofloxacin and other antimicrobials of the fluoroquinolone group are 
restricted in the community with their usage generally limited to hospitals. CA-
MRSA isolates are therefore more likely to develop resistance to ciprofloxacin 
when patients are hospitalised or been previously treated for other infections 
involving organisms such as Gram-negative bacteria where a fluoroquinolone was 
used in the course of treatment (Schmitz, Hofmann, et al. 1998; Schmitz, Jones, et 
al. 1998). 
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4.3 Novel SCCmecs 
 
The SCCmec is classified according to the class of mec complex and the type of 
ccr gene complex and sub-typed according to the elements present in the J 
regions. Several PCR methods have been developed to determine these 
components of the SCCmec (Ito et al. 2001; Lim et al. 2003; Oliveira and De 
Lencastre 2002; Zhang et al. 2005; Kondo et al. 2007). Throughout the time 
period of this study it has become evident that the SCCmec is evolving rapidly in 
WA and new heterogeneous structures are appearing (Coombs et al. 2011). 
 
The SCCmecs of a subset of eight WA CA-MRSA isolates that had novel 
classifications were analysed. The SCCmecs of four isolates, WA MRSA-16, -27, 
-28 and -42 were resolved into existing SCCmec types. WA MRSA-26 encoded a 
type IV (2B) structural variant. WA MRSA-18 and -21 remain novel and the SCC 
region of WA MRSA-40 was completely sequenced. 
 
The SCCmec of WA MRSA-16 contained a class A mec complex and a ccrA4B4 
gene complex, enabling it to be classified as the newly described SCCmec type 
VIII (Zhang et al. 2008). The presence of various structural elements in the J 
regions, possibly originating from other SCCmec types, emphasised the 
heterogeneous nature of the SCCmec. Regions of homology with SCCmec types I 
(1B) and III (3A) were detected which may indicate that WA MRSA-16 is a sub-
type of SCCmec type VIII that has not yet been described. 
 
The SCCmec of WA MRSA-18 contained a class B mec complex. The ccr gene 
complex was not typable and the multiplex PCR utilising the method of Zhang, K 
et al. 2005, detected elements of a type IVa SCCmec, while the multiplex PCR 
utilising the method of Oliveira, D and de Lencastre, H. 2002, indicated that the 
characteristic dcs region was absent. This is a novel SCCmec that requires 
complete sequencing.  
 
The SCCmec of WA MRSA-21 contained a class B mec complex. The ccr gene 
complex was not typable although structural elements were detected that indicated 
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some regions of homology with SCCmec types I and III. This also is a novel 
SCCmec that requires sequencing. 
 
WA MRSA-26 contained a class B mec complex and ccrA2B2 gene complex, 
which classified it as SCCmec type IV. The inability to sub-type the type IV with 
existing primers, appears to be due to the presence of structural elements with 
regions of homology with SCCmec type III. As these have not been found in 
already characterised type IVs, this indicates that WA MRSA-26 is a SCCmec IV 
variant. 
 
The SCCmec of WA MRSA-27 contained a class A mec complex and ccrA2B2 
gene complex, which classified it as SCCmec type II. The presence of type II 
structural elements also confirmed this finding. SCCmec II is generally considered 
to be associated with HA-MRSA and not CA-MRSA. Due to this finding, WA 
MRSA-27 was removed from the ACCESS database of CA-MRSA panel 
organisms and renamed ST5-MRSA-II (2A), New York/Japan epidemic clone. In 
May 2005 an outbreak of the New York/Japan MRSA clone occurred in Western 
Australia involving 31 isolates, with 25 epidemiologically linked to a colonised 
healthcare worker who had previously been hospitalised in the USA (Coombs et 
al. 2007). The isolate that was previously designated WA MRSA-27 was collected 
at the time of the outbreak, May 2005, and would have been included in the study 
if it had been recognised as a New York/Japan MRSA clone at that time. 
Although molecular typing revealed that WA MRSA-27 was the New York/Japan 
clone, an epidemiological link to the outbreak strain carried by the health care 
worker was not apparent. 
 
The SCCmec of WA MRSA-28 contained a class A mec complex and ccrA4B4 
gene complex, which classified it into a SCCmec type VIII. Structural elements 
possessed homology with regions of SCCmec types I and IVa. These features 
indicate that this SCCmec could also be a sub-type of VIII. Our results suggest 
that WA MRSA-28 and WA MRSA-16 encode novel, but different sub-types of 
the type VIII SCCmec. 
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The SCCmec of WA MRSA-40 could not be classified. It contained a class C2 
mec complex with both ccrA2B2 and ccrC gene complexes detected and structural 
elements showed homology with regions of SCCmec type III.  
 
The SCCmec of WA MRSA-42 contained a class B mec complex with a ccrA2B2 
gene complex which classified it as SCCmec type IV. The presence of the 
structural element dcs confirmed that WA MRSA-42 carried a SCCmec IVa. 
 
Analysis of the SCCmecs of WA CA-MRSA isolates with untypable SCCmecs by 
routine PCR primers revealed that while in most cases the core elements could be 
defined the composition of the J regions was heterogeneous. It is apparent that 
these regions readily incorporate genetic material from other sources allowing for 
variants of SCCmec and that this probably facilitates the ability of CA-MRSA to 
adapt to different conditions in the community environment. 
 
 
4.4 SCCmec Region of WA MRSA-40 
 
WA MRSA-40 was isolated from a foot wound of an 89 year old male in a 
nursing home. The isolate was characterised as ST835, clonal complex 5, spa type 
t002, and was resistant to ciprofloxacin. SCCmec typing revealed that the 
SCCmec was type VT (5C2&5) with an extra ccrA2B2 gene complex. Because 
several of these isolates had been found and they appeared to be 
epidemiologically significant in WA, it was decided to completely sequence the 
SCCmec region. To date, four clones with a SCCmec type VT (5C2&5) have been 
isolated in WA ST835, ST59, ST952 and ST5 (ACCESS 2011) suggesting that 
this SCCmec is quite mobile. 
 
 
 
                                                                                                     Discussion 
 170
4.4.1 SCC and SCC-like Elements of WA MRSA-40 
 
Sequencing the entire SCCmec Composite Island of WA MRSA-40 has enabled 
the full characterisation of its SCC and SCCmec components. The location of the 
ccrA2B2 gene complex was found to be in an SCC-like element outside the 
SCCmec. It has been reported that ccr genes are also located on non-mec 
containing SCC elements where they have a role in the incision and excision of 
the elements. SCC elements and the SCCmec integrate into orfX at the same 
attachment site (Mongkolrattanothai et al. 2004; Holden et al. 2004) and SCC 
elements have been found integrated in tandem with the SCCmec in MRSA, 
upstream as with the element SCCfar, and downstream of the SCCmec in USA300 
with the ACME element (Holden et al. 2004; An Diep et al. 2006). The ACME 
element has recently also been reported integrated into orfX upstream of the 
SCCmec (Bartels et al. 2011; Shore et al. 2011). SCC elements have also been 
found in other staphylococcal species. S. epidermidis strain ATCC12228, carries 
an SCC-composite island that contains a SCCpbp4 encoding pbp4 (penicillin-
binding protein 4) and tagF (teichoic acid biosynthesis protein) genes and a 
ccrA2B2 gene complex. Adjacent to this is another SCC element that encodes 
ccrA4B4, restriction modification genes, genes mediating resistance to heavy 
metals and a type II ACME complex (Mongkolrattanothai et al. 2004). 
 
The SCC-like element of WA MRSA-40 contained a region homologous to the 
∆J1 region of SCCmec type I, it encodes a pls gene and was designated ΨSCCpls.  
The gene ORF P03 (Table 3.17), which encodes a surface-membrane protein, was 
characterised as pls due to 100% homology with the LPXTG motif sorting signal 
and its following translated amino acid residues (Mazmanian, Ton-That, and 
Schneewind 2001). See Figure 3.15.  
 
The pls gene of WA MRSA-40 was 100% homologous with ORF 1721 of S. 
epidermidis strain BCM-HMP0060. Homology was also found with the ACME-
Composite Island strain M08/0126 which contains the same ∆J1 SCCmec I 
region. While most of the pls gene of WA MRSA-40 showed high homology with 
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strain M08/0126, there were polymorphisms present in the repeat regions 
especially in the second and third repeat regions (R2 and R3). 
 
The pls gene has been found on mobile elements including the SCCmec and 
plasmids of both animal and human origin (Accession Nos. GQ900485 and 
GQ900474 respectively) in several lineages of MRSA. 
 
Adjacent to the right hand end of the ΨSCCpls was SCCsorbitol, which encoded a 
sorbitol operon, restriction modification genes and a ccrA2B2 gene complex along 
with seven ORFs (Table 3.17). SCCsorbitol was flanked by unique DR sequences 
(DR-5 and DR-6). Following the IWG guidelines of Staphylococcal 
Chromosomal Cassette classification this element has been named SCCsorbitol 
(IWG-SCC 2009). 
 
The sorbitol operon of the SCCsorbitol of WA MRSA-40 is comprised of six 
ORFs (srlD, M, R, A, E, B) that encode a sugar phosphotransferase system which 
transports sorbitol into the cell and mediates its phosphorylation. This is a multi-
component system for the uptake of sorbitol into the bacterium with 
phosphoenolpyruvate as the source of energy. Once sorbitol is imported a 
phosphoryl group from phosphoenolpyruvate is transferred via a series of proteins 
encoded by the sorbitol operon. A concentration gradient is maintained that 
enables the further import of sorbitol through the transporter (Boyd et al. 2000; 
Saier and Reizer 1994). The first gene of the operon, srlD, encodes a protein that 
functions to convert D-sorbitol-diphosphate to D-fructose-6-phosphate. The srlM 
gene is a putative regulator of the sorbitol operon while the srlR encodes an 
activator protein. The srlA, srlE and srlB genes encode putative 
phosphotransferase permease enzymes (EII) (Boyd et al. 2000; Rosenstein et al. 
2009). This is the first time that a sorbitol operon has been reported in a SCC 
element and only the second time that a sorbitol operon has been reported in a 
staphylococcus, with it previously being found in S. carnosus (Rosenstein et al. 
2009). See Table 3.17. The sorbitol operon has a G+C content of 27.7% which is 
lower than the G+C content of the whole SCCmecWA MRSA-40-CI, 30.9%. This low 
G+C content of the sorbitol operon suggests a possible interspecies gene transfer 
(Gill et al. 2005). 
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The SCCsorbitol could mediate an advantage to the bacterial cell by enabling it to 
utilise sorbitol as an energy source. Sorbitol is a common dietary sweetener which 
is used 3.7 times more frequently with elderly individuals as compared to 20-29 
year olds (Boyd et al. 2000; Zanni Rde, Araújo, and Matinez-Mesa 2011). It is 
therefore probable that the index patient of WA MRSA-40, who was an elderly 
individual in a nursing home, could have had an exposure to dietary sorbitol. 
Also, increased production of sorbitol may occur as a complication of diabetes, 
where excess glucose is converted to sorbitol via an aldose reductase pathway 
(Nishikawa et al. 2000). This has been associated with cataract formation in the 
elderly (Lee, Chung, and Chung 1995). 
 
The SCCsorbitol contained a truncated ORF (ORF S24) with 83-91% homology 
with a 276 bp portion of nitrilotriacetate monooxygenase component A of S. 
hominis strains C80 and SK119. Nitrilotriacetate is a synthetic chelator used in 
various domestic and industrial processing and decontamination procedures, such 
as textiles, paper and pulp processing and water treatment. Nitrilotriacetate is a 
non-phosphate alternative used in detergents, and is degradable by microbial 
processes (biodegradable) and the carbon, nitrogen and energy used by the 
bacteria (Cripps and Noble 1973). Nitrilotriacetate monooxygenase requires two 
component proteins, component A and B. Component A oxidises nitrilotriacetate 
using oxygen and component B is an oxidoreductase (Knobel, Egli, and Meer 
1996). Component B was completely absent from SCCsorbitol. 
 
 
4.4.2 SCCmec of WA MRSA-40 
 
The SCCmec of WA MRSA-40 was thought to be novel due to the presence of 
both ccrC and ccrA2B2 gene complexes. Complete sequencing of the SCCmec of 
WA MRSA-40 revealed that it carried a class C2 mec complex and two ccrC1 
gene complexes with ccrC1, alleles 8 and 2. Classification of the SCCmec of WA 
MRSA-40 according to the International Working Group on the Classification of 
Staphylococcal Cassette Chromosome Elements designated it as SCCmecVT (T 
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for Taiwan) or SCCmec V (5C2&5). When compared with the SCCmecVT 
(5C2&5) sequence, the SCCmec of WA MRSA-40 was 99% homologous, with 
most of the polymorphisms occurring in the IS431/257 elements. 
 
The SCCmec of WA MRSA-40 was found to carry a class C2 mec complex with 
mecI deleted and mecR1 truncated by insertion sequence IS431 (IS431R). 
Deletion of mecI de-represses mecA and allows the expression of methicillin 
resistance (Katayama, Ito, and Hiramatsu 2001).  
 
Analysis of the IS431 elements within the mec region of WA MRSA-40 and 
comparison with the IS431 elements of two other type V MRSA, the Taiwan CA-
MRSA and WIS CA-MRSA, revealed that there is diversity among SCCmec type 
V isolates and the IS431 element. Nonsense mutations at nucleotide positions 144, 
150 and 400 of the WA MRSA-40 IS431R transposase gene created premature 
stop codons TAG, TGA and TAG respectively. The presence of these premature 
stop codons would prevent further transposase activity of IS431R, thus stabilising 
the mec complex (O'Brien et al. 2005). Both IS431 elements in the mec region of 
WA MRSA-40 contained non-functioning transposases, with the same nonsense 
mutations in both IS431L and IS431R. When compared with the sequence of WIS 
CA-MRSA, a total of 15 polymorphisms were detected in the WA MRSA-40 
transposase of IS431L, and 10 in IS431R. When compared with the Taiwan clone, 
the transposase of IS431R of both WA MRSA-40 and the Taiwan clone possessed 
the same polymorphisms that generated the same premature stop codons. Base 
pair and amino acid changes for WA MRSA-40 are recorded on Table 3.10. 
 
The transposase of IS431L of the Taiwan CA-MRSA encoded an intact 
transposase even though a polymorphism was detected when compared with WIS 
CA-MRSA at nt 457 (G→C),  but as this did not generate a stop codon the 
transposase would probably remain functional. See Figure 3.6. 
 
IS431 has been associated with transposition of genetic information amongst 
staphylococci, promoter activity and gene regulation (Leelaporn et al. 1994; 
Leelaporn et al. 1996). IS431 is implicated in the transposition of plasmids and 
genes such as antimicrobial-resistance and virulence. Genes and plasmids that 
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have transposed are found to be flanked by IS431 (Lyon and Skurray 1987; 
Kobayashi, Alam, and Urasawa 2001). This study now shows that it also 
possesses polymorphic variations. These variations demonstrate a genetic 
flexibility that probably enhances its utility as an important contributor to the 
evolutionary adaptability of S. aureus. 
 
Two ccrC1 allotype gene complexes were identified in the SCCmec of WA 
MRSA-40. The ccrC1, allele 8, found downstream or to the left of mecA and 
ccrC1, allele 2 found upstream of mecA. These ccrC alleles are in the same 
positions and orientation as those found in the SCCmec of the Taiwan CA-MRSA. 
The three ORFs flanking each side of the ccrC1, allele 8 gene, have a conserved 
ccrC region, designated the ccrC-carrying unit. The ccrC1, allele 3, of 
SCCmercury, the ccrC1, allele 9 of SCCmecZH47, and the ccrC1, allele 8 of the 
Taiwan clone are also encoded in a similar ccrC1-carrying unit. The entire region 
from attB in orfX up to, and including, the carrying unit at ORF  M10 (9,819 bp) 
of ccrC1, allele 8 of WA MRSA-40 was homologous with the Taiwan clone VT 
(5C2&5), SCCmercury and SCCmecZH47 (Higuchi et al. 2008). 
 
Although a ccrA2B2 locus was found during PCR testing the sequence of the 
entire SCCmec did not reveal the presence of a ccrA2B2 gene complex or 
homologue associated with the SCCmec of WA MRSA-40. Furthermore a 
junction between the left-hand end and orfX could not be found. This suggested 
that the ccrA2B2 gene complex may exist in a SCC element adjacent to the 
SCCmec.  
 
The insertion sequence ISSau4-like was found in the J2 region inserted into ORF 
M19 which encodes a hypothetical protein of unknown function. This insertion 
sequence has no known function and the impact of this insertion is not known. It 
is 1,269 bp in size and had 100% homology with the insertion sequence found in 
VT (5C2&5) of the Taiwan CA-MRSA. Frequently insertion sequences are found 
inserted into regulatory genes where they influence the expression of other genes 
and that may be its function in WA MRSA-40. 
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The left and right extremities of the SCCmec of WA MRSA-40 are flanked by 
characteristic DR sequences of 15 bp in length (DR-3 and DR-4) and inverted 
repeats of 23/24 bp in length (IR-5 and IR-6). See Table 3.15. The DR at the left 
hand end were identical to those of VT (5C2&5) of the Taiwan CA-MRSA and 
there was one base pair difference in the DR (G→A) at the right hand end. The 
IR, IR-5 and IR-6 were identical to the IR of VT (5C2&5) of the Taiwan clone at 
the corresponding ends. The junction at the left hand extremity of WA MRSA-40 
was found to be adjacent to another SCC element.  
 
Contained within the SCCmec are three mobile elements IS431L, IS431R and 
ISSau4-like, that are flanked by IR. See Table 3.14. IS431L and IS431R are 
flanked by 15 bp IR while ISSau4-like is flanked by 38 bp IR. IR define the 
boundary of a mobile element, such as an insertion sequence or transposon, and 
have a role in DNA recombination, rearrangement and gene amplification (Lin et 
al. 2001). 
 
Overall, the SCCmec of WA MRSA-40 possessed 99-100% homology with the 
SCCmec of the Taiwan CA-MRSA, even though the strains are of different 
genetic lineages. WA MRSA-40 is clonal complex 5 and PVL negative while the 
Taiwan CA-MRSA is clonal complex 59 and PVL positive. As the same SCCmec 
type is in a different clonal complex type this indicates that the integration of the 
SCCmec into WA MRSA-40 was a separate genetic event. 
  
 
4.4.3 The Formation of a SCC Element 
 
The integration site of SCCmec and SCC-like elements into the bacterial 
chromosome is at attB in the 3' end of the hypothetical protein gene orfX. The 
boundaries of the SCC elements are demarcated by direct and, in most cases, also 
IR. Upon integration, the 15 bp DR of the integrating element attaches in orfX 
with the corresponding DR of orfX subsequently found at the right hand end of the 
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inserted element. Integration is mediated by the ccr gene complex (Ito, Katayama, 
and Hiramatsu 1999; Ito et al. 2003a). 
 
The 11,736 bp ΨSCCpls element of WA MRSA-40, flanked by and including, 
DR-1 and DR-2, is highly homologous with a region within a possible SCCmec-
ACME-CI of the S. epidermidis strain BCM-HMP0060. At the left hand end of 
the BCM-HMP0060 region, is a 15 bp DR sequence, with 12 bp similar to the DR 
at the integration site attB of orfX. It is possible that genetic DNA containing 
ΨSCCpls has been transferred from S. epidermidis BCM-HMP0060, or a related 
S. epidermidis, into WA MRSA-40 resulting in a recombination event with 
ΨSCCpls inserting into the attB of orfX to form the SCC element. 
 
A nucleotide search of the genome of the strain BCM-HMP0060 found 15 
matches of 11 bp or more which matched the 15 bp sequence of the attB site of 
the orfX gene. With a maximum ambiguity of four base pairs required for 
integration (Ito, Katayama, and Hiramatsu 1999), these 15 matches of DR 
homologues could also serve as orfX attB attachment sites and potentially form 
SCC elements. Further analysis revealed that of these 15 matches, nine were 
together with the flanking sequence that contained the characteristic IR sequences 
found at the SCC junctions. Some of these DR and IR occurrences could in fact be 
flanking already existing elements on the BCM-HMP0060 genome. This finding 
has further supported the hypothesis that S. epidermidis is a reservoir for genetic 
information for S. aureus. 
 
The genetics of the ΨSCCpls and SCCsorbitol elements and their possible origin 
from coagulase-negative staphylococci (CoNS) such as S. epidermidis can offer 
an explanation as to the origin and formation of other SCC elements and the 
SCCmec and the heterogeneous nature of its sub-types. The SCCmec-composite 
island of WA MRSA-40 would have certainly resulted from a number of 
recombination events. 
 
The SCCmec has been termed a “hot spot” for recombination with genetic 
information moving in and out of the element, as a survival strategy for the host 
cell. Coagulase-negative staphylococci are considered to be potential reservoirs of 
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antibiotic-resistance genes and genetic elements that are being shuttled between 
staphylococci by horizontal transfer (An Diep et al. 2006; Hanssen and Ericson 
Sollid 2006). Transfers resulting in recombination and rearrangement of the 
staphylococcal genome may provide the necessary genetic material for survival in 
a changing environment. 
 
 
4.5 Achievements from this study 
 
The following have been accomplished as a result of this study. 
1.  spa typing has been established as a useful molecular typing technique for 
MRSA and is now used routinely by the  ACCESS Typing and Research 
Unit. 
2.  It has been revealed that ciprofloxacin resistance in WA CA-MRSA is due 
to chromosomal mutations and probably emerged in response to the 
exposure of CA-MRSA to ciprofloxacin or other fluoroquinolones in 
hospitals. 
3.  Four novel SCCmecs or SCC regions have been identified.  
4. A new SCCmec composite island, SCCmecWA MRSA-40-CI, has been 
sequenced. 
5.  A new SCC element, SCCsorbitol, has been described. 
6.  A possible mechanism for the formation of SCC elements and their 
distribution amongst staphylococcal species has been presented. 
 
 
4.6 Further Studies 
 
The results from this study have yielded valuable information and opened the 
possibility to explain one way that genetic transfer occurs. However nothing is 
known about how the SCC elements are transferred horizontally. Known methods 
                                                                                                     Discussion 
 178
of genetic transfer in staphylococci need to be investigated to see if transfer can 
occur between candidate organisms in the laboratory. 
 
spa typing was shown to be a valuable typing tool for MRSA. One isolate 
remained non-typable with the existing spa method and will require further 
investigation to determine if it is possible to improve the PCR reaction conditions 
to enable a typable sequence of WA MRSA-8, ST75-MRSA-IV to be produced. 
Other clones of the ST75 lineage also remain non-typable by the current spa 
typing method. These could also be possibly typable by adjusting PCR conditions 
and/or designing different primers. 
 
The SCCmecs of WA MRSA-18 and WA MRSA-21 remain novel due to non-
typable ccr gene complexes. Investigation of these regions will involve designing 
primers in the flanking ORFs either side of the ccr genes to attain a PCR product 
for sequencing of the entire ccr region. This would be followed by phylogenetic 
analysis with reference known ccr sequences to determine if they are related to 
known types or are new types of ccr sequences. Ultimately these SCCmecs 
require complete sequencing. 
 
The formation of a SCC element and the rearrangement of the SCCmec to form 
sub-types require more study. An investigation of the role of DR and IR in 
SCCmec and SCC elements in the movement and arrangement of elements needs 
to be explored, involving genome scanning using the GenBank database and site 
directed mutagenesis directed at the repeat region. The movement of J1 regions 
among SCCmec types to form sub-types also may be related to a function of the 
flanking DR and/or IR sequences. Such as the J1 region of SCCmec IVb that 
occurs in SCCmec IIA. The role of CoNS, such as S. epidermidis and their 
contribution as a reservoir for potential SCC elements needs to be investigated, 
also using genome scanning to search for the occurrence of regions of sequence 
with homology with direct and inverted SCC-like repeats within genomes of 
CoNS and their potential role in the formation of SCC elements.
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